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Abstract 
The age-related loss of skeletal muscle mass and function is a key contributor to 
physical frailty in older individuals. In addition to this, the increased development 
of bone and joint disorders such as osteoporosis and osteoarthritis with ageing 
present a complex problem. Current understanding of the mechanisms responsible 
for age-related musculoskeletal deterioration is poor.  
The overall aims of this study were to integrate methods of measuring and 
visualising age-related changes in musculoskeletal tissues in a mouse model of 
ageing and to test a range of differing potential interventions known to protect 
individual tissues during ageing on the whole musculoskeletal system. Data 
demonstrated that C57Bl6 mice are a reliable model to study ageing, particularly 
in muscle and bone (Muscle mass reduced by ~40% and trabecular bone halved 
between 3 and 28 months of age); however these mice did not demonstrate 
evidence of any gross changes in the hind limb joints or tendons. C57Bl/6 mice 
were supplemented dietary sodium nitrate for either a short (18-24 months old) or 
longer (9 to 24 months old) to determine whether supplementation at key stages of 
development of musculoskeletal tissue dysfunction would result in preservation of 
muscle or bone without the need for more invasive treatment. No significant 
differences were reported in the long term treatment, however short-term 
treatments of mice with nitrate resulted in a significant decrease in muscle mass 
and function and this was associated with changes in trabecular bone disputing 
our initial hypothesis. HSP10 overexpression in muscles of mice has been shown 
to preserve muscle force generation and cross-sectional area in old mice 
previously. As proof of principle, the direct effect of such preservation of muscle 
on bone was tested. Preservation of muscle was evident as in the previous study; 
however, little effect of this was seen on bone disputing the dominant role the 
muscle has over bone tissue.  
A cohort of wild mice was then used to challenge the widely used Bl/6 mouse 
model and demonstrated substantial spontaneous deterioration of joint tissues as 
well as increased loss of muscle and bone tissue compared to the Bl/6 mice. These 
results indicated a possible altered ageing process in the lab bred C57Bl/6 mouse 
which may impact the research using them.  
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1.1 Ageing: the role of musculoskeletal decline 
We currently live in an increasing ageing population both within the UK and in 
other developed countries. Figures from before 2000, based on the current UK 
population of that time estimated that the number of people over 65 would reach 
13 million by 2030 (Statistics, 2013). In 2010, the UK parliament reported that the 
UK population over the age of 65 was currently at 10 million people and further 
estimated that by 2030, over 15 million people would be in this age group. 
The UK-based charity, Age UK, published more recent findings (June 2016) 
suggesting that 11.4 million people in the UK are currently over the age of 65 
(Statistics, 2015), with 23.2 million people over the age of 50 – this equates to 
roughly a third of the population (Statistics, 2015). There are now more people 
over the age of 60 than under the age of 18 (Statistics, 2015) but despite the 
growing aged population, 11% of older people would describe their life as very 
poor, poor or neither good nor poor (Voice, 2008). On mean, women today will be 
in poor health for around the last ten years of life, with men having seven years of 
poor health (Statistics, 2015). Thus, it is clear that research based interventions 
should aim to not solely extend lifespan, but to increase health span (Kirkland and 
Peterson, 2009) keeping people healthier for longer and reducing the time spend 
in poor health (Figure 1.1).  
 
 
 
 
 
 
 
 Fig 1.1 Differing approaches to treating increasing age. A shows the normal 
lifespan of an average person. B shows the effect of lifespan extension only. C 
shows the extension of health span only. Redrawn from Kirkland and Peterson 
(2009) 
A 
 
 
B 
 
 
C 
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There are a number of age-related conditions that can cause a reduction in health 
span (Kirkland and Peterson, 2009, Burch et al., 2014). These include the 
presence of cancers (Statistics, 2015, Ahmad et al., 2015), cardiovascular and 
respiratory diseases (Statistics, 2015), cognitive disorders (Fratiglioni et al., 
1997), metabolic disorders such as diabetes (Kirkman et al., 2012) and 
musculoskeletal disorders (Degens and Alway, 2003, Kelsey, 1989). Classically, 
basic research has focused on one of two approaches – to slow ageing or to 
prevent death. This has often been reduced to specific prevention or treatment of 
one of the age-related conditions (Figure 1.2).  
 
 
 
Fig 1.2 Differing approaches to treating age-related conditions. A shows how 
ageing can be slowed to prevent the onset of age-related conditions as much as 
possible, or preventing death by treating the age-related diseases and 
prolonging life. B shows a more realistic example where one specific disease is 
either prevented or treated allowing other age-related conditions to develop. 
A 
B 
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Fig 1.3 Example of placing musculoskeletal decline as the centre of age-related 
health decline. The decrease in musculoskeletal function can lead to increasing 
falls and decreasing activity which both feedback directly and indirectly causing 
further declines. These effects are known to influence other age-related conditions 
and co-morbidities. (Martini et al., 2012) 
Although there have been successes with using specific approaches, it 
undervalues the level of connectivity of a majority of the age-related conditions. 
Removing cancer as an exception, the remaining conditions can be considered 
closely connected e.g. decline in musculoskeletal function leads to both an 
increased risk of falls (Montero-Fernandez and Serra-Rexach, 2013) 
(compounded by decreases in cognitive function (Rosano et al., 2006)) and 
decreases in daily activity (Hamrick et al., 2006, Roubenoff and Hughes, 2000). 
Both can feedback to further reduce musculoskeletal function (Perkin et al., 2015, 
Wijlhuizen et al., 2007). The decrease in daily activity can lead to increased mass 
(Wang et al., 2008), reducing activity further, and can lead to metabolic disorders 
(Colditz et al., 1995, Wisse, 2004) which can lead to cardiovascular and 
respiratory disorders (Kannel et al., 1996, Aaron et al., 2004). All three of these 
effects can further reduce musculoskeletal function (Moseng et al., 2014) (Figure 
1.3).  
This may well go some way to explain the rapid decline in health in later life – 
declines in one tissue can lead to knock-on effects which all feedback onto each 
other.  
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Based on the above, although not as life threatening when compared to other age-
related conditions, decline in musculoskeletal function can be highly influential in 
coordinating the general decline we see in later life. Musculoskeletal disorders are 
currently the leading causes of disability in the aged population (Statistics, 2015). 
The UK Global Burden of Disease study placed musculoskeletal conditions as the 
largest single cause of years lived with disability, this increases in the older 
population (Murray et al., 2013).  
Musculoskeletal disorders consist of reduced quality or function of one or a 
combination of bones, muscles, joints or tendons and ligaments. These states can 
be brought about through reduction or dysfunction in tissues specifically (e.g. 
reduction in bone mass leading to osteoporosis and increased fracture risk) or 
through a reduction in multiple tissues causing limited mobility, function and 
overall frailty. Conditions can broadly be placed into three categories consisting 
of conditions causing pain, conditions which increase fragility and conditions 
brought about by increases in inflammation. 
Approximately a third of people aged over 65 will fall at least once per year (3 
million people) (Statistics, 2015), compounded by high levels of osteoporosis 
(Bilezikian et al., 2008), costing the NHS upwards of £6 million a day (based on 
hip fractures alone) (Statistics, 2013). Of the 70,000 osteoporotic hip fractures 
each year, about 30% of patients will die within a year due to causes related to the 
fracture (Statistics, 2015). Compounding this, 1 in 2 women and 1 in 5 men over 
the age of 50 will have an osteoporosis induced fracture, between 50-70% of 
women will have an osteoporotic fracture (Statistics, 2013). This shows that with 
the ageing population growing at a faster rate than predicted, certain age-related 
illnesses are not being successfully managed. Lifespan is unfortunately outpacing 
health span. 
On mean an older person loses between 2-4% of muscle mass (Lexell, 1995) and 
1% of bone mass every year of life (Pouilles et al., 1996). Despite this, there is no 
clear understanding of this process. Thus, musculoskeletal ageing is placed in the 
centre of the cause of a large proportion of age-related morbidity and death. In 
order to fully research a beneficial solution, first a fundamental knowledge of 
musculoskeletal ageing is needed, not from a selective, single tissue approach, but 
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from a multi-tissue multidisciplinary approach and from this we can begin to 
successfully test interventions with an aim of improving the whole 
musculoskeletal system. 
There is a clear need to both improve musculoskeletal function in older people 
and prevent the decline for as long as possible if not indefinitely. There is strong 
evidence to place this as the most important step in improving the quality of later 
life. 
1.2 Structure and function of musculoskeletal tissue 
1.2.1 Skeletal muscle structure and function 
Skeletal muscle as an organ has evolved to provide us with wide ranging and 
hugely beneficial functions including coordinated movement such a 
running/walking and for posture maintenance. Being highly adaptable with both a 
robust and plastic nature, it has allowed for many steps in evolution to commence. 
The muscle bulk itself is a bundle of differing tissues including muscle, nerve, 
blood vessels and connective tissue. Muscles connect to the skeleton via tendons 
(Figure 1.4) (MacIntosh, 2006).  
The main function of skeletal muscle is that of locomotion. Muscle also aids in 
maintaining body temperature and is a major source and store of dietary protein. 
Muscle makes up 40-50% of total body mass on mean and stores 50% of total 
protein within the body, (MacIntosh, 2006).  
Skeletal muscles develop early in the embryo from somites (Buckingham et al., 
2003). Early muscles require a large number of external signals and factors before 
they commit to forming a skeletal muscle cell with the expression of Pax3, c-met, 
Lbx1, MyoD, Myf5, Myogenin, Mox2, Six and Mef2 (Buckingham et al., 2003). 
In humans the first muscle fibres start to form at around embryonic day 11-14 
(primary fibres) with further fibre formation (secondary fibres) and innervation 
occurring before embryonic day 16. Primary fibres will tend to develop into slow 
glycolytic fibres, secondary fibres tending to form fast twitch fibres (Buckingham 
et al., 2003). 
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Fig 1.4 The musculoskeletal tissues are in close proximity. The arrangement of 
musculoskeletal tissues is as above. Innervated muscles surround bone and are 
attached via tendons. Bones are joined via ligaments forming joints with the 
protective cartilage present at the ends of each bone (Martini et al., 2012).  
The fully formed skeletal muscle has a consistent architecture despite large 
plasticity. Muscles contain long bundles of muscle fibres formed initially from 
myoblasts. Each fibre has a plasma membrane called the sarcolemma. Each fibre 
is in turn made up of up to 1000 myofibrils of roughly 1-2um in diameter which 
are made up of proteins including actin and myosin providing the contractile 
properties (MacIntosh, 2006). 
The actin and myosin filaments are highly organised into structures termed 
sarcomeres (Huxley and Hanson, 1954). These units give the striated appearance 
visible in skeletal muscles. Dark bands and light bands are the cause of this 
striation. Dark bands termed A bands are caused by the overlapping actin and 
myosin filament and are divided by the M line (a dark line) whilst lighter bands 
called I bands are divided by the Z disk (filament anchoring site) and are 
composed of non-overlapping filaments. Sarcomeres are the area between two Z 
disks (MacIntosh, 2006).   
The structure of these filaments allows the maximum force to be produced with 
the least amount of energy input. The contraction is first initiated upon receipt of 
Nerve 
Bone 
Cartilage 
Ligament 
Tendon 
Muscle 
Nerve 
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neural signals from the neuromuscular junction (MacIntosh, 2006). This causes 
the opening and activation of voltage gated Na/K channels along the fibre which 
cause large influxes of Na and a net positive charge along the fibre, propagating 
an action potential (Sandow, 1952a, Sandow, 1952b, Huxley, 1957). 
The action potential spreads down specialised sections of the fibres called 
transverse tubules (T tubules) causing release of Ca from the sarcoplasmic 
reticulum. These free ions bind to troponin located on the actin filament. This 
causes allosteric modification of the related protein tropomyosin, freeing up 
myosin binding sites on the actin protein. Myosin heads then readily bind to actin 
filaments forming cross bridges. Hydrolysis of ATP bound to the myosin head by 
myosin ATPases allows movement of myosin heads along the actin filament, a 
process known as the power stroke (Sandow, 1952a, Sandow, 1952b, Huxley, 
1957). 
This process will continue in a cyclical nature along the actin filament 
(approximately 10nm movements per power stroke) as long as ATP is present and 
can be hydrolysed. A sliding motion occurs and as the length of actin and myosin 
filaments remain constant, the muscle fibre as a whole contracts (Sandow, 1952a, 
Sandow, 1952b, Huxley, 1957). 
Fibres within a muscle can be divided according to how each performs under 
stimulation and their biochemical characteristics once fully developed. Type I 
fibres are also termed slow twitch. Type II fibres can be classed as fast twitch 
(MacIntosh, 2006). Type I fibres have larger numbers of mitochondria and 
contract slowly compared to type II. These do however have a larger capacity for 
aerobic metabolism and a higher fatigue resistance (MacIntosh, 2006). 
Type II fibres can be further subdivided. Type IIA fibres are relatively fatigue 
resistant with intermediate levels of glycolytic activity. Type IIB fibres contain 
smaller numbers of mitochondria leading to a limited capacity for aerobic 
respiration but a high capacity for anaerobic metabolism. Muscles with a larger 
proportion of these fibres are ideal for fine rapid movements (MacIntosh, 2006). 
Muscle is clearly still of much interest as it is hugely plastic. Muscle can 
hypertrophy after exercise but more importantly to our ageing population, there is 
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atrophy in muscle mass and decline in force generation through age known as 
sarcopenia which severely limits mobility. The cause of this is yet unknown 
although several hypotheses have been proposed (Rennie et al., 2004, Rennie, 
2009). 
1.2.2 Bone structure and function 
Bone is a highly specialised tissue which forms the skeleton with cartilage (Figure 
1.4). Like muscles, bone is pliable. Bones throughout life are formed, removed, 
modelled and remodelled numerous times (Bilezikian et al., 2008). Bones are 
needed to produce locomotion in tandem with the muscle. Bones are also a major 
source and store of calcium within the body (Smith and Wordsworth, 2005). 
Despite being in close proximity to muscles, the developmental pathway of bone 
is relatively distinct from muscle. 
Early bones are formed by mesenchymal stem cells which migrate from the neural 
crest and condense into appropriate clusters (Olsen et al., 2000). These cells first 
differentiate into chondrocytes at approximately embryonic day 11 and begin to 
produce cartilage templates for bone (Smith and Wordsworth, 2005). Although 
not fully understood, Transforming Growth Factor beta (TGFβ), Bone 
Morphogenic Protein (BMPs) and Fibroblast Growth Factors (FGFs) along with 
Sox9 are essential for this process to occur (Smith, Smith and Wordsworth, 2005).  
As the cartilage templates in the embryo increase in size, chondrocytes within the 
centre start to dehydrate, enlarge and calcify via production of alkaline 
phosphatase. This may be due to parathyroid hormone related peptide signalling 
(Chung et al., 1998). The increase in cell volume drives bone growth (Smith and 
Wordsworth, 2005). At this stage blood vessels form and invade the cartilage 
templates, forming the periosteum which contains osteoprogenitor cells later 
becoming osteoblasts. These cells form a bone collar to support the newly 
forming bone. These cells continue to enter the bone using the calcified inner 
matrix as scaffolds to produce trabecular bone via secretion of osteoid. 
Osteoclasts formed from the macrophage cell line enter via blood vessels to break 
down bone from the centre to create the bone marrow cavity. This process is 
continually active and allows for further bone growth and maintenance until after 
puberty (Smith and Wordsworth, 2005). 
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The final bone structure (in long bones) consists of a thick, dense outer layer of 
bone named the cortical bone, with the trabecular bone forming struts within this 
casing (Figure 1.5) (Smith and Wordsworth, 2005). 
Between 80-90% of the volume of cortical bone is calcified, under 25% of the 
volume of trabecular bone is calcified. This is due to the presence of other tissues 
such as blood vessels, fat and other connective tissues within the trabecular bone 
compartment. Although both compartments contain osteogenic cells, the 
trabecular bone compartment is the site of most cell activity and interaction with 
other tissues (Smith and Wordsworth, 2005). 
 
 
 
 
 
 
 
Fig 1.5 Schematic displaying the difference in position of cortical and trabecular 
bone. 
 
Once formed, bone undergoes remodelling events to counteract stresses and 
strains. Osteoblasts and osteoclasts are the cells primarily involved in this growth 
and remodelling of bone tissue. Their effects are controlled through multiple 
pathways involving both mechanical and chemical stimuli in a similar fashion to 
muscle cells. 
Osteoblasts work simultaneously with each other to synthesize collagen, 
osteocalcin and osteopontin as well as hydroxyapatite to produce the bone matrix. 
It is this matrix which provides both large compressive strength and elastic 
deformation (Smith and Wordsworth, 2005).  
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Osteoclasts are also present within bone and function to breakdown the bone 
matrix into component parts to release minerals such as calcium. This is achieved 
by releasing large amounts of hydrogen ions to acidify and dissolve the 
mineralised bone matrix (Smith and Wordsworth, 2005). 
Between these two classes of cells, bone is resorbed and formed to allow for 
modelling events. The cells involved in these events form bone multicellular units 
(BMUs) and comprise of osteoclasts cutting and absorbing into bone with 
osteoblasts following with new bone matrix, blood vessels and nerves (Smith and 
Wordsworth, 2005). This process can occur on both types of bone and it is 
estimated that approximately 20% of the bone surface is undergoing remodelling 
processes, with millions of BMUs occurring at any one time in a process that 
takes between 2-8 months (Smith and Wordsworth, 2005). 
A third class of bone cell is also present, the osteocyte. Although this is the most 
abundant cell located in bone (Bilezikian et al., 2008), both function and 
regulation are poorly understood. Osteocytes are formed from osteoblasts that 
become encased in the bone matrix they themselves are producing (Smith and 
Wordsworth, 2005). These cells remain viable and highly functional, with a half-
life of approximately 25 years.  
Osteocytes stay within space inside the matrix named lacunae with long 
protrusions called processes being found within canaliculi (Smith and 
Wordsworth, 2005). The processes are important in nutrient exchange as well as 
in mechanosensory mechanisms (Noble, 2008). Although the nature of these 
mechanisms has not yet been elucidated, it is thought that nitric oxide may play a 
role (Klein-Nulend et al., 2014). There are also theories suggesting the flow of 
fluid surrounding the osteocyte may be the method of mechanosensing 
(Verbruggen et al., 2014). It is proposed the osteocytes die via apoptosis (Figure 
1.6) (Smith and Wordsworth, 2005). 
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Fig 1.6 Schematic displaying function of bone cells during normal bone 
maintenance. External sources such as mechanical forces or hormonal 
responses trigger osteoclasts (OC) to break down bone. Following this, 
osteoblasts (OB) lay down new bone. During this bone laying, some osteoblasts 
are encased and become osteocytes (OCy). 
1.2.3 Tendon structure and function 
Tendons connect muscles to bone to facilitate locomotion and transmit forces 
(Figure 1.4). Although there are subtypes of tendons, the most useful are the 
energy storing tendons, such as the Achilles tendon in humans, allowing the 
attached muscles to generate greater force (Thorpe et al., 2012). 
Tendons are made up of parallel arrangements of collagen (mainly type 1 
collagen) interspersed with elastin, proteoglycans and other inorganic components 
such as copper and calcium (Lin et al., 2004). Collagen molecules are arranged in 
fibrils, these in turn arrange to form fascicles (Caldini et al., 1990). These 
fascicles are joined together in bundles by an endotendineum and groups of 
fascicles are bound by the epitenon (Caldini et al., 1990). Proteoglycans found 
along the length of the fibrils aid the tendon by providing resistance to 
compressive stress complementing the resistance of collagen fibrils to tensile 
stress (Raspanti et al., 2002). The turnover of tendon fibres is controlled by 
tenocytes, the fibroblast-like cell found within tendons. 
1.2.4 Joint structure and function 
Joints are the location where two or more bones meet and allow movement and 
provide some mechanical support during locomotion (Figure 1.4). Joints are 
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classified depending on how the bones are arranged to each other. In most cases 
the bones are not directly connected to one another and are surrounded by a 
synovial cavity and facilitated by an articular capsule and associated ligaments. 
Articular cartilage is located on both ends of the bones to facilitate free movement 
of the joint as well as essential shock absorbance whilst moving (Martini et al., 
2012). 
1.3 Pathophysiology of ageing in musculoskeletal tissues 
Ageing of certain musculoskeletal tissues in humans can occur as early as thirty to 
forty years of age and this occurs at a comparable time in the lifespan throughout 
a large proportion of species. 
Musculoskeletal ageing is a complex and highly intertwined process. It involves 
the loss of tissue and function in muscle, bone, tendons and ligaments as well as 
articular cartilage. This has effects on the level of physical activity (Hamrick et 
al., 2006). Reduced activity correlates with an increase in fat deposition which can 
further influence the ageing process (Wang et al., 2008). Not only is there a 
general loss of function with age, there are also distinct features that can be 
regarded as disease.  
1.3.1 Loss of muscle mass and function with age 
By the time a person reaches their 80s, they will have lost approximately 50% of 
their muscle mass (Faulkner et al., 2007). As muscle mass represents 60% of total 
body mass, this loss is clearly detrimental to each individual through reductions in 
locomotion, strength, co-ordination as well as more metabolic processes. It is to 
be noted that the more muscle mass a person has developed in earlier life, the 
longer a person can remain fully mobile (Pollock et al., 1997, Steen, 1988). 
Despite this, there is still not a current clinical definition of sarcopenia, due in part 
to the lack of standardised measurements for muscle function. Although muscle 
mass measurements are well defined, mass does not always correlate with 
function.  
Most studies use muscle mass, muscle strength or a functional measure of muscle 
capability through physical exercise as a marker, either alone or in any number of 
 14 
 
combinations. More recently a common use of grip strength, walking speed and 
muscle mass measurements have been used to determine if a patient has 
sarcopenia. A European working group produced guidelines to this end consisting 
of patients being aged 65 or over, displaying gait speed of less than 0.8m/s and 
have low muscle mass, with low grip strength being another deciding factor. 
Other co morbidities related to sarcopenia should also be factored in however 
such as cancer, heart disease, renal failure and strokes. From this definition we see 
incidences varying widely from population groups, incidence also varying 
dramatically when taking into account other recognised definitions of sarcopenia 
(Woo et al.). 
The consensus states however that loss of muscle mass is due to loss of individual 
fibres and eventual atrophy and weakening of remaining fibres, in particular type 
II fibres (Larsson, 1978) (Coggan et al., 1992). This leaves a larger proportion of 
type I fibres in muscles of older people. What compounds this muscle loss is the 
replacement of muscle with fat and connective tissues which disrupts muscle 
function (Taaffe et al., 2009). This loss of muscle mass and individual fibre loss 
has a direct impact on force production and overall strength which can also 
influence associated musculoskeletal tissues (Thom et al., 2007). There also 
appears to be a greater susceptibility of muscle to contraction-induced damage in 
the remaining fibres and an inability to repair the damage once it occurs (Close et 
al., 2005). Although the cause of this muscle fibre loss is still unknown, there are 
related events that may be involved such as inflammation, disease, genetics or as 
discussed next, the innervation of muscle.  
Nerve input to muscle motor units is an essential part of muscle contraction. It is 
the release of excitatory neurotransmitter from the nerve that potentiates the influx 
of calcium that lead to the muscle contraction. Denervation of these motor units or 
poor structure and transmission through neuromuscular junctions is evident with 
increasing age leading to a large decrease in force production (Finkelstein et al., 
1993). There are currently no known mechanisms identified as responsible for this 
deterioration. Animal models have provided some theories as to the cause of 
neuronal dysfunction. One of the most interesting studies has used transgenic 
mice with SOD1 removed at the whole body level as well as specifically in 
muscle or nerve, or re-introduced into the nerve in the whole body knockout 
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mouse (Jang et al., 2010). Whole body deletion of SOD1 leads to premature loss 
of muscle mass mimicking that of age-related sarcopenia (Jang et al., 2010). It has 
been shown that reintroducing SOD1 back into the nerves only is sufficient to 
restore function in both nerves and muscle (Sakellariou et al., 2014b). This would 
strongly suggest that age-related increases in reactive oxygen and nitrogen species 
occur in the nerves and that this potentially is the initiating factor in the loss of 
innervation. There are also decreases in anabolic signals and hormones such as 
IGF1 and conversely there are increases in catabolic signals which both combine 
to cause decreases in muscle mass (Barton-Davis et al., 1999). IGF1 is produced 
in response to growth hormones and is a key driver of muscle growth in 
particular. One way in which it is thought to achieve this is by improving muscle 
satellite cells’ ability to proliferate (Barton-Davis et al., 1999). However in 
environments with high levels of inflammatory markers, this ability is reduced 
and may, at least in part, be the cause of the age-related reduction in IGF1 
sensitivity (Barbieri et al., 2003). 
1.3.2 Age-related changes in tendons  
Age-related changes in tendons and ligaments centre on a change in collagen 
production and maintenance leading to a reduction of elasticity (Narici and 
Maganaris, 2006). Tendon cell function also changes with age with dramatic 
reductions in cell number (possibly due to increasing extracellular matrix) 
although the vast majority of this reduction in cell numbers has been proposed to 
occur earlier in life (between 2-9 months of age in the rat) (Nagy et al., 1969). 
However other studies show no changes with age (Thorpe et al., 2016). Studies 
have shown a decrease in tendon tissue turnover after late teens in humans 
(Heinemeier et al., 2013), (although there have been reports of small increases in 
tendon cross-sectional area (Magnusson et al., 2003)) and a likely decrease in 
strength (Connizzo et al., 2013). Inconsistent studies mean that no firm conclusion 
can be made. Although these are not major influential changes, together with a 
loss of force generation by the muscles, this may lead to a compounded effect on 
locomotion. This change in movement can further impact on balance and can 
increase the risk of falls within older people. The lack of human studies in this 
field mean no firm conclusions can be made on the age that changes occur within 
the tendon (Magnusson et al., 2003, Couppe et al., 2009). 
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1.3.3 Loss of bone mass and structure with age 
Bones lose strength as a result of loss of bone tissue, particularly around the 
trabecular bone which normally functions to provide strength and support, a 
condition known as osteoporosis. Thus, there is an increased risk of fractures with 
increasing age. 1 in 5 men over the age of 50 will have an osteoporosis induced 
fracture; between 50-70% of women will have an osteoporotic fracture (Statistics, 
2015). Osteoporosis was first recorded by Cooper in 1829 (Cooper, 1829) and a 
full description of the disorder given by Cooke in 1955 (Cooke, 1955). Despite 
this, the cause of the disorder is not yet fully understood. However, the close links 
between muscle and bone may suggest that age-related loss of muscle force and 
therefore loss of mechanosensation is a key mechanism in the age-related loss of 
bone. As with the muscle, bone also becomes less responsive to anabolic signals 
such as IGF1 and vitamin D and bones are affected by increases in inflammatory 
factors (Redlich and Smolen, 2012) which serve to reduce osteoblast numbers and 
increase osteoclast activity eventually shifting the balance of bone 
formation/resorption into a highly resorptive state (Redlich and Smolen, 2012). 
Trabecular bone appears to be more at risk of this change. The effect on each bone 
is unique, although it can be broadly split into two categories – bone thinning and 
bone erosion/deletion (Fig 1.7) (Smith and Wordsworth, 2005). The mechanical 
need for each trabecular bone may be the determining factor (Smith). The higher 
the bone mass present at earlier life, the later a person will display symptoms of 
osteoporosis suggesting that the rate of bone loss is similar for all individuals. 
1.3.4 Age-related changes in cartilage 
Along with age-related changes in bone tissue, articular cartilage also diminishes 
and with it there is a large reduction in shock absorption within the joints. This 
breakdown exposes bone surfaces to each other and can lead to painful joints (Li 
et al., 2013). Inflammatory markers and cytokine changes may also be associated 
with joint conditions such as osteoarthritis which can also damage the underlying 
bone (Sokolove and Lepus, 2013). 
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Fig 1.7 Differential age-related loss of trabecular bone showing both loss of bone 
through thinning and loss through deletion of trabecular bone. Also displayed is 
age-related thinning of cortical bone (Smith and Wordsworth, 2005).  
1.3.5 Other age-related changes that affect musculoskeletal tissues 
Although the changes outlined above are the most influential concerning 
musculoskeletal tissues, there are other age-related changes that can impact these 
tissues and contribute to the detrimental changes. Fat tissue is known to produce 
numerous factors including cytokines that can alter the inflammatory environment 
of nearby tissues (Bucci et al., 2013). During increasing age, fat deposition is 
increased in the body and can integrate into both muscle and bone tissues (Bucci 
et al., 2013). These fat depositions can then produce local detrimental effects 
compounding the already negative environment. 
Elevated pro-inflammatory cytokines and increases in reactive oxygen species 
systemically can also influence musculoskeletal tissues and have been widely 
discussed in the literature and will be further discussed later. Age-related changes 
in hormones are also prevalent and particularly influential in bone health and have 
been widely discussed elsewhere (Riggs, 2000, Kamel et al., 2002). Furthermore, 
reduction in neural signalling and reduction in small blood vessels also occur 
through age and have additional effects for all musculoskeletal tissues (Faulkner 
et al., 2007). 
It is clear that ageing of musculoskeletal tissues is a complex and intertwined 
process. There are still many gaps in our knowledge that can only be filled with 
basic, clinical and translational approaches to research.  
 
 18 
 
1.4 Muscle-bone cross-talk 
Muscle bone cross-talk has been long proposed since the late 1800s (Wolff, 
1988). The interactions between muscle and bone through life and the changes 
related to ageing display a close link between the two tissues above a physical 
association due to proximity. 
Some links are clear. As discussed previously, both tissues originate in close 
association from somites during early development and both reach their peak 
mass through shared environmental and physical stimuli, albeit at potentially 
different times. For example, increases in both muscle and bone mass are tightly 
correlated during bouts of exercise, conversely both tissues atrophy during times 
of disuse at similar rates (Wolff, 1988, Rubin, 1984). Even prior to birth, muscle 
contractions are needed for bone development (Bren-Mattison et al., 2011). 
Without this, bone develops without being mechanically suitable for movement. 
In knockout mouse models were skeletal muscle does not develop (MyoD
-/-
, 
Myf5
-/-
) foetuses are born with deformed bones lacking mineralisation (Gomez et 
al., 2007).  
Whether changes are brought about by one tissue or both is still contentious. 
Many studies suggest muscle has a dominant role over bone in synchronicity of 
the two tissues (Bren-Mattison et al., 2011, Jang et al., 2010). 
Regardless of possible synchronicity, both tissues share a number of signalling 
pathways in development and throughout life. An example of this is growth 
hormone and IGF1 which both cause proliferation and differentiation of 
osteoblasts and myoblasts therefore increasing mass in both tissues (Alzghoul et 
al., 2004, Banu et al., 2003). Wnt signalling is also important in development of 
both tissues (Rudnicki and Williams, 2015). These signalling molecules however 
are by no means specific signalling molecules to muscle and bone.  
There are more specific examples of a close link between muscle and bone. The 
gross structures of long bones within the body are often unique and show various 
asymmetries through differential bone deposition (Sharir et al., 2011, Auerbach 
and Ruff, 2006). This has been described to be due to site-specific mechanical 
stress and strain laid on the bone from the attached muscle (Vickerton et al., 
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2014). This works in an attempt to counteract the weakest parts of the bone to 
gain overall strength and stability (Vickerton et al., 2014). The forces applied to 
bone from muscle far outweigh the environmental forces in order to generate 
movement. Strains applied to bone above 3000 microstrain (A strain expressed in 
terms of parts per million) will typically cause bone formation, strains under 500 
microstrain cause bone resorption (Rubin and Lanyon, 1985, Burger and Klein-
Nulend, 1999). It is theorised that the mechanotransduction occurs in the 
osteocyte in response to changes in fluid movement along the bone (Burger and 
Klein-Nulend, 1999). Tail suspension models in mice have been used to develop a 
model of inactivity separate from disrupting the nerves, which may have a 
separate effect on the bones (Roland et al., 2005, Amblard et al., 2003). Although 
muscles were still able to contract in this model, the removal of mass bearing 
activities can lower the force generated by muscles. Within 24 hours there were 
signs of repression of actin and myosin and after 10 days this model had showed 
reduction in both muscle and bone mass (Roland et al., 2005). These effects are 
reversed when the tail suspension has ceased (Roland et al., 2005). Only load 
bearing exercise is capable of affecting the skeleton – swimming has been shown 
to have no effect on bone mineral density even with improvements of shoulder, 
back and grip strength (Courteix et al., 1998, Emslander et al., 1998). 
Experiments have shown that there is more detail to the cross-talk of muscle and 
bone then a simple application of forces. Muscle paralysis can decrease bone mass 
even when the muscle is loaded (Warden et al., 2013). This would suggest another 
level of interaction. More subtle links can also be found and often become more 
prominent during ageing. During sarcopenia a number of pathways all act to 
reduce the overall muscle mass. These include Akt-mTOR signalling, 
inflammatory cytokines, NFkB, myostatin, increases in reactive oxygen species 
and more (Meng and Yu, 2010). As mentioned above there are still uncertainties 
as to the cause of sarcopenia and sarcopenia is often accompanied by 
osteoporosis. Many of the pathways that impact on muscles ability to maintain 
mass also impact osteoblasts and the potential to increase bone mass e.g. oxidative 
stress (Bai et al., 2004).  
Although there is substantial evidence for a close relationship between both 
muscle and bone, a growing theory is that further communication occurs between 
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these tissues through release of signalling molecules, creating the possibility of an 
endocrine loop that directly concerns muscle and bone. This theory arose through 
the study of bone fracture healing rates. The rate is accelerated when surrounded 
by fully functioning muscle. In mouse studies the introduction of muscle 
coverings (Harry et al., 2008) or minced muscle (Zacks and Sheff, 1982) are 
beneficial to fracture healing and this beneficial effect can be blocked by small 
pore filters. This would suggest other external signals could be converted within 
the muscle to induce further signals influencing bone biology (Schnyder and 
Handschin, 2015). These external signals are termed myokines. 
One such molecule released from muscle is irisin which has been recently shown 
to have a possible role in this bone-muscle cross-talk. Researchers showed that 
irisin injected systemically can elicit an anabolic response in the cortical aspect of 
bone only (Colaianni et al., 2015). This was through increased activation of 
osteoblasts (Colaianni et al., 2015). There is currently no evidence that this 
molecule is present within humans and as with many of the reported myokines, is 
the subject of much controversy.  
It should however be noted that most data published thus far on muscle bone 
crosstalk is purely correlative and hypothetical. Bone has a surrounding 
membrane that physically separates bone and muscle tissue called the periosteum 
(Allen et al., 2004). There are some doubts as to whether even the smallest 
myokines could cross this bone membrane and diffuse into the cellular levels to 
affect a response (Hamrick et al., 2010). The periosteum has been described as 
being completely sealed in some papers or semi permeable using hydraulic 
mechanisms to facilitate movement (Qin et al., 2003, Gardinier et al., 2010), a 
hypothesis which may have been partially confirmed with irisin (Colaianni et al., 
2015). Recent studies have shown that the periosteum will act as a semi-
permeable sieve for any molecules under 40kDa (Lai et al., 2014). This study also 
showed that penetration times for potential myokines range from 10 seconds to 6 
hours and this would potentially allow for myokines to penetrate and reach bone 
targets (Lai et al., 2014). The range of charges and structures of each myokine is 
an influencing factor on time of transport. This also gets further complicated with 
the addition of fat and collagen deposits with increasing age (Fasshauer and 
Bluher, 2015). 
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1.4.1 Muscle as a source of chemical signals 
Muscle is a secretory organ capable of releasing a variety of compounds. These 
factors, termed myokines, may act in an autocrine, paracrine or even endocrine 
manner to facilitate changes in the body (Schnyder and Handschin, 2015). Studies 
suggest that muscle itself has the ability to produce several hundred different 
factors. 
The first protein found to be secreted by muscle was myostatin (Allen et al., 
2008). This protein has many wide ranging functions (Elliott et al., 2012). 
Myostatin is principally concerned with inhibiting muscle growth and 
differentiation (Elliott et al., 2012). It is also involved in metabolism and 
maintaining adipose tissue mass (Allen et al., 2011). Myostatin is suppressed by 
aerobic and strength exercise (Allen et al., 2011, Hittel et al., 2010). It is therefore 
clear to see that during age, myostatin may play a greater role, as less activity 
would mean possible increases in myostatin levels further preventing muscle 
maintenance. 
The first myokine found to be secreted into the bloodstream after muscle 
stimulation was the cytokine interleukin 6 (IL6) (Pedersen and Febbraio, 2008). 
Levels of IL6 in the plasma can rise up to 100 fold in response to exercise and 
increases proportional to the level of exercise (Febbraio and Pedersen, 2005). This 
occurred without any evidence of muscle damage, indicating that IL6 may have a 
role in signalling separate to the IL6 mediated pathways in macrophages (Scheller 
et al., 2011).  
The function of IL6 is not certain and there is compelling evidence suggesting 
both positive and negative effects. The theorised beneficial role for IL6 signalling 
was to mediate metabolism within the muscle to improve muscle mass (Serrano et 
al., 2008). IL6 release was greater when muscular levels of glycogen are low; 
glucose intake during exercise reduces IL6 release (Febbraio et al., 2003). There 
may also be a role for IL6 in anti-inflammatory responses related with exercise, in 
particular reducing TNFα levels (Starkie et al., 2003). However chronic release of 
IL6 directly induces muscle loss (Scheller et al., 2011). Of interest to bone health, 
IL6 released from mechanically stimulated myotubes in culture can improve 
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osteoclastogenesis and therefore increase bone resorption (Juffer et al., 2014). IL7 
has a similar double edged role in bone formation (Lee and Surh, 2005). 
Some other notable myokines are also produced by muscle, often in relation to 
exercise. Brain derived neurotropic factor (BDNF) is produced within the muscle 
however this has not been shown to be released into circulation (Pedersen, 2011). 
BDNF has roles in the oxidation of fat tissue and also has positive effects on 
neurological tissue to improve innervation (Pedersen, 2011). IL15 overexpression 
has also been shown to affect fat tissues when released into the circulation 
(Pedersen, 2011); there is also an increase in bone mass in IL15 overexpression 
transgenic mouse models (Quinn et al., 2009). Decorin is a leucine rich 
proteoglycan secreted by muscle during contraction (Kanzleiter et al., 2014). 
Decorin is involved in muscle hypertrophy and actively reduces atrophy pathways 
in the muscle by binding to and blocking myostatin (Kanzleiter et al., 2014). 
Other proteins include FGF2, FGF21, IGF1, IL4, calprotectin and irisin (which 
has been described above) (Pedersen, 2011). Whether these proteins are released 
in sufficient amounts to affect other tissues remains unclear.  
1.4.2 Bone as a source of chemical signals 
Classically bone has been seen as an inert, structural organ within the body. More 
recent advances however have shown the bone as a contributor to whole body 
physiology through secretion of proteins into the blood stream which in turn play 
a role in metabolism. The key cell to this appears to be the osteocyte (Dallas et al., 
2013). There are some in vitro studies suggesting that osteocyte like cells will 
express factors such as IL6, VEGF (Juffer et al., 2012, Kaji, 2013) and IGF1 
(Sheng et al., 2013) that are known to influence muscle mass. 
Osteocalcin, in particular undercarboxylated-osteocalcin (OCN), is an osteoblast-
derived hormone shown to increase muscle sensitivity to insulin and can increase 
mitochondrial number in mice (Lee et al., 2007, Ferron et al., 2012). OCN 
knockout mouse models show reduced muscle mass and reduced running ability 
indicating an important role for this hormone (Brotto and Abreu, 2012). In 
knockout models, the bone defects appear before the muscle loss, indicating that 
at least in this model, OCN may play an important role in maintaining muscle 
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mass (Tagliaferri et al., 2015). This suggests disruption of the bone can feedback 
to muscle. 
1.5 Current treatment options to maintain musculoskeletal structure and 
function in older people 
Despite the increase in the aged population and the work undertaken in this field 
of research, the current treatment options for combating age-related 
musculoskeletal conditions are few and often ineffective. What is detrimental to 
work in this field is that older people can have decreased ability to process drugs, 
thus a normal dose of medicine can build-up in the body leading to an adverse 
reaction. Adverse Drug Reactions (ADRs) account for 6.5 per cent of hospital 
admissions for older people (Pirmohamed et al., 2004). 
Treating sarcopenia currently appears to be a combination of improved diet and 
resistance training to increase muscle mass with some improvements seen 
although the longer-term effects of such treatments are unclear (Waters et al., 
2010). A major problem with treating sarcopenia is that there is currently no 
clinical definition of sarcopenia (Santilli et al., 2014).  
A common age-related joint problem is osteoarthritis. Treatment options here are 
similar to those seen in sarcopenia with gentle exercise and improvements in diet 
being the major treatments (Messier et al., 2013). Above these lifestyle 
interventions the NHS recommend a steady increase in pain management from 
paracetamol to codeine depending on length of disease state and level of pain 
(NHS, 2017). When painkillers are no longer effective enough, intra-articular 
corticosteroid injections are advised however a patient will only be given up to 
three injections per year. The only definitive treatment option is joint replacement 
(Fortin et al., 2002). 
Tendon problems can be wide ranging from acute tears from excessive force, or 
inflammatory conditions can develop from overuse. The outcome of the repair 
depends highly on the location of the injury. According to the NHS, tendon 
injuries are treated in a similar method to joints with rest and pain management 
until surgery becomes a viable option (NHS, 2017). There has been very little 
work on finding successful treatments to aid tendonopathies.  
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According the NHS, treatment of osteoporosis mainly consists of drugs called 
bisphosphonates which are thought to reduce the rate of bone break down within 
the body (NHS, 2017). These drugs are given as either tablet or injection and 
improvements often not seen until between 6 and 12 months after commencing 
treatment. The possible length of treatment is up to 5 years (Diab and Watts, 
2013). This treatment does however have side effects including irritation of the 
oesophagus, difficulty swallowing, stomach pain and in rare instances 
osteonecrosis of the jaw (Kennel and Drake, 2009). Further treatments include 
strontium ranelate which is known to cause nausea and diarrhoea (Cianferotti et 
al., 2013); selective oestrogen receptor modulators which can cause menopausal 
symptoms and can rarely cause deep vein thrombosis (Diez-Perez, 2006), 
parathyroid hormone which can be prescribed in special cases where other 
treatments are not showing improvement, and an improvement of diet to include 
more calcium and vitamin D. More detail on each treatment plus treatment 
options that are not currently used in the UK will now be described. 
1.5.1 Current bone anabolic agents 
1.5.1.1 Parathyroid hormone 
Parathyroid hormone (PTH) is a naturally occurring hormone found within the 
blood of reptiles, birds, mammals and fish. This hormone was first recorded in 
experiments carried out in the early 1970s. It is produced and secreted by the 
parathyroid glands chief cells as a polypeptide 84 amino acids in length, 9.4 kDa 
in mass (Jin et al., 2000). PTH has a half-life in serum of approximately 4 minutes 
(Bieglmayer et al., 2002). The normal concentrations of PTH range from 8-
51pg/ml in humans (Jin et al., 2000).  
PTH is primarily released in response to low serum levels of calcium recorded by 
calcium sensitive receptors in the parathyroid gland. Small decreases in 
magnesium and increases in phosphate are also triggers for PTH release (Poole 
and Reeve, 2005). 
PTH acts through two types of receptor to facilitate different outcomes. PTH 
receptor 1 is found in high concentrations in the bones and kidneys. PTH receptor 
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2 is found within the central nervous system, testes, placenta and pancreas 
(Martini et al., 2012). 
In bone, PTH causes the release of calcium from reservoirs contained within the 
bone (Poole and Reeve, 2005). This is achieved through augmentation of the 
normal bone turnover processes. PTH binds to osteoblast cells (functioning to lay 
new bone) which in turn increases the release of Receptor Activator of Nuclear 
Factor kappa-B Ligand (RANKL). RANKL binds to RANK on premature 
osteoclast cells (functioning to resorb bone), causing fusion and maturation of the 
premature osteoclasts, in turn increasing bone resorption (Poole and Reeve, 2005). 
Short-term PTH exposure will however activate osteoblasts more than osteoclasts 
leading to a net increase in bone mass (Poole and Reeve, 2005).  
In the kidneys, the action of PTH binding to PTHr1 enhances the reabsorption of 
the minerals calcium and magnesium from the distal tubules of the thick 
ascending limb increasing the levels of calcium in the circulation (Smith). 
The only current anabolic therapy for osteoporosis is a recombinant form of PTH 
named Teriparatide (PTH1-34) (Eli Lilly and Company, Indiana, USA). 
Teriparatide has been FDA approved since 2002 for use in osteoporotic men and 
high risk postmenopausal women and is commonly administered via daily 
intramuscular injection. Teriparatide has some adverse effects including nausea, 
headaches and some limb pain. There is also a slight risk of osteosarcoma (1 in 
100,000) (Rizzoli and Reginster, 2011). 
Despite being used clinically for 12 years, there is still much debate surrounding 
the method of administration of Teriparatide, the dose and whether combination 
therapies are more beneficial. The number of publications on the effect of PTH 
particularly in mice (through varying experimental designs) is still escalating. 
Since 2000, a large amount of research has been undertaken to understand both 
the mode of action for PTH, and the best method of administering the drug to 
maximise the outcome for patients. Focusing on mouse studies in particular there 
has been little progress, due in part to differing experimental designs. However, 
some interesting findings have been reported. 
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Between 2000 and 2002 when Teriparatide was first introduced, only a small 
number of papers were published detailing the effect PTH has in “wild 
type”/normal mouse. In 2002, Iida-Klein et al. described the site-specific action of 
PTH in C57BL/6J mice (Iida-Klein et al., 2002). Here the authors used 10 week 
old female C57BL/6J mice and subjected them to a subcutaneous dose of 40ug/kg 
human PTH (1-34), for 5 days a week for both 3 and 7 weeks. This study showed 
an anabolic effect of PTH on bone within 2 weeks of treatment with increased 
bone mineral density (BMD) displayed in the femur and tibia. Using 
histomorphometric analysis of the tibia, clear increases in trabecular number, area 
and width were shown with increases in osteocalcin, tartate-resistant acid 
phosphatase and RANKL. The lumbar spine however only showed significant 
increases in these measures at the 7 week time point. This study clearly shows a 
site-specific effect of PTH (Iida-Klein et al., 2002). 
The study of Mohan et al. (2002) compared the actions of PTH analogues to 
improve the increases in bone mass. This study compared the effects of treatment 
of PTH (1-34) with PTH (1-31) and PTH (2-34) in mice via daily subcutaneous 
administration of the PTH analogues at 80ug/kg for 15 days (Mohan et al., 2000). 
This was then followed up with a 22 week study using only PTH (1-34) and PTH 
(1-31). This work showed that PTH (1-34) was by far the best analogue for 
increasing bone mass, however, with each type exhibiting differing effects on the 
bones studied (Mohan et al., 2000). 
A key paper by Masiukiewicz (2000) showed that the cytokine interleukin (IL)-6 
is an important mediator in PTH action (Masiukiewicz et al., 2000). This group 
show that IL6 promotes osteoclastogenesis (formation of new osteoclasts) which 
in turn leads to bone resorption. When oestrogen-deprived female mice were 
given PTH infused for 5 days, IL6 was significantly increased with a greater 
increase in bone reabsorption markers (Masiukiewicz et al., 2000). Treatment 
with oestrogen prevented this increased response (Masiukiewicz et al., 2000). 
This combination study showed that although PTH is a useful drug, its action can 
be affected by a large number of factors. 
The second of these studies by Samuels et al (2001) used 17beta-estradiol (E2) in 
combination with PTH (Samuels et al., 2001). Ten week old female mice were 
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given 10µg/kg of PTH and 40µg/kg E2 and showed that in combination, mice 
displayed a greater increase in bone mineral density of the femur when measured 
with Dual-energy X-ray absorptiometry (DEXA) scan with increased cortical and 
periosteal bone formation (Samuels et al., 2001).  
A more recent study (Feng et al., 2015) showed an increase in PTH effectiveness 
(80μg/kg per day) combined with high calcium levels (2% of diet) (Feng et al., 
2015). This study showed significant increases in bone mineral density with 
increased osteoblast activity and viability time (Feng et al., 2015). However, mice 
used in this study were 4 weeks of age, so this study has not shown whether this 
action is enough to maintain bone mass or repair age-related declines in bone. 
Taking these latter studies together, we see that although PTH (1-34) is a highly 
effective drug for increasing bone mass, female hormones are needed to improve 
the effect. 
Other studies have caused confusion within the field due in part to varied 
experimental designs and outcome measures. Some similarities can be drawn 
however. The majority of papers published since 2001 have used female mice, 
usually under the age of five months. These studies all showed an improvement in 
bone quality and mass but the relevance in terms of osteoporosis is unclear.  
Only two papers published since 2000 have used old mice in a study of PTH 
action. Knopp et al (2005) studied the effect of daily subcutaneous injections of 
95ng/kg PTH for 4 weeks in C57BL/6 mice aged 3 and 18 months (Knopp et al., 
2005). This study showed that through this regime, the action of PTH was more 
pronounced in the old mouse, with particular effects in the spine (Knopp et al., 
2005). Jilka et al (2010) showed similar increases in the spine as well as the femur 
(Jilka et al., 2010). One further finding was that PTH appeared to reduce cellular 
reactive oxygen species generation in the bones of old mice. Here it was 
hypothesised that PTH had a greater action in older mice due to the higher 
oxidative stress found within tissues (Jilka et al., 2010) which is also seen in many 
tissues of aged mammals and different species. 
The effects PTH appear to have in younger mice cannot be fully extrapolated to 
an older mouse due, in part, to the severe age-related changes these mice undergo 
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in all tissues. There should be care when choosing animal models to study with a 
greater use of old animals. 
Despite the large volume of research in the wider PTH field, less significant 
progress has been made in terms of mouse studies. It is clear however that 
attempting to study an ageing phenomenon in younger mice does not provide 
relevant answers. This may also explain why PTH is currently not widely used as 
a treatment option and rarely prescribed in the UK.  
Recently, interest in PTH has been revitalised following work detailing the use of 
PTH in tendon repair. Lee et al. (2015) showed significant increases in tendon 
extracellular matrix deposition combined with increased fibre organisation and 
tensile strength of the repairs with daily subcutaneous injections of 40ug/kg (Lee 
et al., 2015). However the mice used where aged between 6 and 8 weeks of age 
and so more studies are required to confirm these effects in old age. 
1.5.1.2 Bisphosphonates 
Bisphosphonates are a further class of osteoporosis drugs which are a family of 
compounds sharing two phosphonate groups. Bisphosphonates can be further 
divided into two classes, non-nitrogen containing and nitrogen-containing 
bisphosphonates. Bisphosphonates work to encourage osteoclast apoptosis, 
slowing the loss of bone. These drugs achieve this effect by mimicking the 
structure of pyrophosphate, an important enzyme in cells, and target bone by 
preferentially binding to calcium (van Beek et al., 2003). The bisphosphonate is 
ingested by osteoclasts during bone turnover (van Beek et al., 2003). Non-
nitrogen containing bisphosphonates are metabolised by the osteoclasts and 
competes with ATP, eventually reducing the cells’ ability to respire, leading to 
apoptosis (Frith et al., 1997). Nitrogen-containing bisphosphates bind and block 
farnesyl diphosphate synthase, an enzyme in the HMG-CoA reductase pathway 
(van Beek et al., 2003). This in turn disrupts protein trafficking within the cell. 
These drugs may also disrupt lipid modification of important cell signalling 
proteins (van Beek et al., 2003). 
Bisphosphonates were first used in the 1960s for bone disorders, however it was 
not until the 1990s when the first commercial drug was released for use (Shinkai 
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and Ohta, 1996). There are currently two bisphosphonate drugs widely used for 
the treatment of osteoporosis, alendronate (Merck, Massachusetts, USA) and 
risedronate (Warner Chilcott, New Jersey, USA). Zoledronate (Novartis, Basal, 
Switzerland) has also been in use from 2007.  In recent literature, alendronate has 
been the most studied, however the majority of studies in mice have been with a 
combination of drugs at varying concentrations and differential experimental 
designs. 
These studies provide a valuable insight into how best to use bisphosphonates for 
the treatment of osteoporosis. When alendronate is given in combination with 
PTH, an increase in bone mineral density (Samadfam et al., 2007), an 
enhancement of the beneficial effects of PTH alone (Yamane et al., 2009) and 
evidence that alendronate is site-specific with synergistic effects with PTH in the 
spine but additive effects in the femur is seen (Johnston et al., 2007). 
There is some conflicting evidence. Alendronate appears to blunt remodelling of 
the trabecular bone when combined with PTH (Yamane et al., 2009) but was 
shown to improve trabecular bone mineral density when combined with vitamin 
K2 (Sasaki et al., 2010). 
Risedronate has been less studied. As with alendronate, risedronate has only been 
examined in combination with other drugs or treatments. Prior treatment with 
vitamin K2 significantly improved the action of risedronate, particularly in the 
femur (Matsumoto et al., 2009). Risedronate is capable of preventing and 
reversing the deleterious effects on bone of both glucocorticoids (Balooch et al., 
2007) and lipopolysaccharides (LPS) (Kwak et al., 2009). 
Since 2000, little research has been published looking in depth at the actions of 
bisphosphonates in mice. Publications show large variations in experimental 
design and the relevance is diminished by using younger mice. Although the drug 
is effective and combination therapies appear to increase these benefits, until 
larger more detailed studies have been undertaken in aged animals, there cannot 
be direct correlations between these findings and the potential for the treatment of 
the human disease. 
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1.5.1.3 Sclerostin 
Sclerostin is a protein consisting of 213 amino acids and secreted by osteocytes 
found within the bone matrix (Winkler et al., 2003). The function of Sclerostin 
has only recently been alluded to; it appears to bind to the low-density lipoprotein 
receptor related proteins 5 and 6 (Li et al., 2005), members of a family of 
transmembrane receptors. 
Sclerostin works to inhibit the Wnt signalling pathway and thus decrease bone 
formation by osteoblasts in a negative feedback loop (Fig 1.8) (Winkler et al., 
2003). The production is inhibited by the actions of parathyroid hormone, loading 
and some cytokines and the production is increased via calcitonin (Bellido et al., 
2005). 
 
 
 
 
 
 
 
 
Fig 1.8. Action of Sclerostin to prevent bone formation in the osteoblast. 
Antibodies to neutralise the presence and effect of Sclerostin are currently being 
developed for use in osteoporosis and associated bone disorders. Although not 
expected to reach the market until at least 2017, pre-clinical trials are ongoing 
with an anti-Sclerostin antibody (Romosozumab, Amgen) and have shown 
positive results. 
Research in mice using inhibitors of Sclerostin has only become prominent in the 
last 10 years. Despite this, many papers clearly show one such inhibitor, 
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Romosozumab, can be a very powerful drug in reversing the effects of 
osteoporosis (Graeff et al., 2015). 
Some of the earliest studies involving Sclerostin used mouse knockout (KO) 
models. Two papers using the KO models (Li et al., 2008, Lin et al., 2009) 
showed that whole body knock out Sclerostin increased bone mineral density and 
bone volume with increased bone formation rate. These models were also resistant 
to mechanical unloading-induced bone loss. 
Further work using antibodies to reduce Sclerostin have been increasing in 
popularity and form the basis for ongoing clinical trials. These studies clearly 
show increase in bone strength and volume. There were also improvements in 
trabecular bone strength and mass. There was a higher force and maximum load to 
failure with some extra benefits in protecting the articular cartilage and increased 
fracture repair. Roschger, et al. 2014 found however that in a Col1a1 mouse 
model, anti-Sclerostin has a reduced effect in more severe disease states 
(Roschger et al., 2014). 
Although the majority of this work has focused on differing mouse models, the 
benefits with anti-Sclerostin antibody therapies are clearly defined. As with other 
studies, differing experimental designs make drawing firm conclusions difficult 
however the improvements in bone structure and function seen in short time 
frames are promising. It is hoped that future work in mice can complement the 
ongoing human trials to produce a highly beneficial drug treatment. 
1.5.1.4 Non-Pharmacological Interventions  
Bone is mainly built upon a bone matrix consisting of both organic and inorganic 
materials. Considering the process of bone formation, resorption and remodelling, 
the diet provides a large amount of essential vitamins and minerals necessary to 
facilitate this.  
The bone mineral content or inorganic bone matrix is formed around a mineral 
form of calcium named hydroxyapatite. Hydroxyapatite consists of calcium and 
phosphate mineral ions. The organic portion of bone matrix is primarily made up 
of type 1 collagen. Vitamin C has an important role in the synthesis of collagen 
through its action on the collagen precursor procollagen.  
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The need for correct collagen formation and functional inorganic matrix is made 
clear when looking at disease states. Both osteogenesis imperfecta and 
chondrodysplasias are conditions affecting the skeleton caused by mutations in 
collagens (Smith and Wordsworth, 2005). 
Bone remodelling is a continuous process throughout life. Approximately 10% of 
the adult skeleton is remodelling every year. One of the main triggers for this 
bone remodelling is calcium homeostasis. At times of low calcium in the diet, 
calcium is released from the bones through PTH action described previously, 
when calcium is high in the bloodstream bone formation occurs to hold calcium in 
the mineral form to lay new bone matrix (Smith and Wordsworth, 2005). 
Another vitamin needed from correct bone structure and function is vitamin D 
(Lips and van Schoor, 2011). Vitamin D has a major role in the intestines to allow 
efficient calcium absorption by the intestines. Although vitamin D can be 
synthesised through sunlight exposure, in countries such as Britain, Russia and 
other Northern European countries, exposure is generally not sufficient and 
skeletal conditions such as rickets or osteomalacia can occur. Vitamin D can be 
found within the diet and further supplementation or fortification has been used in 
the past to improve dietary levels (Lips and van Schoor, 2011). 
Early in 2000, Kodama, et al (2005) published a study detailing the effect 
calcium-free diets have on the skeleton of two wild-type mouse strains (C3H/HeJ 
and C57Bl/6) (Kodama et al., 2000). Over a course of 2 weeks, femur mass 
decreased along with rate of bone formation. This effect was reversed when 
calcium was reintroduced to the diet (Kodama et al., 2000). Kasukawa, et al 
(2003) using IGF1 knockout mouse models, showed that with a low calcium diet 
for two weeks, that loss of IGF1 exacerbates the effect of calcium depletion 
(Kasukawa et al., 2003). It was also shown from this work that PTH levels were 
increased and vitamin D concentrations were reduced suggesting a deficiency 
(Kasukawa et al., 2003). This work was followed up by Niziolek, et al (2009) who 
used rapamycin (a downstream IGF1 inhibitor) for 6 weeks (Niziolek et al., 
2009). This group showed marked increases in Trap5b (a bone resorption marker) 
and suppression of the anabolic effects of PTH (Niziolek et al., 2009). 
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IGF1 is known to cause hypertrophy in a large number of cell types including 
those found in bone (Sheng et al., 2014). A number of sources claimed that large 
amounts of IGF1 could be found in deer antler extracts associated with its fast 
growth. Antler has been fed to 2 month old female SAMP8 mice (Chen et al., 
2007) in order to test the effect of increased IGF1. The extract was introduced into 
the diet of ovarectomised mice for 15 months and showed opposite effects to the 
IGF1 KO studies (Kasukawa et al., 2003). Chen et al, 2007 showed that the 
decreases in bone density and calcium contents were maintained with antler 
extract and that PTH levels were moderated. 
The effect of increases in the protein content of the diet on bone tissue has also 
been studied. Increased collagen levels in diet given to mice following 
ovariectomy were shown to reduce bone loss and improve cortical thickness 
(Guillerminet et al., 2012). Given prior to ovariectomy, increased collagen was 
shown to prevent bone loss altogether (Rouy et al., 2014). When diets were 
replaced with soy protein and given to mice there was reduced cortical and 
trabecular bone thickness reduced bone volume and reduced rate of bone 
formation (Rouy et al., 2014). These studies demonstrate the need for an 
appropriate level of protein in the diet to maintain bone mass. 
Due to the components of bone, plant and vegetable extracts have been examined 
for beneficial effects on bone. The benefit of using plants and vegetables is that 
this would allow for a non-pharmaceutical treatment option. Polycan, a beta 
glycan polysaccharide extracted from yeast, suppressed the ovariectomy 
associated decreases in bone mineral content, density, and bone thickness and 
decrease numbers of osteoclasts after 4 weeks of 125mg/kg (Shin et al., 2007). 
The detrimental effects of low calcium diets can be reversed with high levels of 
sap from the Acer trees (known to contain extremely high levels of calcium) when 
given for 7 weeks (Lee et al., 2008). Dried plum extract was used at 25% of 
normal diet for 6 months in both 6 and 18 month old mice (Halloran et al., 2010). 
This study showed a 50% increase in bone volume and increase in total bone. 
Less concentrated extract resulted in the same effect in the younger group 
(Halloran et al., 2010). 
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Vitamins and minerals play an important role in bone quality and strength. 
Vitamin D in particular is necessary in the absorption of calcium into the body. A 
study in 4 month old mice given 18pmol/day of vitamin D for 6 weeks showed an 
increase in bone volume and quality and increases in circulating bone formation 
markers indicating that added vitamin D can facilitate the formation of new bone 
(Duque et al., 2005). Vitamin K2 has also been shown to improve bone mass and 
strength, in particular, when given in combination with other known bone 
anabolic agents (Matsumoto et al., 2009, Sasaki et al., 2010). Another vitamin, 
vitamin B12 may, in early life, aid maintenance of bone mass and in the growth 
and development of bone (Roman-Garcia et al., 2014). Nutrients such as 
magnesium and selenium are also required for bone formation. Two studies using 
low levels or none at all in the diet led to decreases in osteoblast numbers, loss of 
trabecular bone and bone volume as well as increases in bone resorption markers 
(Rude et al., 2003, Cao et al., 2012). 
It is evident that maintaining a healthy and balanced diet throughout life can at 
least partially counteract the negative ageing effects of a poor diet on bone and 
could improve bone mass in older people. This may be an attractive alternative to 
drug interventions, or complementary therapies to modulate and enhance drug 
effects. The converse is also evident, poor diets can have a greater detrimental 
effect then that of ageing alone. 
1.5.1.5 Nitrates 
Following on from the recent interest in dietary interventions for use in improving 
bone health (along with other tissues); dietary nitrates have shown potential due to 
the recent increase in popularity within athletes and sports nutritionists.  
The active molecule of interest is nitric oxide which is now known to be achieved 
through stepwise reductions from nitrate. This appears to be facilitated through 
commensal bacteria in the oral cavity of mammals. The common effect of 
conversion to NO is to modulate blood flow but it has been shown that the body 
can store and recycle the nitrate-nitric oxide products. 
The most common source of nitrates is from the diet with leafy green vegetables 
being particularly high in nitrates (van Velzen et al., 2008). The nitrate is actively 
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taken up into the blood via the salivary glands whereby it is concentrated 10-20 
times within the saliva. Approximately 25% of nitrates are taken up this way. 
Whilst remaining in the oral cavity, anaerobic bacteria containing nitrate 
reductase enzymes reduce approximately 20% of nitrate to nitrite (Doel et al., 
2005). These bacteria use the nitrate to produce ATP in the absence of oxygen 
forming nitrite as a by-product (Doel et al., 2005). The level of nitrite found in 
saliva is also increased (Lundberg and Govoni, 2004). 
This nitrite is converted to NO through the acidic conditions in the stomach 
(Benjamin et al., 1994). Much of the nitrite found here can pass into the 
circulation without being converted (Lundberg and Govoni, 2004). Once within 
the circulation, there are numerous tissues that can convert nitrite into the active 
NO molecule. 
Early studies using NO for bone treatment were promising. In 2001, a review was 
published summarising the effects of NO on bone cells (van't Hof and Ralston, 
2001). This review detailed a biphasic effect of NO, low concentrations caused 
induction of bone resorption, and high concentrations inhibited bone resorption. A 
similar effect was seen with bone formation (van't Hof and Ralston, 2001). Small 
amounts of NO produced constitutively by osteoblasts may act as autocrine 
stimulators of growth within osteoblast cells (Ralston et al., 1994). When using 
animals with a subtype of nitric oxide synthase (eNOS) knocked out, major 
defects in bone formation and osteoblast activity were found (Armour et al., 
2001). This group also demonstrated the formation of NO during mechanical 
stress of both osteoblasts and osteocytes (van't Hof and Ralston, 2001). This 
process may be active in increasing bone formation in times of increased 
mechanical stress. 
Studies in vivo in animals examining the role of NO on bones have been 
promising, but complement the work showing a biphasic response to NO. The 
major NO donor used is nitroglycerin, an organic nitrate, used primarily for heart 
related conditions. It has been shown that nitroglycerin prevented ovariectomy 
(OVX) and corticoid induced bone loss above and beyond the effect of oestrogen 
(Wimalawansa, 2000). Nitroglycerin has also been shown to have beneficial 
effects on both trabecular and cortical bone when given in combination with more 
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recognised therapies (Wimalawansa, 1995). Furthermore, one daily application of 
nitroglycerin was sufficient to induce these effects, cumulative effects were not 
evident. 
Orally administered nitrates produce headaches as their side effects. These 
however can often be tolerated by the patient. The need for only a small dose 
removes the effect of lowering blood pressure which may have detrimental effects 
in older people with underlying heart conditions. 
It is therefore plausible to suggest that increases in dietary nitrates may lead to 
increases in NO reaching the skeleton and having beneficial effects in older 
people and individuals diagnosed with osteoporosis. 
1.5.2 Effect of bone anabolic agents on skeletal muscle 
There have been very few studies focusing on the action of bone anabolic agents 
and their effect on skeletal muscle. Considering how closely interlinked both 
tissues appear to be in both mechanical and biochemical pathways, any action on 
one tissue could influence the other either directly or indirectly. 
1.5.2.1 Parathyroid hormone 
Despite parathyroid hormone being used extensively for treating bone disorders, 
its relationship with muscle has not been fully studied. Early studies from the 
1980 are focused on increases in PTH levels in uremia and hyperparathyroidism. 
Here, three studies showed that high levels of PTH reduced the ability of muscle 
to metabolise protein, amino acids and nucleotides sufficiently (Garber, 1983). 
Further studies outlined a diminished ability of muscles to produce and utilise 
energy sufficiently (Baczynski et al., 1985). This was hypothesised to be the 
reason for muscle dysfunction within these conditions. However a paper 
published in 1987 disagreed with this hypothesis suggesting PTH had no effect on 
muscle with respect to glucose uptake, protein synthesis or degradation or amino 
acid release (Wassner and Li, 1987). Thompson et al (1996) showed that PTH had 
no effect on oxidative ATP capacity despite altering phosphate levels within the 
muscle (Thompson et al., 1996). Visser et al (2003) published data from the 
longitudinal ageing study of Amsterdam showing that the serum levels of PTH 
rise with age and may be influential in the progression of sarcopenia in 
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association with reduced vitamin D (Visser et al., 2003). Although noting many 
weaknesses with the study, this paper suggested a possible link between PTH and 
muscle. Citing earlier papers where changes in energy production and protein 
metabolism were evident, the authors also suggested the role for PTH in 
maintaining calcium levels could influence the disruption of muscle structure and 
function (Visser et al., 2003). These authors also hypothesised that due to close 
links between PTH and IL6; there may be secondary effects on muscle because of 
the detrimental effect IL6 may have muscle (Visser et al., 2003).  
Komrakova et al (2010) measured muscle mass, fibre size and mitochondrial 
activity in the gastrocnemius muscle of 3 month old normal and ovarectomised 
rats during PTH treatment for fracture healing (Komrakova et al., 2010). This 
study found no significant changes in muscle measures during this period 
although later study by the same author did show the potential for increased 
vascularisation in muscle following PTH treatment (Komrakova et al., 2010). 
1.5.2.2 Bisphosphonates 
There have been very few studies examining the action of bisphosphonate drugs 
on muscle tissue. Some of the first patient reports indicated an early onset of bone, 
joint and/or muscle pain after bisphosphonate use, suggesting that the drugs 
appear to be influencing other nearby tissues. This was again reported in 2007 and 
was noted to be a dose-dependent effect, however no further insight into the 
causes of the pain was given (Bock et al., 2007). Widrick, et al (2007) published a 
study monitoring the effects of endurance exercise and alendronate treatment in 
ovarectomised mice (Widrick et al., 2007). This study showed that exercise 
increased muscle mass in soleus and extensor digitorum longus muscles as well as 
increasing tetanic and twitch forces (Widrick et al., 2007) but that the 
bisphosphonate treatment had no influence on this (Widrick et al., 2007). The 
most recent study published in 2015 showed data on female human patients using 
bisphosphonate drugs for at least 3 years (Uchiyama et al., 2015). This group 
measured age, BMI, BMD and muscle cross-sectional area of the muscle 
surrounding the thigh. A significant reduction in muscle cross-sectional area in the 
group of long-term bisphosphonate users was shown and this was uncoupled to 
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increases in bone mineral density indicating that bisphosphonate action was only 
on the bone and did not improve muscle mass (Uchiyama et al., 2015).  
Overall, bisphosphonate drugs appear to be detrimental to the muscle tissue, or at 
best have no effect. However more robust studies are required before any firm 
conclusion can be made. 
1.5.2.3 Vitamin D. 
Studies have demonstrated that Vitamin D has the potential to of improve both 
muscle and bone structure and function. Several studies have recently been 
published showing the beneficial effects of vitamin D on muscle, the positive 
effects on bone have already been outlined above. Park et al in 2014 demonstrated 
a clear association between vitamin D levels and sarcopenia in women (Park et 
al., 2014). This group showed a 1.46 fold increased risk of sarcopenia with a 
reduction in vitamin D by 10ng/ml in women (Park et al., 2014). Cangussu et al 
(2015) showed data from a double-blind, placebo-controlled clinical trial in 
postmenopausal women receiving oral doses of 1000IU/day of vitamin D3 
demonstrating a 25.3% increase in muscle strength after 9 months and controlled 
muscle mass loss when compared to the placebo group (Cangussu et al., 2015). A 
further multicentre, randomized, controlled, double-blind, 2 parallel-group trial 
among 380 patients with sarcopenia (Bauer et al., 2015) showed similar trends, 
using a vitamin D and leucine-enriched whey protein nutritional supplement twice 
daily for 13 weeks, the authors showed increased muscle mass, and muscle 
function in the leg (Bauer et al., 2015). 
Thus it appears that modifications to dietary intake are a potential for 
musculoskeletal improvement in older age. It also highlights how small changes 
to diet may influence ageing without the need for drug intervention. 
1.5.2.4 Nitrates 
There is strong body of evidence for beneficial effects of nitrates on skeletal 
muscle especially in relation to improved exercise outcomes. Larsen et al. (2011) 
showed improvement in oxidative phosphorylation efficiency, improved 
mitochondrial P/O ratio and a reduction in oxygen cost during exercise in 
individuals treated with daily doses of 0.1mmol/kg of sodium nitrate (Larsen et 
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al., 2011). This was followed up by Ferguson et al. (2013) with data showing that 
supplementation with 0.1mmol/kg/day of nitrate improved vascular control and in 
predominately fast twitch muscle, elevated skeletal muscle oxygen delivery 
during exercise (Ferguson et al., 2013a). As well as direct influences on muscle, 
indirect effects can also improve muscle function such as the effect of nitrate on 
blood vessels leading to vasodilation, which in turn promotes better oxygen 
delivery to muscles and organs (Ferguson et al., 2013a, Ferguson et al., 2013b), 
particularly where bloody supply is reduced, as is proposed in old age. 
It is clear that despite the large amount of research being carried out in this field, 
many conflicting views, methods and outcomes have cast doubt on what may be 
valuable results in the treatment of musculoskeletal dysfunction in old age. If a 
robust study could be undertaken to accurately determine the effects that nitrate 
has on muscle, there is a potential for increased dietary nitrates as an intervention 
to improve structure and function of multiple musculoskeletal tissues. 
1.5.3 Potential muscle anabolic agents 
The lack of consensus, and the fact that sarcopenia is such a multifactorial 
disease, has had a direct impact on the development of potential interventions and 
thus is significantly under represented when compared to bone anabolic therapies. 
1.5.3.1 Dietary Protein 
The muscle within our body is reliant on a large source of protein from the diet. 
Dietary protein is needed for the correct maintenance of muscle mass through the 
use of amino acids to trigger muscle anabolic pathways (Martini et al., 2012). 
There is sufficient opinion to state that the levels of protein recommended through 
adulthood are not enough to maintain muscle mass in the elderly. This contributes 
to the loss of muscle mass in old age (Landi et al., 2016). 
The most effective method of increasing protein within the diet of older people is 
still highly debated. One key paper showed that giving older people 80% of the 
daily protein needed in one meal was more effective over a two week time period 
then evenly distributing the protein over four meals (Arnal et al., 1999). However 
giving this amount of protein in one meal has been shown to be difficult to 
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maintain over large time periods and so older people are recommended to eat 
approximately 25-35g of protein at every meal daily (Bauer et al., 2013). 
Often, increased dietary protein is given in combination with an increase in 
physical activity. It has been shown that resistance exercise in particular is the 
most beneficial form of exercise as long as the protein levels are high. There is 
however some debate over when is the best time to ingest this protein. Protein 
intake following activity has been shown to stimulate protein synthesis, when 
given at the same time, there is the production of an anabolic environment 
throughout the body (Landi et al., 2016). The highest level of muscle protein 
synthesis is observed 60 minutes following activity, so ingesting protein at this 
time would appear to be the most beneficial (Landi et al., 2016). 
1.5.3.2 Heat shock proteins 
An intervention that has been extensively researched in muscle is the potential 
benefit of increased cellular content of heat shock proteins (HSPs). HSPs are 
molecular chaperones and are a cellular defensive mechanism in response to 
stresses such as pathological increases in reactive oxygen species (Velichko et al., 
2013). HSPs protect cellular proteins from damage. HSPs in muscle have been 
studied due to evidence of significant reductions in the ability of cells of old 
mammals to produce these proteins (Vasilaki et al., 2003, Vasilaki et al., 2006a).  
Transgenic animal studies have been used in this area to demonstrate the effects 
of lifelong over-expression of HSPs on muscle function. HSP70 overexpression 
protected against age-related decreases in muscle force generation and allowed for 
improved muscle regeneration in old mice (McArdle et al., 2004). HSP10 also 
preserved force generation and the cross-sectional area of the muscles in old mice 
(Kayani et al., 2010). Both displayed a reduced level of oxidative damage 
hypothesising this is the mechanism responsible for the age-related benefit. There 
are however very few drug interventions to induce a similar effect to the 
transgenic models. Treatment of mice with 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG) resulted in increased HSP70 levels in the 
muscles of both adult and old mice but did not result in increased muscle mass or 
function in the old mice but did improve muscle regeneration (Kayani et al., 
2008a). A further HSP70 inducer, arimoclomol, has been shown to slow the 
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progression of the muscle wasting disease amyotrophic lateral sclerosis (Kalmar 
et al., 2008). 
1.5.3.3 Antioxidant drugs 
One of the major hypothesises concerning the cause of musculoskeletal ageing 
involves the altered production or inadequate removal of reactive oxygen species 
within tissues (Szczesny et al., 2010). SS31 has been used in animal studies (Min 
et al., 2011). SS31 is a potent antioxidant that locates to the mitochondria and can 
significantly attenuate the production of the reactive oxygen species, H2O2, which 
is known to be elevated in old age (Min et al., 2011). It has been shown to reverse 
age-related depletion of ATP synthesis, improving muscle function and provides 
an attenuation of H2O2 production preventing damage to the muscle proteins 
(Siegel et al., 2013).  
1.5.3.4 Myostatin 
Animal studies have focused on myostatin – a negative regulator of muscle mass. 
Inhibition of myostatin leads to a dramatic increase in muscle mass and muscle 
force generation however this does not improve specific muscle force production 
(Gentry et al., 2011). Treatment of mice with bimagrumab (an antibody that 
targets a receptor ActRII which myostatin binds to inhibiting myostatin) resulted 
in increased muscle mass with attenuation of muscle weakness (Lach-Trifilieff et 
al., 2014). 
1.5.3.6 Effects of muscle anabolics on the skeleton 
Despite evidence that increases in muscle mass and muscle force production can 
have direct beneficial effects on the underlying bone, there have been few studies 
investigating the effect of muscle anabolic drugs on bone. Studies have often 
presented opposing views.  
Inhibition of activin A has been looked at in a similar vein to myostatin to induce 
muscle hypertrophy (Yaden et al., 2014). Studies have shown an increase in bone 
volume in mice whilst using this inhibitor. In post-menopausal women, treatment 
with this drug resulted in increases in bone formation and bone density (Yaden et 
al., 2014). Inhibiting activin via soluble activin receptor IIB fusion proteins results 
 42 
 
in improved muscle mass even compared to myostatin studies. It has also been 
shown to directly improve trabecular bone throughout the skeleton (Lotinun et al., 
2012).  
1.5.4 Treatment options known to improve both bone and muscle tissue 
1.5.4.1 Exercise 
One of the most common potential therapies aimed at improving mass and 
function of musculoskeletal tissues is regular weight-bearing and resistance 
exercise (Tang et al., 2006). The benefits of these include increased muscle mass, 
improved balance, reduced falls and improvement to bone mass. Exercise may 
achieve these improvements through targeting the MTORC1 pathways to increase 
muscle protein synthesis. The optimal amounts and form of exercise may also 
reduce the loss of key type II muscle fibres that are reduced during age, increasing 
the area of those that remain. Aerobic exercise such as swimming or running is 
known to improve cardiovascular function, increasing heart rate, lung capacity 
and blood flow (Frankel et al., 2006). It has been shown that this type of exercise 
can lead to increases in muscle fibre cross-sectional area, mitochondrial volume 
and muscle enzyme activity (Short et al., 2004). 
Resistance exercise has the largest effect on muscle tissue and can increase 
muscle mass and improve muscle function including increased muscle force 
generation (Sipila and Suominen, 1995). Improvements can be seen with just one 
session of resistance training per week (Taaffe et al., 1999). The key to improving 
muscle mass and function in older people appears to be through prolonged 
resistance exercise. 2-3 sessions a week of resistance exercise improved physical 
function, gait speed, balance and muscle strength in older people (Latham et al., 
2003). 
However, prolonged exercise regardless of type does not prevent the onset of 
sarcopenia. In a group of veteran athletes of either endurance or power activities, 
there was still evidence of similar rates of muscle loss with increased age (Drey et 
al., 2016). These veteran athletes do however have the benefit of increased muscle 
mass compared with community dwelling older people which may allow for the 
continuation of muscle function until a later point in life (Drey et al., 2016). 
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Another benefit of exercise on muscle in particular is the adaptation, with 
improvement of antioxidant defences via upregulation of relevant enzymes 
(Kayani et al., 2008b) and decreased inflammatory cytokines (Marzetti et al., 
2008, Nicklas et al., 2008). Exercise has also been shown to reduce inflammatory 
cytokines which are detrimental throughout the body (Greiwe et al., 2001, 
Petersen and Pedersen, 2005). Exercise also clearly increases mitochondria 
number via activation of PGC1a and by doing so potentially increases the muscles 
functionality.  
Studies into the effect of exercise on osteoporosis are a subject of contention. 
Although many studies are published, very few follow similar experimental 
designs and protocols, making comparisons difficult. 
Despite this, regular exercise is proposed as the most a beneficial approach for 
osteoporosis (Berard et al., 1997, Gomez-Cabello et al., 2012). The type of 
exercise that is potentially beneficial differs slightly to what is reported for muscle 
and suggests a programme of high load non mass bearing exercise should be used 
in the elderly. 
Positive effects of exercise on muscle and bone are not permanent and differ 
between old and young populations, however regular exercise appears to be 
important. After 6 months of exercise cessation, positive effects in muscle and 
bone are lost (Taaffe and Marcus, 1997, Taylor et al., 2004). 
There are currently no exercise types in particular that result in universal benefits 
for all musculoskeletal tissues however resistance exercise is clearly beneficial for 
muscles and this may induce improvements in the other tissues. There is a need 
for increased exercise to be introduced prior to reaching old age to ensure people 
are reaching their peak muscle and bone mass before the declines are seen.  
1.5.4.2 Antioxidant therapies 
One of several hypothesises proposed as a mechanism of musculoskeletal ageing 
involves the aberrant production of or inadequate removal of reactive oxygen 
species within tissues (Szczesny et al., 2010). 
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The function of reactive oxygen species (ROS) has been studied over a 
considerable time period and a large amount of research has been undertaken to 
characterise the potential sources of ROS. The overarching assumption was that 
ROS were detrimental to cells and tissues and that cumulative damage by ROS to 
lipids in cellular membranes, DNA, proteins and other sub cellular structures lead 
to cellular damage and eventually death (Vasilaki et al., 2006b). 
In the tissues of older people and animals including muscle tissues, oxidation of 
integral proteins such as myosin is present, preventing adequate functionality. 
There is also evidence of increased levels of mitochondrial DNA damage and 
decreased numbers of functional mitochondria with age (Vasilaki et al., 2006b, 
Vasilaki et al., 2006a). Damaged mitochondria are proposed to produce excessive 
ROS which in turn feedback to cause further damage (Miquel et al., 1980, Baines 
et al., 2014). However, recent work in animal models have shown no correlation 
between oxidative damage and life span, potentially arguing against the 
hypothesis that oxidative damage is the direct cause of ageing, although it may be 
a compounding factor (Gems and Doonan, 2009, Perez et al., 2009). 
With further understanding of the role of ROS as essential signalling molecules, 
the theory has been altered to incorporate recent interest in defective signalling 
involving these reactive oxygen species (Jackson, 2016). Signalling by ROS is 
essential for a number of processes, including increased expression of protective 
proteins within cells, (Jackson, 2016). In young adult mammals, increased ROS 
leads to an increase in cellular protective proteins. However in older mammals 
this response does not occur. It is proposed that there is already a chronic 
increased level of ROS within the tissues of older species and a chronic activation 
of the regulatory, protective pathways (Jackson, 2016). This in turn leads to a lack 
of further increases in ROS when additional stimuli are present, leading to a lack 
of adaptations to acute stresses (Vasilaki et al., 2006b). In addition to this, the 
chronic increased production of ROS continues to damage lipids, proteins and 
DNA within the cell (Vasilaki et al., 2006b). Thus, researchers have focused on 
modifying the chronic increase in ROS generation in tissues of older mammals in 
an attempt to reduce the inability to produce ROS in response to acute stimuli and 
a number of drug targets are being developed. SS31 is proposed to be a potent 
antioxidant that locates to the mitochondria (Cho et al., 2007) although whether it 
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is the action of SS31 as an antioxidant that provides protection is controversial. It 
has been shown to reverse age-related depletion of ATP synthesis and improve 
muscle function. Another drug, MitoQ has been developed however long-term 
supplementation did not produce beneficial effects in old mice, failing to improve 
muscle function in old age compared with placebo treated mice (Sakellariou et al., 
2016). 
1.5.4.3 Heat shock proteins 
HSPs are molecular chaperones found within the cell within various subcellular 
compartments. The main function of HSPs during normal cellular conditions is 
maintenance and control of protein folding, transportation and maturation of 
nascent proteins. Heat shock proteins are rapidly synthesized when cells are 
exposed to a wide variety of stresses including inflammation, hypoxia in an 
attempt to maintain this control on protein formation and to avoid denaturing or 
misfolding (Vasilaki et al., 2003). 
Increasing HSP content of cells is an attractive proposition, since evidence shows 
a clear decline in the amount and functionality of heat shock proteins with age. 
Currently being studied are the effects of HSP10 and HSP70 as mentioned 
previously in relation to preserving muscle (Kayani et al., 2008a, Sasaki et al., 
2010).  
In bone, less work has been done in this area due in part to the complexity of 
studying the skeleton in detail compared to the musculature and the impossibility 
of studying oxidant levels in vivo in bone. It has been shown that free radicals and 
reactive oxygen species are a driver of osteoclastogenesis and are essential in 
bone resorption (Srinivasan et al., 2010). It is therefore reasonable to suggest 
increases in antioxidants will reduce the production of osteoclasts and prevent the 
resorption of bone. One study has correlated that decreases in bone mineral 
density follows increases in oxidative stress (Smietana et al., 2010). Further 
papers stress the possibility for associations but often fail to reach significant data. 
Despite this, Pycnogenol has been used in animal studies in an attempt to reduce 
the reactive oxygen species in bone and has produced significant benefits in a 
model of ovariectomy (Huang et al., 2015).  
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1.5.4.4 Anti-inflammatory agents 
Age-related increase in inflammatory cytokines is a condition in a large 
proportion of older animals and people. Whether this is a consequence of ageing 
of tissues or caused by the presence of pathologies is debatable (Bartlett et al., 
2012). Inflamm-ageing as it has been termed has been linked to decline in muscle 
mass and function and to the decline in bone mass and function as well as joint 
problems and other age-related conditions (Franceschi et al., 2000).  
Age-related inflammation includes the chronic increased release and circulation of 
cytokines such as TNFα and IL6 which are both highly correlated with declines in 
muscle function (Franceschi et al., 2000). More recently, evidence that muscles 
can express and secrete cytokines (myokines) has led to the theory that muscle 
may play some role in the increase of inflammatory cytokines in old age (Nielsen 
and Pedersen, 2008). 
TNFα has a direct effect on muscle fibres resulting in reduction in total muscle 
protein as it initiates protein degradation (Li et al., 1998, Li et al., 2000). Further 
studies with hospitalised old patients have shown significant declines in grip 
strength with increasing incidence of inflammatory mediators with further studies 
supporting this link (Norman et al., 2014). 
It is proposed that use of non-steroidal anti-inflammatory drugs may reduce the 
detrimental effects of increased inflammatory cytokines with age however very 
few studies have been carried out examining the role of anti-inflammatory drugs 
for muscle and bone (Munoz-Ortego et al., 2014). A study in Crohn’s disease has 
suggested that anti TNFα drug named infliximab is a potential intervention to 
reduce the loss of muscle mass caused by increases in inflammation. TNFα 
inhibitors have also shown promise in treating osteoporosis as osteoclasts (bone 
removing cells) are highly dependent on TNFα to function (Allali et al., 2003). 
Studies in patients with Ankylosing Spondylitis display promising improvement 
in bone mass and strength when treated with such drugs (Kang et al., 2014).  
Studies have also focused on the potential use of dietary anti-inflammatory 
compounds to modify musculoskeletal function. Resveratrol is a naturally 
occurring substance found in plants which has recently been shown to have anti-
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inflammatory effects. Recent studies show beneficial effects of this agent on both 
muscle and bone however there is no evidence that treatment will prevent the loss 
of muscle mass (Jackson et al., 2011). In bone the effects are clearer, displaying 
improved bone in rodent models of post-menopausal osteoporosis as well as 
improved responses to age-related bone loss when given prior to bone loss 
(Durbin et al., 2014, Pearson et al., 2008). 
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1.6 Hypothesis 
The main hypothesis of this study is that with increasing age in mice, there is a 
decline in the mass and function of all musculoskeletal tissues. The secondary 
hypothesis is that this decline could be prevented through a series of interventions 
including increased lifelong activity, a whole body over-expression of Heat Shock 
Protein 10 (HSP10) or an increase in dietary nitrates.  
1.7 Aims 
This aims of this study were as follows: 
 To integrate methods of visualising and measuring age-related changes in 
musculoskeletal tissues. 
 To identify changes in musculoskeletal tissues throughout the life span of 
C57BL/6 mice. 
 To determine the effects of increased sodium nitrate intervention, both 
short-term and longer-term, on changes seen in the musculoskeletal system 
of C57Bl/6 mice with age. 
 To examine the effect of lifelong overexpression of HSP10, known to 
preserve muscle CSA on other tissues from the musculoskeletal system. 
 To compare data from C57Bl/6 mice with changes in musculoskeletal 
tissues of male and female wild mice which demonstrate a significant 
increase in activity 
The use of an integrated approach to measuring and visualising age-related 
change in musculoskeletal tissues is primarily found in Chapter 3 but is addressed 
throughout the thesis. Chapter 3 looks to complete aim 2 and will identify changes 
in musculoskeletal tissues of the C57Bl/6 mouse through age. We will then move 
into providing these mice with a non-invasive dietary intervention of sodium 
nitrate in Chapter 4. Chapter 5 will address how overexpressing an antioxidant 
protein in the C57Bl/6 mice through life will affect ageing of musculoskeletal 
tissues. Chapter 6 will address whether C57Bl/6 mice are the ideal model to study 
musculoskeletal ageing in mice and whether lab based mice are artificially ageing 
compared to wild mice. 
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Chapter 2 
Experimental Methods 
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2.1 Chemicals and reagents 
Unless stated otherwise, all chemicals and reagents used in this study were 
obtained from Sigma chemical company, Dorset, UK 
2.2 Mouse husbandry 
All experiments were undertaken in accordance with UK home office guidelines 
under the UK Animals (scientific Procedures) Act 1986 and with ethical approval 
from the University of Liverpool Animal Welfare Ethical Reviews Body 
(AWERB). 
2.2.1 C57 Bl6 mice 
For the ageing study presented in Chapter 3, a total of 42 C57BL/6 mice were 
used (6 mice per group) at a range of ages with power calculations based on 
previous studies. Mice were culled at 3, 6, 9, 12, 18, 24 and 28 months of age. 
These ages were based on literature and previous experiments by the McArdle 
group. C57Bl/6 mice were purchased from Charles River (Lyon, France) and was 
delivered 1 month prior to the required age except for the 28 month cohort which 
were delivered at 24 months of age and allowed to age within the Biomedical 
Services Unit at the University of Liverpool. Mice were fed a CRM (P) rodent 
diet with ad libitum access to food and were maintained under barrier conditions 
in microisolator cages on a 12-h dark/light cycle. A detailed breakdown of mouse 
chow is included in Figure 2.1. Twenty eight months was deemed a suitable end 
point based on survival data provided by Jackson laboratories, Maine, USA (Fig 
2.1) 
2.2.2 Wild mice 
Mice used in the wild mouse study of Chapter 4 were obtained from an ongoing 
behavioural study led by Professor Jane Hurst at the Leahurst campus at the 
University of Liverpool. 
Male and female mice where captive bred Mus musculus domesticus derived from 
ancestors captured from five differing populations around the North West of 
England, UK. Ancestor mice were captured within 20 miles of each other except 
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for two, which were captured 80 miles away. This was to introduce genetic 
variance.  
Fig 2.1 Detailed breakdown of CRM (P) rodent diet provided by Special Diets 
Services. 
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Each male mouse was individually housed in a 48 cm × 11.5 cm × 12 cm cage for 
the duration of the experiment (M3, North Kent Plastic Cages Ltd., UK), females 
were housed in 45 x 28 x 13cm cages (MB1, North Kent Plastics, UK) in single-
sex small family groups (2-4 animals) with Corn Cob Absorb 10/14 substrate and 
paper-wool nest material, with ad libitum access to food (LabDiet 5002) and 
water.  
Fig 2.2 C57Bl/6 survival data showing human age comparisons. Adapted 
from The Mouse in Biomedical Research 2nd Edition. Fox JG, et al, (2007). 
2.2.3 HSP10 overexpressor mice 
Male HSP10 overexpressor mice studied in Chapter 5 have been previously 
described (Kayani et al., 2010). Mice were originally produced to overexpress 
both HSP60 and HSP10. Mice were generated via chimeric transgenes containing 
of human gene variants of HSP10 and HSP60 which were inserted into pCAGGS 
vectors. The pCAGGS construct should allow both genes to be under the control 
of the human cytomegalovirus (CMV) intermediate early (hCMV-IE) enhancer 
and chicken β-actin promoter and intron 1. The CAGGS-HSP10 fragment was cut 
from the Bluescript II KS vector using Xho1/Not1 digestion to produce a 3.3kb 
fragment. The CAGGS-HSP60 fragment was cut from the BlueII KS vector using 
Sal 1/Not1 digestion to produce a 4.8kb fragment. Both fragments were purified 
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and used for microinjection into mouse oocytes. Previous western blot analysis 
demonstrated that only HSP10 content was significantly elevated but HSP60 was 
not overexpressed in skeletal muscle or other tissues of these transgenic mice at 6 
months old. HSP10 levels remained elevated until at least 24 months old (Kayani 
et al., 2010). The mice from this study are therefore referred to as HSP10 
overexpressor mice. Mice were housed within the Biomedical Services Unit at the 
University of Liverpool. Mice were fed a CRM (P) rodent diet and were 
maintained under barrier conditions in microisolator cages on a 12-h dark/light 
cycle. 
2.2.4 Mice used for sodium nitrate intervention 
Two groups of male C57Bl/6 mice used for the sodium nitrate intervention were 
purchased at 7 and 16 months of age from Charles River and allowed to age 
within the Biomedical Services Unit at the University of Liverpool. Mice were fed 
a CRM (P) rodent diet and were maintained under barrier conditions in 
microisolator cages on a 12-h dark/light cycle. 
The long-term nitrate study was started when the male mice reached 9 months of 
age and involved 20 mice split into two groups of 10 mice. The control group was 
given 250ml standard drinking water changed weekly. The treatment group was 
given 1mM sodium nitrate (21mg/250ml) in the drinking water which was also 
changed weekly. This was repeated until the mice reached 24 months of age. The 
short-term study was started when mice were 18 months of age. For the short-term 
study, 16 mice were split into two groups of 8 and treated as above. The study 
ended when the mice reached 24 months of age. 
2.3 Sample collection and preparation 
Following completion of all procedures, mice were killed by cervical dislocation. 
Muscles from both hindlimbs and a range of organs were dissected and mass were 
recorded. Following this, tissues were snap-frozen in liquid nitrogen and stored at 
-80°C. 
For tendon analysis, the Achilles tendon and posterior tibialis tendon with 
associated muscle tissue were left attached to the foot prior to dissection and were 
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snap-frozen in liquid nitrogen and stored at -80°C. Tendons mass and function 
was only assessed for the C57Bl/6 ageing study presented in Chapter 3.  
Hindlimbs had all remaining muscle tissue removed from the bone. Bones were 
then stored in Formalin solution for 24 hours. Following this, hindlimbs were 
transferred to 70% ethanol for long-term storage. 
2.4 Microscopy and imaging 
Microscopy and imaging of samples used in this study has been detailed in 
Sakellariou et. al (2016). Anterior tibialis muscles were cryosectioned at -20
o
C 
through the mid-belly with a thickness of 12µm and sections were stained with 
fluorescent immunohistochemical staining. Sections were rinsed in phosphate 
buffered saline and permeabilized in 0.2% Triton X-100 for 5 minutes. 
Extracellular matrix was identified through fluorescein labelled wheat germ 
agglutinin (Vector Laboratories, Burlingame, California). Nuclei were identified 
with 4,6-diamidino-2-phenylindole (DAPI, 1µg/ml). Cross sections from 6 
muscles/age group were examined by blinded observers to allow total number of 
fibre and individual fibre CSA to be measured. Image J software was used to 
quantify fibre CSA. 
2.5 In situ muscle contractions induced by electrical stimulation 
Mice subjected to in situ muscle force measurements were anesthetised with 
intraperitoneal (IP) injections of ketamine hydrochloride (66 mg/kg) and 
medatomidine hydrochloride (0.55 mg/kg), with supplemental injections provided 
to maintain an adequate level of anaesthesia throughout the procedure. 
The contractile properties of extensor digitorum longus (EDL) muscles were 
measured in situ as previously described (McArdle et al., 2004). To assess the 
maximum isometric tetanic force (Po) of the EDL muscle, the distal tendon from 
anesthetised mice was secured to the lever arm of a servomotor (Aurora 
Scientific, Ontario, Canada). The knee of the hindlimb was fixed, the peroneal 
nerve was exposed, and platinum wire electrodes were placed across the nerve. 
Muscle optimal length (Lo) was determined using a series of 1 Hz stimulations 
and the muscle was set at the length that generated the maximal force. For 
determination of Po, EDL muscles were electrically stimulated to contract at Lo 
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and optimal stimulation voltage (8–10 V) at 2min intervals for 300ms with 0.2ms 
pulse width. Po was assessed by increasing the frequency of stimulation from 10 
to 50 Hz and subsequently in 50-Hz increments to a maximum of 300Hz. Po was 
identified when the maximum force reached a plateau despite increasing 
stimulation frequency.  
Fig 2.3 Schematic displaying arrangement for in situ muscle force measurements 
(Taken from Brooks & Faulkner) 
2.6 Tendon stretching through application of force 
2.6.1 Preparation of the posterior tibialis tendon sample 
Intact mouse feet were removed with the posterior tibialis muscle attached via the 
tendon and stored at -80°C until use. Prior to testing, each specimen was removed 
from the freezer and allowed to defrost for 1hr before excising the tibialis 
posterior tendon from the intact foot and removing any excess tissue leaving only 
the tendon (Fig 2.3). 
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Fig 2.4 Representative mouse foot sample with Achilles and posterior tibialis 
tendon visible. 
 
Samples were placed on glass slides along with three drops of PBS to maintain 
tissue hydration. Images were taken of each tendon. Five diameter measurements 
were taken from each image at approximately 100 µm intervals using a Nikon 
Eclipse Ci microscope equipped with a 10x/0.30 lens and a Nikon DS-Fi2 camera. 
Means of the five measurements were used to calculate the cross-sectional area of 
the tendon. 
2.6.2 Mechanical testing of the posterior tibialis tendon 
All tensile tests were performed on an Instron 3366 material testing machine 
(Instron, Massachusetts, USA) equipped with a 10N load cell in conjunction with 
Bluehill materials testing software (Instron, Massachusetts, USA) (Fig 2.4). 
Samples were secured into custom clamps using a cyanoacrylate adhesive 
(superglue). Specimens were allowed to hydrate in phosphate-buffered saline 
(PBS) for 15 minutes prior to the start of the test. 
Specimens were secured into the clamps using a 2 mm spacer to ensure consistent 
gauge length. Prior to loading into the uniaxial tensile testing machine, the grip-
to-grip distance was measured using a digital Vernier micrometre. In instances 
where glue overran, the glue-to-grip distance was measured for strain calculations. 
Each specimen was loaded into the custom clamps initially under slight 
compression and then each specimen was elongated until a load of 0.01 N was 
achieved, so that a reference point could be established for repeatable testing.  
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Fig 2.5 Instron 3366 material testing machine 
 
Each specimen was subjected to 6 loading cycles to a peak load of 1.0 N and the 
results from the last cycle were used to determine the stress-strain behaviour of 
the specimen.  
The selected strain rate was chosen as it has been previously used on mouse 
achilles tendons (Ansorge et al., 2011). Specimens were subjected to a 6 minute 
recovery period succeeding each cycle. Due to a large percent of specimens 
slipping out of the clamps at larger loads, failure properties were not reported. 
The load-elongation parameters were obtained, so the stress and strain could be 
calculated. The stress, σ, was calculated by dividing the applied load, F, by the 
mean cross-sectional area (πr^2), A, and the strain, ε, was calculated by dividing 
the elongation, ΔL, by the original length, L.       
In addition, the tangent modulus, a measure of material stiffness, was calculated 
from the gradient of the corresponding tangent line of the stress-strain curve (i.e. 
dσ/dε). 
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2.7 Histological analysis of mouse knee joint 
2.7.1 Preparation of knee joints 
Knee joints were stored as hindlimbs in 70% ethanol. Prior to sectioning, 
hindlimbs were decalcified in EDTA solution at room temperature in a non-
agitated environment for 4 weeks. Following decalcification knee joints were 
embedded in paraffin in a coronal orientation with the back of the joint facing 
downwards. Sections were cut on a HM355S microtome (Thermo Fisher 
Scientific, Massachusetts, USA) at 6 micron thickness throughout the joint.  
2.7.2 Haematoxylin and eosin (H&E) staining 
Sections were placed in Harris’ Haematoxylin for 3-5 min, rinsed in distilled H2O 
and counterstained in eosin for 30 sec. Sections were then dehydrated in 3x 
Absolute alcohol and cleaned in xylene. Cover slips were mounted onto 
microscope slides using DPX mountant. Sections were analysed with the use of an 
inverted microscope (Zeiss Axiovert 200M microscope (Oberkochen, Germany)). 
2.7.3 Safranin-O staining 
Sections were placed in Weigert’s Iron Haematoxylin for 5 minutes and rinsed in 
distilled H2O. Sections were then differentiated in 1% acid-alcohol solution for 2 
seconds and rinsed. Following this, sections were placed in 0.02% Fast Green 
solution for 1 minute, 1% acetic acid for 30 seconds, 1% Safranin O for 30 
minutes and then briefly rinsed in 95% ethanol. Sections were then dehydrated in 
3x Absolute alcohol and cleaned in xylene. Cover slips were mounted onto 
microscope slides using DPX mountant. 
2.7.4 Histological scoring of the mouse joint 
Histological scoring was undertaken by experts at Leahurst campus, University of 
Liverpool as previously described (Glasson et al., 2010). Femoral and tibial 
cartilage was scored for lesions on a scale between 0-6, formation of osteophytes 
were also assessed based on a scoring scale of 0-3 (Glasson et al., 2010). Samples 
were scored blindly and performed twice to assess inter observer variability at 
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Leahurst campus. Normality test (Kolmoigorov-Smirnov test) was performed on 
data. This indicated the n number was too small to allow for wild male and female 
to be separated based on sex in Chapter 4. Therefore wild female and male results 
were pooled together.   
2.8 MicroCT scanning of mouse hindlimb bones 
2.8.1 Preparation of hindlimbs for MicroCt scanning 
Both hind limbs with knee joint intact were dissected from each mouse. Muscle 
tissue was removed and bones stored in Formalin for 24hrs. Bones then washed 
with PBS and placed in 70% ethanol.  
2.8.2 MicroCT scanning 
Both the tibia and femurs bones of each hindlimb were scanned using a μCT 
system across the knee joint (Skyscan 1272 X-Ray microtomograph, Bruker 
Corporation, Kontich, Belgium) to evaluate trabecular architecture and cortical 
bone measures (Fig 2.5).  
 
 
 
 
 
 
 
Fig 2.6 Representative X-Ray image of mouse hindlimb showing general area of 
bones scanned for analysis. 
For trabecular scanning, high-resolution scans with an isotropic voxel size of 
4.3 μm were acquired (60 kV, 0.5 mm aluminium filter, 0.3° rotation angle). The 
isotropic voxel size was changed to 10 μm for cortical analysis.  
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2.8.3 Analysis of mouse hindlimb bones following MicroCT scan 
The scans were reconstructed using NRecon software (Bruker, Massachusetts, 
USA). For analysis, a 1 mm section of the metaphysis was taken for the 
measurement of trabecular bone, using the base of the growth plate as a standard 
reference point. A 500 μm section of the mid-shaft was taken for the analysis of 
cortical bone, using the base of the growth plate as a standard reference point. 
CTAn software (Bruker, Massachusetts, USA) was used to analyse the 
appropriate parameters previously outlined (Bouxsein et al. 2010) as shown in 
Table 2.1. 
 
 
Fig 2.7 Representative MicroCT images of the femur highlighting different 
regions for analysis – Red area represents the trabecular bone area analysed, blue 
area represents the cortical region. 
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Table 2.1 Table of commonly used bone measures within this study with units 
and description. 
 
2.9 Statistical analyses 
Data was tested for normality and equal variance using SigmaPlot (v11.0) (Systat 
Software, Inc., London, UK). Direct comparison between two sets of data was 
made by Student's t-test. For multiple comparisons, data was analysed for 
statistical significance by one-way ANOVA incorporating pairwise comparisons. 
Data are presented as mean ±SEM. Values P<0.05 were considered significant. 
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Chapter 3 
Characterising age-related changes in 
musculoskeletal tissues of C57Bl/6 mice   
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3.1 Introduction 
Signs of musculoskeletal ageing such as a loss of muscle mass and force, loss of 
bone mass or loss of joint functionality do not commonly present until the 4
th
 
decade of life in humans. Once the decline in these tissues appears, it often takes a 
further forty years to develop into a full pathology (Faulkner et al., 2007). This 
slow time course of changes presents a challenge to studies examining the effects 
of ageing on musculoskeletal tissues in humans and has resulted in a lack of 
robust studies into the pathology and pathophysiology of musculoskeletal ageing, 
despite a large number of studies focusing on individual tissue pathologies. 
Animal models are commonly used to address this issue. Animals are used to 
study the effects of age-related conditions in a reduced time scale due to their 
shorter lifespan. Despite the quadruple locomotion used by mice, multiple 
musculoskeletal tissues display many similarities between mice and humans. 
Since the sequencing of the C57Bl/6 mouse genome, it has been shown that 99% 
of mouse genes have human homologues (Mouse Genome Sequencing et al., 
2002). There are also many examples of mouse studies involving alterations of 
genes/proteins to potentially accelerate or slow the ageing process. In muscle, this 
includes a lack of antioxidant enzymes (Sakellariou et al., 2014a), deletion of 
maintenance proteins such as heat shock proteins (Kim et al., 2006) or a reduction 
of calorie intake (Sohal and Forster, 2014). In bone, many studies involve the 
removal of mouse ovaries in order to replicate the effects of post-menopausal 
osteoporosis in women (Bouxsein et al., 2005). These ovarectomised mice are 
commonly studied but experiments are often undertaken in relatively young mice 
and so the results cannot always be deemed translatable to ageing. Although there 
has been some cataloguing of changes in bone tissue throughout life in mice 
which allow us to base further research on, they are not comprehensive 
(Willinghamm et al., 2010). 
Description of the ageing process through life in a robust mouse model would 
allow for the discovery of potential interventions to prevent or delay any decline. 
However, despite the large amount of work in this area, very little work has been 
done which details ‘normal’ lifelong effects of age of muscle and bone tissues in 
animals. Less common are age-related studies of cartilage and tendon tissues as 
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well as changes in extracellular factors which may drive such changes such as 
cytokines and/or hormone levels. 
3.1.1 Fundamental changes in musculoskeletal tissues through life 
With increasing age, muscle mass and muscle function is reduced resulting in a 
pathology termed sarcopenia. In humans, the decline of muscle mass starts at the 
age of ~40 and decline occurs leading to approximately 40-50% loss of muscle 
mass by the time a person is in their 80s (Faulkner et al., 2007). 
The cause of this decline in muscle mass and function is yet to be fully elucidated. 
As discussed in Chapter 1  
Tendons and ligaments are also subject to age-related changes. These changes 
centre on altered collagen production and maintenance leading to a reduction of 
elasticity (Narici and Maganaris, 2006). Although not a major influential change, 
taken in combination with the reduced ability of the muscles to generate force, 
this can compound the loss of muscle force and ultimately leads to a change in 
gait and locomotion. 
Osteoporosis is the term describing the loss of bone mass and strength. This is not 
solely an age-related condition with both menopause and certain drugs (such as 
glucocorticoids) causing loss of bone; however it is highly prevalent in older 
populations. With this, there is an increased risk of fractures with increasing age. 
Despite this, the cause of the disorder is not yet fully understood, however the 
close links between age-related changes in muscle and bone may suggest that loss 
of muscle force generation and therefore loss of mechanosensation is a key factor. 
Whatever the cause, the balance between bone formation and resorption is altered 
in favour of resorption which causes a net loss of bone tissue. This is summarised 
in Section 1.3.4. 
Along with changes in bone tissue, articular cartilage also diminishes with age 
and with it there is a large reduction in shock absorption capability within the 
joints (Li et al., 2013). Changes in inflammatory markers and cytokine levels may 
also lead to joint conditions such as osteoarthritis which can affect the underlying 
bone (Sokolove and Lepus, 2013). 
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3.1.2 Interplay between musculoskeletal tissues 
Throughout life, there are close interactions and relationships between all tissues 
of the musculoskeletal system. The changes in the way that these tissues interact 
in later life are theorised to be a key factor in overall decline in musculoskeletal 
tissues as a whole. 
The interactions between muscle and bone described previously through life 
suggest a close link between the two tissues.  
It is suggested that differential mechanical events and other external signals could 
be converted within the muscle to induce further signals influencing bone biology 
(Schnyder and Handschin, 2015) and possibly within bone to effect muscle in a 
feedback loop mechanism. 
There are also close links between bone tissue and cartilage. As articular cartilage 
is removed with age there is a large reduction in the ability of bones to absorb 
shock within joints. This breakdown exposes bone surfaces to each other and can 
lead to painful joints (Li et al., 2013).  
3.2 Aims 
This aims of this chapter were as follows: 
 To integrate methods of visualising, measuring and quantifying age-
related changes in musculoskeletal tissues in C57Bl/6 mice. 
 To identify changes in musculoskeletal tissues throughout the life span of 
C57BL/6 mice with particular focus on muscle, bone, tendon and 
cartilage. 
 To determine interactions between the musculoskeletal tissues studied. 
Hypothesis – as mice age, there is a detrimental loss of mass and function in 
muscle, bone, tendons and in the joint and that there is a close association between 
the tissues that can influence the ageing process. 
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3.3 Methods 
3.3.1 Mice 
All experiments were undertaken in accordance with UK home office guidelines 
under the UK Animals (scientific Procedures) Act 1986 and with ethical approval 
from the University of Liverpool Animal Welfare and Ethical Review Body 
(AWERB). 
A total of 42 male C57BL/6 mice were used with 6 mice per group. The number 
of mice per group was determined using power calculations based on previous 
studies. Exclusion of mice with overt pathology at 28 months old resulted in the 
reduction of the group to n=4. Mice were culled at 3, 6, 9, 12, 18, 24 and 28 
months of age. These ages were chosen based on the current published literature. 
C57Bl/6 mice purchased from Charles River (Lyon, France) were used for this 
study and delivered to the Biomedical Services Unit at the University of Liverpool 
at least 1 month prior to the required age.  
3.3.2 Tissue collection and preparation 
All tissues were removed post-mortem as described in Section 2.3. Briefly, all 
muscles and organs were removed and snap frozen in liquid nitrogen prior to 
storage at -80°C. Feet with both achilles and posterior tibialis tendon attached 
were stored at -80°C. Hindlimbs, with the remaining muscle tissue removed were 
stored in formalin solution for 24 hours before being transferred into 70% ethanol. 
3.3.3 Muscle analysis 
Anterior tibialis, EDL, soleus and gastrocnemius muscles from both hindlimbs 
were dissected and weighed. Following this, muscles were snap frozen in liquid 
nitrogen and stored at -80°C. 
3.3.4 Bone analysis 
Detailed analysis of bones is described in Section 2.8. Briefly, both tibia and 
femurs of each hindlimb were scanned using a μCT system (Skyscan 1272 X-Ray 
microtomograph, Bruker Corporation, Kontich, Belgium) at high-resolution with 
an isotropic voxel size of 5 μm for trabecular bone (60 kV, 0.5 mm aluminium 
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filter, 0.7° rotation angle). The isotropic voxel size was changed to 10 μm for 
cortical analysis. Two images were taken at each rotation angle. The scans were 
reconstructed using NRecon software (Bruker, Massachusetts, USA). CTAn 
software (Bruker, Massachusetts, USA) was used to analyse the appropriate 
parameters (Bouxsein et al. 2010). 
3.3.5 Tendon analysis 
Tendon analysis was described in detail in Section 2.6. Briefly, images were taken 
of each tendon specimen, using a Nikon Eclipse Ci microscope equipped with a 
10x/0.30 lens and a Nikon DS-Fi2 camera (Nikon, Tokyo, Japan).  
Tensile tests were performed on an Instron 3366 material testing machine 
(Instron, Massachusetts, USA) equipped with a 10N load cell in conjunction with 
Bluehill materials testing software (Instron, Massachusetts, USA). Samples were 
secured into custom clamps using a cyanoacrylate adhesive (superglue).  
Each specimen was subjected to 6 loading cycles to a peak load of 1.0 N and the 
results from the last cycle were used to determine the stress-strain behaviour of 
the specimen.  
3.3.6 Joint analysis 
Joint analysis has been described in detail Section 2.7. Briefly, one hindlimb from 
each mouse was transferred into a decalcification solution (EDTA, pH 7) and left 
at room temperature for 4 weeks without agitation. Samples were then embedded 
coronally in paraffin. Sections were cut using a HM355S microtome (Thermo 
Fisher Scientific, Massachusetts, USA). The cutting was carried out until the 
condyles could be seen. Sections were stained for Haematoxylin & Eosin and 
Safranin-O. 
Joints from two age groups (6 and 24 month old) of mice were initially analysed 
since the process is a laborious process from dissection to analysis. As no 
significant differences were seen between these two age groups, no further age 
groups were analysed. 
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3.3.7 Statistics 
Data was tested for normality and equal variance using SigmaPlot (v11.0) (Systat 
Software, Inc., London, UK). Direct comparison between two sets of data was 
made by Student's t-test. For multiple comparisons, data was analysed for 
statistical significance by one-way ANOVA incorporating pairwise comparisons. 
Data are presented as mean ±SEM. Values P<0.05 were considered significant. 
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3.4 Results 
3.4.1 Measurement of age-related changes in body mass 
Fig 3.1 Mean body mass of male C57Bl/6 mice at different ages (Data presented 
as mean +/- SEM) (n=6 except n=4 in 28 month old group). * represents a 
significant difference compared with mice at 3 months old, # represents a 
significant difference compared with mice at 6 months old, + represents a 
significant difference compared with mice at 18 months old. 
 
 
Mean body mass of C57Bl/6 mice at different ages are presented in Figure 3.2. 
There was a steady increase in mean body mass up to nine months old compared 
with body mass of mice at 3 and 6 months. Body mass did not change 
significantly from 9 months of age in the mouse until 24 months old when there 
was a significant decrease in body mass compared with body mass at 18 months 
old.. 
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3.4.2 Age-related changes in organ mass 
Table 3.1 Mean organ mass (mg) from mice at different ages. a represents a 
significant difference in values compared with mice at 3 months old, b represents 
a significant difference compared with 6 months old, c represents a significant 
difference compared with 12 months old, d represents and significant difference 
compared with 18 months old and e represents a significant value compared to all 
preceding ages (n=6 per group except n=4 in 28 month old group). Data presented 
as mean +/- SEM.  
Table 3.2 Mean organ mass as a proportion of body mass (mg/g). a represents a 
significant difference in values compared with mice at 3 months old, b represents 
a significant difference compared with 6 months old, c represents a significant 
difference compared with 12 months old, d represents and significant difference 
compared with 18 months old and e represents a significant difference compared 
to all preceding ages (n=6 per group except n=4 in 28 month group). Data 
presented as mean +/- SEM. 
Table 3.1 shows that heart mass significantly increased at 6 months old compared 
with mice at 3 months old and this was maintained until 28 months old. When 
expressed as a proportion of body mass, heart mass was again significantly 
increased by 6 months old but significantly reduced at 24 months of age compared 
with mice at 6, 12 and 18 months old. Lung tissue shows a significant increase in 
mass in mice at 6 month old but this remained consistent in mass until 28 months 
of age where a further increase was seen. The increase at 28 months old remained 
3 Months 6 Months 9 Months 12 Months 18 Months 24 Months 28 Months
Average 147 197  a 179 a 240 a 236 a,b 205 a 198 a
SEM 5 13 13 31 13 9 35
Average 156 208 a 222 a 240 a 231 a 228 a 269 a,b
SEM 10 12 11 11 10 13 15
Average 1382 1580 a 1632 a 1758 a 1888 a 1212 e 5441 e
SEM 51 76 94 131 40 128 1138
Average 334 402 a 452 a 496 a,b 525 a,b,c 450 a,d 461 a,b,d
SEM 13 13 14 24 26 35 22
Average 68 71 100 a,b 100 a,b 129 a,b 66 d 281 e
SEM 2 5 9 7 21 11 137
Average 254 388 a 386 a 386 a 344 a 383 a 369 a
SEM 25 31 18 25 46 23 37
Spleen
Brain
Heart
Lungs
Liver
Kidneys
3 Months 6 Months 9 Months 12 Months 18 Months 24 Months 28 Months
Average 5.5 6.5 a 5.5 b 7.2 a 6.9 a 5.0 b,c,d 6.1
SEM 0.2 0.3 0.3 0.8 0.3 0.6 1.4
Average 5.8 6.9 a 6.9 a 7.3 a 6.8 a,c 6.7 8.0 a,b,d
SEM 0.3 0.3 0.3 0.3 0.1 1.4 0.5
Average 51.6 52.3 50.1 53.3 55.0 39.1 a,b,d 156.9 e
SEM 1.0 1.5 2.3 3.4 1.5 9.8 26.1
Average 2.6 2.3 3.1 a,b 3.0 a,b 3.8 a,b,c 5.6 7.6 a,b,c,d
SEM 0.1 0.1 0.3 0.2 0.1 3.0 3.2
Heart OW/BW
Lungs OW/BW
Liver OW/BW
Spleen OW/BW
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significant when expressed as a proportion of body mass. Liver mass showed 
significant increases at 6 months of age, with a small but significant reduction in 
mass at 24 months of age. At 28 months there was a >3 fold significant increase in 
liver mass, however the large standard error would indicate that this was variable. 
When taken as a proportion of body mass liver mass remained consistent in the 
mouse until 24 months old when a reduction was seen. Again liver mass in mice 
at 28 months old was significantly increased. The spleen mass significantly 
increased at 9 months of age. As with the liver, at 24 months a reduction in spleen 
mass was seen which was followed by a large increase in mice at 28 months old. 
When taken as a proportion of body mass there was a gradual age-related increase 
in spleen mass. Kidneys showed an age-related increase in mass from 9 months 
until 18 months of age at which point the mass was reduced. Brain reached a peak 
mass in mice at 6 months old and remained consistent throughout the life span 
studied. 
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3.4.3 Age-related changes in muscle mass 
Table 3.3 Mean muscle mass (mg) at different ages from four hindlimb muscles. 
a represents a significant difference in values compared with mice at 3 months 
old, d represents and significant difference compared with 18 months old, e 
represents a significant difference compared with all preceding ages, f represents 
significant difference compared with 24 months old (n=6 per group except n=4 in 
28 month old group). Data presented as mean +/- SEM.  
Table 3.4 Table displaying mean muscle mass as a proportion of body mass 
(mg/g). a represents a significant difference in values compared with mice at 3 
months old, b represents a significant difference compared with 6 months old and 
e represents a significant difference compared with all preceding ages (n=6 per 
group except n=4 in 28 month old group). Data presented as mean +/- SEM 
Table 3.3 shows data for mean hindlimb muscle mass at different ages in 
C57BL/6 mice. There was no significant change in anterior tibialis muscle mass 
of mice until 24 months old and mass was further declined in mice at 28 months 
of age. There was no significant change in EDL mass until mice were 28 months 
of age. Soleus muscles significantly increased in mass in mice at 6 months old 
when compared with 3 months old; there was a significant decline in soleus mass 
in mice at 28 months of age. For the gastrocnemius muscle, there was a small but 
significant decrease in muscle mass at 12 months old, which then further declined 
at 28 months of age. 
Interestingly, when presented as a proportion of body mass (Table 3.4), anterior 
tibialis muscle showed an apparent decline in mass from 6 months of age with the 
3 Months 6 Months 9 Months 12 Months 18 Months 24 Months 28 Months
Average 63 56 64 58 57 45 e 38 e,f
SEM 5 4 7 4 5 4 1
Average 11 12 13 12 12 12 6 e
SEM 1 1 1 2 3 2 1
Average 9 0 0 11 11 10 7 e
SEM 1 1 1 2 1 1 1
Average 174 175 184 160 a 159 a 138 a 105 e
SEM 8 7 13 5 6 12 5
AT
EDL
Sol
Gas
3 Months 6 Months 9 Months 12 Months 18 Months 24 Months 28 Months
Average 2.3 1.9 a 1.9 a 1.7 a,b 1.7 a,b 1.7 a,b 1.2 e
SEM 0.1 0.0 0.2 0.1 0.1 0.1 0.2
Average 0.4 0.4 0.4 0.4 0.4 0.4 0.2 e
SEM 0.1 0.0 0.0 0.1 0.1 0.0 0.0
Average 0.3 0.3 a 0.3 b 0.3 b 0.3 b 0.4 0.2 e
SEM 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Average 6.5 5.8 a 5.6 a 4.9 a,b 4.6 a,b 4.9 a,b 3.2 e
SEM 0.2 0.1 0.2 0.2 0.1 0.2 0.3
AT MW/BW
EDL MW/BW
Sol MW/BW
Gas MW/BW
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largest decline seen in mice at 28 months old. Gastrocnemius muscle showed a 
significant decline from 6 months of age in the mouse with the largest decline in 
mass at 28 months of age. 
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3.4.4 Analysis of age-related changes in anterior tibialis fibre number and 
CSA 
Fig 3.2 Mean fibre number and cross-sectional area in anterior tibialis muscles of 
C57Bl/6 mice at 3 ages. * represents a significant difference compared with mice 
at 12 months old (Data presented as mean +/- SEM) (n=6)  
Fibre number data and CSA measurements are extremely time consuming and so 
muscle of mice at the ages 12, 18 and 28 months were chosen for further analysis 
based on changes seen in muscle mass data (Table 3.3) at time points when 
muscle mass appeared relatively stable, through to the age where the largest 
decline in mass was seen. There was a significant decline in the number of fibres 
in the anterior tibialis muscle at 18 months old compared with mice aged 12 
months. No further decline was seen in fibre number of muscles of mice at 28 
months old. Mean CSA increased in the anterior tibialis of mice between 12 and 
18 months old but was reduced in mice at 28 months of age compared with 18 
months of age. 
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3.4.5 Age-related changes in the posterior tibialis tendon 
 
Fig 3.3 Microscopic images of posterior tibialis tendon at 10x magnification. 
Displayed images are taken from mice at 6(A), 9(B), 12(C), 18(D) and 24(E) 
months of age.  
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Fig 3.4 Mean diameter of posterior tibialis tendon of mice at different ages. (Data 
presented as mean +/- SEM) (n=6) 
There were no significant differences in mean diameter of the posterior tibialis 
tendon at any age. 
Fig 3.5 Mean cross-sectional area of posterior tibialis tendon in C57BL/6 mice at 
different ages. (Data presented as mean +/- SEM) (n=6). 
There were no significant differences in mean cross-sectional area of the posterior 
tibialis tendon at any age.  
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Fig 3.6 Age-related changes in stress/strain relationship of posterior tibialis 
tendons (Data presented as mean +/- SEM) (n=6). A presented as stress over 
strain, B is presents as tangent modulus (MPa). 
No significant differences were seen in stress/strain curves at any age in the 
posterior tibialis tendon. The tendon of older mice appears to be unable to process 
higher stress/strains (based on the tangent modulus).  
 78 
 
3.4.6 Analysis of joint and ligament structure in 6 and 24 month old C57Bl/6 
mice 
Fig 3.7 Representative histological sections of the knee joint in the C57Bl/6 mice 
at 6 and 24 months of age. Sections were stained with H&E. A was magnified x4 
to show the whole joint, B (cartilage region) and C (cruciate ligament region) 
were magnified x20 to show detailed structures. 
There was a visible reduction in the total number of cell present in both the 
cartilage and ligament with increasing age. The ligament showed a visual 
reduction in size with increased age and also appeared to have fibril 
disorganisation. The meniscus also showed some reduction in size.  
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Fig 3.8 Representative histological sections of the knee joint in the C57Bl/6 
mouse at 6 and 24 months of age. Images SA-SC were stained with Safranin-O to 
show proteoglycans (red). SA was magnified x4 to show the whole joint, SB 
(cartilage region) and SC (cruciate ligament region) were magnified x20 to show 
detailed structures. 
There did not appear to be any major loss of proteoglycan content in the cartilage 
and there were no signs of cartilage damage or lesions.  
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3.4.7 Visualisation of age-related changes in hindlimb bones 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.9 Representative MicroCT images of the tibia (A) and femur (B) in the 
C57Bl/6 mouse at different ages. 
Representative images are presented from both the femur and tibia of the mouse at 
different ages (Figure 3.9). Images were chosen based on mean cortical and 
trabecular bone values. Images clearly show both the cortical and trabecular bone 
regions in both tibia and femur. A change in 2D shape of both bone sites was 
seen. Loss of trabecular bone was also seen with increasing age. 
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Fig 3.10 Representative reconstructed 3D scans of trabecular bone of tibia (A) 
and femur (B) of mice at different ages. 
When images were reconstructed, loss of trabecular bone was clearly evident in 
both bones analysed (Figure 3.10). The trabecular bone mass appeared less 
connected with increasing age. Smaller trabecular bones appeared to be lost first 
with the larger trabeculae becoming thinner with increasing age. 
 
A 
B 
A 
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3.4.8 Age-related changes in cortical and trabecular bone of tibia and femur 
bones 
 Fig 3.11 Mean cortical bone thickness of tibia (A) and femur (B) in mice at 
different ages (Data presented as mean +/- SEM) (n=6) * p <0.05 compared with 
mice at 3 months old, # p <0.05 compared with mice at 6 months old, + p <0.05 
compared with mice at 18 months old. 
The tibia showed a significant increase in cortical bone thickness at 6 months of 
age. This remained at a constant level until 18 months of age, after which levels 
decreased to values similar to those seen at three months old. There was a further 
 83 
 
significant decrease in tibia cortical bone thickness at 28 months of age which was 
significantly reduced compared to values at 3, 6 and 18 months old. 
Figure 3.11 B shows the cortical thickness of the femur. There was a significant 
increase in thickness between 3 and 6 months of age. This remained at a similar 
value for up to 12 months of age in the mouse. At 18 months of age in the mouse, 
femur cortical thickness was significantly reduced compared with values at 6 
months old and the decline continued at both 24 and 28 months of age.  
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Fig 3.12 Mean cross-sectional area of tibia (A) and femur (B) in mice at different 
ages (Data presented as mean +/- SEM) (n=6) # p <0.05 compared with mice aged 
6 months old, + p <0.05 compared with data for mice aged 18 months old. 
 
There was a significant reduction in cross-sectional area of both the tibia and 
femur from 18-24 months of age in the mouse which remained evident at 28 
months of age, and was significant in the tibia.  
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 Fig 3.13 Mean trabecular bone surface density of tibia (A) and femur (B) at 
different ages (Data presented as mean +/- SEM) (n=6) * p <0.05 compared with 
mice aged 3 months old, # p <0.05 compared with mice aged 6 months old, ^ p 
<0.05 compared with mice aged 12 months old and + p <0.05 compared with 
mice aged 18 months old. 
 
There was a dramatic age-related loss of bone surface density in both the tibia and 
femur throughout life. In particular, there was a 31% decrease in the tibia and a 
35% decrease in the femur surface density in mice at 6 months old compared with 
3 month old mice. This was followed by a more gradual decrease in bone surface 
density in mice after 12 months of age which continued for up to 24 months old.   
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Fig 3.14 Mean number of trabecular bone/mm
2
 present in the tibia and femur in 
mice at different ages (Data presented as mean +/- SEM) (n=6) * p <0.05 
compared with mice aged 3 months old, # p <0.05 compared with mice aged 6 
months old, ^ p <0.05 compared with mice aged 12 months old and + p <0.05 
compared with mice aged 18 months old. 
 
There was a large reduction in the trabecular number present in both the tibia and 
femur in mice between 3 and 6 months of age which equated to approximately 30-
35% loss of trabeculae. A further decrease in trabecular number was seen in mice 
at 12 months old which was further significantly reduced at 24 months old.   
A 
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Table 3.5 (A) shows the percentage change at chosen age points of trabecular 
number in the tibia trabecular bone. (B) shows the percentage change at chosen 
age points of trabecular number in the femur trabecular bone. (C) shows total 
percentage loss of trabecular bone in the tibia and femur between 6 and 24 months 
in the mouse. (Data presented as mean +/- SEM) 
The percentage of trabecular bone lost over time appeared to differ between bone 
sites. The tibia appeared to lose more trabecular bone between 6 and 12 months 
compared with the femur but lost less between 12 and 24 months. At both sites 
more bone loss occurred between 12 and 24 months of age compared with 6-12 
months. 
In general, both bone has lost >50% of trabecular bone by 24 months old 
compared with 6 months old. 
 
C 
A 
B 
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Table 3.6 Pearson correlation calculations comparing the cortical thickness (A) 
and trabecular number (B) of the tibia and femur and their attached muscles mass.  
There was a total positive correlation when the relationship between anterior 
tibialis mass and tibia cortical thickness was compared. There was a strong 
positive correlation between gastrocnemius mass and femur cortical thickness. 
There were strong correlations between loss of muscle mass and loss of trabecular 
bone at both sites however the correlation was stronger for the gastrocnemius and 
femur. This would indicate a close relationship between the mass of the muscle 
and the characteristics of the underlying bone. 
 
  
A 
B 
A 
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Fig 3.15 Correlations showing muscle mass against the cortical bone thickness of 
the underlying bone. A shows gastrocnemius and femur, B shows anterior tibialis 
and tibia  
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Fig 3.16 Correlations showing muscle mass against the trabecular bone number of 
the underlying bone. A shows gastrocnemius and femur, B shows anterior tibialis 
and tibia   
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Fig 3.17 Changes in trabecular bone thickness in the tibia and femur of mice at 
different ages. (Data presented as mean +/- SEM) (n=6) * p <0.05 compared with 
mice aged 3 months old, # p <0.05 compared with mice aged 6 months old, + p 
<0.05 compared with mice aged 18 months old. 
Increases in trabecular thickness were seen in both bones of the mouse at 12-18 
months of age. However, a significant decrease in trabecular bone thickness was 
seen at 24 months of age compared with values at 18 months old. This reduction 
remained evident in both the tibia and femur in mice at 28 months old. 
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Fig 3.18 3D representation of trabecular bone thickness through age in the tibia. 
White colours represent the thicker areas, purple colours representing the thinner 
areas. Scale is specific to each individual bone based of mean and SEM as such, 
no key is present.  
There were visual decreases in trabecular thicknesses in the tibia between 3 and 
28 months of age. The loss of trabecular bone was also evident. 
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Fig 3.19 3D representation of trabecular bone thickness through age in femur. 
White colours represent the thicker areas, purple colours representing the thinner 
areas. Scale is specific to each individual bone based of mean and SEM as such, 
no key is present.  
There were visual decreases in trabecular thicknesses in the femur between 3 and 
28 months of age. The loss of trabecular bone was also evident 
B 
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 Fig 3.20 Combined range of mean trabecular thickness in the tibia for each age 
point in the mouse. (Data presented as mean +/- SEM) 
Figure 3.19 shows the range of trabecular thicknesses in the mouse tibia at 
different ages. Data show an apparent shift towards thicker trabecular up to 18 
months old, followed by a reduction at 24 and 28 months old. 
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 Fig 3.21 Combined range of mean trabecular thickness for each age point in the 
femur. (Data presented as mean +/- SEM) 
Figure 3.20 shows the range of trabecular thicknesses in the mouse femur at 
different ages. Data show an apparent shift towards thicker trabecular up to 18 
months old, followed by a reduction at 24 and 28 months old. 
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3.5 Discussion 
3.5.1 C57Bl/6 mice as a model of ageing 
A mouse model was chosen for this study to produce successful and reproducible 
methods of measuring age-related changes in musculoskeletal tissues. By using 
mice, the aims could be achieved in an appreciable timescale and provide fully 
characterised data sets that could be used to examine potential effects of possible 
future interventions. 
C57Bl/6 mice are a well-recognised strain of mice and was chosen as it has been 
widely used in laboratory settings; often these mice have been used to produce 
transgenic mice with altered genetics. Despite this, little work has focused on 
lifelong changes in the musculoskeletal system of these mice. 
From the data presented, it is apparent that C57Bl/6 mice are a good model of 
musculoskeletal ageing, particularly for muscle and bone ageing. The data were 
correlative to changes seen in human studies (Faulkner et al., 2007).  
3.5.2 Age-related changes in the C57BL/6 mouse 
3.5.2.1 Changes in body mass 
Body mass increased with increasing age up to 9 months of age with no further 
significant increases in body mass between 9 and 18 months (Figure 3.2). There 
was a decrease in body mass of mice seen at 24 months of age. Despite this 
decrease, body mass at 24 months of age was still significantly increased 
compared with 3 months old. Body mass increased again at 28 months of age.  
The early increases in body mass can be attributed to increases in muscle tissue, 
organ tissue and a previously observed but not recorded deposition of fat tissue 
which all increase with age (Table 3.1, 3.3). The lack of any further increases in 
mass during 9 to 18 months of age in the mouse reflects the data showing relative 
stability of tissue mass during the time period. The decrease in mass of mice at 24 
months of age reflects concurrent loss of muscle mass particularly evident in 
larger muscles such as the anterior tibialis and gastrocnemius (Table 3.3). The 
following increase in body mass at 28 months was theorised to be an artefact of 
this study. In the 28 month group, there was an increased presence of liver 
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tumours which was not evident in the 24 month old mice (Table 3.1, Figure 3.24). 
This excess growth of the liver was noted and seems to have resulted in an 
increase in overall body mass. Removing mean liver mass from mean body mass 
resulted in the body mass remaining steady after 12 months of age, suggesting that 
the mass of the liver is a major factor in the age-related increase seen in body 
mass (Figure 3.23). Thus, care needs to be taken when expressing tissue mass 
relative to body mass and it may be more accurate to express tissue mass relative 
to body mass minus liver mass, or at least be aware of potential effects of 
increased liver mass on data.  
Fig 3.22 Mean body mass of C57Bl/6 mice minus liver mass at different ages 
(Data presented as mean +/- SEM, n=6) * p <0.05 compared with mice aged 3 
months old, # p <0.05 compared with mice aged 6 months old.  
3.5.2.2 Age-related changes to organ mass 
The mass of all measured organs are shown in Table 3.1. In general in a similar 
manner to body mass, the mass of all tissues reached peak values between 12-18 
months old. The heart did not reach peak mass until 12 months of age, after 18 
months this began to decline again however by 28 months the mass was still 
significantly higher than values recorded at 3 months of age in the mouse. Lung 
mass increased until mice were 12 months old at which point mass remained 
constant until a further increase at 28 months of age. The liver appeared to 
gradually increase in mass until 18 months old at which point mass was reduced. 
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However, at 28 months of age in mice this mass was increased. This was an 
artefact of increased presence of liver tumours (Figure 3.24). Considering the 
increased risk of tumours in the liver, and the influence liver mass has on the body 
mass, it would suggest that 28 months may not be a suitable age to use.  
 
 
 
 
 
 
 
 
 
Fig 3.23 An example of a liver tumour taken from a 28 month old C57Bl/6 mouse. 
 The combined kidney mass also gradually increased in mass with age until 18 
months old, at which point mass starts to decline. The brain of the mice reached 
its peak mass at 6 months and did not decline until the mice were 28 months old. 
The mass of the spleen continued to increase throughout life reaching a peak at 28 
months old. The spleen is an organ that is known to have roles in active immune 
responses. Increases in spleen size can be due to infection or changes to the 
regulation of the immune system which may potentially suggest a modified 
inflammatory environment within the mice at older ages (Zhu et al., 2014). 
By expressing organ mass as a proportion of body mass, the heart mass remained 
relatively constant. Lungs still reached a peak at 12 months. Liver mass remained 
constant throughout life until 24 months where they appeared to decrease in mass 
until 28 months of age. There was a clear age-related increase in the size of the 
spleen throughout life in the mouse indicating increased inflammatory or diseased 
states with increased age (Table 3.2).  
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Changes in organ mass through life in this study are similar to published data 
(Lessard-Beaudoin et al., 2015) with the exception of liver mass. In the current 
study, this has been shown to be due to increased tumours in the 28 months 
cohort. This would suggest that the mice in this study (Lessard-Beaudoin et al., 
2015) do not present with tumours or that data may have been (correctly) removed 
for mice with showing liver tumours, although this is not explicitly stated. 
Interestingly, this increase in liver mass with increased incidence of liver tumours 
has been reported previously in a mouse model of accelerated ageing, the SOD1
-/-
 
mouse (Jang et al., 2010), suggesting that modified ROS signalling plays a role in 
the increase of tumour incidence. 
3.5.2.3 Changes in hindlimb muscle mass 
Four muscles of the hindlimbs were used to measure changes in muscle mass. 
These were chosen due to ease of dissection with clear tendon demarcation. 
Overall declines in muscle mass were seen with increasing age consistently 
throughout the 4 measured muscles (Table 3.3). In the larger anterior tibialis and 
gastrocnemius muscles, a decline was seen from an earlier age when compared 
with the smaller soleus and EDL muscles. This may be due in part to the larger 
changes in mass being easier to measure. The gastrocnemius loses approximately 
13% of mass (21mg) between 18 and 24 months old whereas the 8% loss by the 
soleus does not reach significance as this equates to a loss of only 1mg. Clearly a 
difference of 21mg is easier to measure and will therefore influence the data 
analysis. 
 Focusing on gastrocnemius muscle, there was a significant decline in 
gastrocnemius muscle mass by 12 months old. In the anterior tibialis this was 
seen at 24 months of age. Both muscles saw a further, large decline in mass in 
mice between 24 and 28 months. 
When expressed as a proportion of body mass, all muscles lost mass through age 
and again the largest decreases were seen in mice aged 24 and 28 months 
although, for reasons stated earlier, data for 28 month old mice need to be treated 
with caution. The mass of the EDL and soleus remained consistent in these mice 
until 28 months of age however both gastrocnemius and anterior tibialis muscles 
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displayed significant declines in mass from 6 months of age with a further 
decrease at 12 months old (Table 3.4). 
When removing the liver mass from the total body mass, no major changes in the 
pattern of muscle loss were seen and only minimal changes in terms of muscle 
mass to body mass value. This suggests that although changes in liver mass at 28 
months old does influence body mass, this does not significantly influence the 
muscle mass (Table 3.9). 
Table 3.7 Mean muscle mass as a proportion of body mass following removal of 
liver mass (Data presented as mean +/- SEM). 
These data are similar to other studies examining muscle loss in mice and add to 
the current information on life-long loss of muscle mass in this species (Hamrick 
et al., 2006, Graber et al., 2015, Brooks and Faulkner, 1988, Larsson and Ansved, 
1995, Brooks and Faulkner, 1991).  
The presence of significant liver tumours in mice at 28 months old is also likely to 
play a significant role in the muscle loss seen in mice at this age. There are well 
characterised cachectic effects of tumours on skeletal muscle and so additional 
caution is needed when using this age of mice as a model of ageing. 
When studying muscle changes in more detail in the anterior tibialis muscle, 
changes in the total muscle fibre number were seen despite no significant change 
in overall muscle mass. In mice aged between 12 and 18 months, a significant 
reduction in the number of muscle fibres was seen. This was offset by significant 
increases in individual fibre cross-sectional area which appears to have resulted in 
the muscle mass remaining constant at the 18 month time point. In 24 month old 
mice, muscle mass was significantly lower compared with earlier time points and 
this seems to be caused by atrophy of the remaining muscle fibres with no further 
loss of fibres evident at this age (Figure 3.3). 
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This would suggest that although muscle mass may remain steady until 18 months 
old in C57Bl/6 mice, underlying changes to the muscle structure and function 
were occurring prior to this, in agreement with other reported studies (Graber et 
al., 2015). 
The causes of the muscle fibre loss are still unclear. This is proposed to be due to 
changes in innervation. In particular the neuromuscular junction that controls fibre 
contraction is known to deteriorate with age. If a muscle fibre is dennervated, it 
undergoes atrophy and is eventually is lost. If this occurs over a long period of 
time, surrounding fibres may adapt to increasing demand and there is a 
hypertrophy in these fibres in an attempt to maintain the overall need of the 
muscle to produce force. Once the muscle reaches a critical threshold where the 
muscle fibre loss continues, the remaining fibres cannot adapt any further and a 
loss of the ability of muscles to produce sufficient force will then be seen. This 
will manifest as muscle weakness in the older person. As discussed in Chapter 1, 
there are a number of additional factors which may play a role in this later stage 
fibre atrophy, including the need for adequate dietary protein intake. 
3.5.2.4 Age-related changes in tendon characteristics 
The posterior tibialis tendon was chosen to study due to the ease at which it could 
be reproducibly dissected and analysed and ease of measurement of a wide range 
of tendon properties (Figure 3.4). However, analysis of mouse tendons is 
particularly challenging given their small size. 
There were no statistically significant changes in mean tendon diameter (Figure 
3.5) or total cross-sectional area (Figure 3.6). There are currently no studies that 
have determined the cross-sectional area of the posterior tibialis tendon to directly 
compare these data to but it is possible that, due to the small size of the tendon, 
any changes were too small to record, in a similar manner to the mass of the 
smaller hindlimb muscles such as the soleus and EDL muscle discussed 
previously. 
Due to the small size of the tendons, it is also possible that stress-strain 
measurements may have been influenced directly by the grips needing to attach to 
the tendon. Despite this, a decrease in the tangent modulus with increasing age 
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was seen when higher forces were applied (Figure 3.7). This would suggest an 
inability of tendons in old mice to tolerate larger forces applied from muscle. This 
may have arisen due to reduction in the forces applied by the muscle on the 
tendon in vivo at older ages, as mean muscle mass and force generation was 
reduced with increasing age. The age-related changes in mechanical properties of 
tendons described here may reflect morphological and biochemical changes 
previously reported in mice (Shadwick, 1990) which include increased collagen 
content, increased fibril diameter, reduction of fibril crimp angle and decreased 
water content (Elliot, 1965). These data also support the study by Dunkman 
(2013) (Dunkman et al., 2013) who reported that tendons of 18 month old 
C57Bl/6 mice showed less stress in response to strain and were more viscous, so 
more likely to lose energy from applied forces, ultimately leading to a functional 
deficit (Dunkman et al., 2013). 
3.5.2.5 Age-related changes in the knee joint of C57Bl/6 mice 
Using histological sectioning, the joint was visualised and the major structures 
identified for characterisation and comparison (Figure 3.8). No major structural 
changes in terms of bone shape were seen at the joint and there were no signs of 
osteophyte structures growing which are signs of osteoarthritis (Gelse et al., 
2003). There were also no clear signs of cartilage loss which is common with 
human ageing (Figures 3.8, 3.9).  
There were some structural changes in the soft tissues such as the ligament which 
appeared to lose fibril organisation and visually appeared to be reduced in 
diameter. The meniscus also became smaller with age (Figures 3.8, 3.9). There 
was a clear loss of cells within the cartilage and ligaments with age indicating a 
reduced cellular activity and therefore reduced tissue maintenance (Figure 3.8, 
3.9). These may cause restricted movement within the hindlimb. 
Although the lack of deterioration of cartilage in the joint was unexpected, this 
has been reported in other studies especially with the C57Bl/6 mice which rarely 
show loss of cartilage with increasing age on the patellar/femur joint or medial 
views of the tibia femur joint (van der Kraan et al., 2001). This would suggest that 
C57Bl/6 mice do not naturally develop osteoarthritis and that joints remain in a 
stable state from the age of 6 months until at least 24 months of age. This could 
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possibly be due to the quadrupedal movement of mice and so equal distribution of 
mass between four joints rather than two as with humans. Although models of 
osteoarthritis have been established within the mouse through disrupting the joint 
via disruption of the medial meniscus (DMM) (Culley et al., 2015) or through 
gene knockouts to provide some pathophysiology, the lack of evidence of this 
event occurring naturally would suggest that wild type laboratory mice are not 
suitable models for studying the development and treatment of osteoarthritis. The 
DMM model in particular is a process aiming to mimic meniscus injury which is 
presumed to be a predisposing factor for osteoarthritis (Culley et al., 2015).  
3.5.2.6 Age-related changes in hindlimb bones of C57Bl/6 mice 
Using a combination of original microCT images and 3D renderings of the 
internal skeletal compartments, age-related changes in bones could be clearly seen 
(Figures 3.10, 3.11). 
MicroCT images provide contextual imagery to see changes at comparable 
positions in each bone with both cortical and trabecular bone compartments being 
visible at different ages in the mouse. Images also allowed for the shape of each 
bone to be determined, which can often be lost from other measurements such as 
mean bone cross-sectional area. Via 3D rendering, visualisation of the trabecular 
bone in 3D space can also be achieved. This allows for the age-related changes in 
bones to be identified more clearly (Figure 3.11). 
Measurements were taken on the two main bones found within the hindlimb, 
representing differential effects of mass bearing as well as the attachment of 
anterior tibialis and gastrocnemius muscles to these bone sites were shown. 
Measurements taken from the tibia and femur are shown in Figures 3.12-3.22 and 
representative images are shown in Figures 3.10 and 3.11. In cortical bone, the 
thickness of the measured bone peaked at 6 months old. This remained relatively 
steady until 18-24 months old, following which was a reduction in values. There 
was a further decrease between 24 and 28 months of age (Figure 3.12). This initial 
increase was not as marked when examining mean bone cross-sectional area, CSA 
remained relatively constant until 18-24 months at which point values decreased 
and remained low through to 28 months old, particularly in the tibia (Figure 3.13). 
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This would suggest that the small increases in cortical bone thickness in mice up 
to 18 months old contributes at least in part to the small increases seen in CSA at 
these ages, but that cortical bone thickening occurs primarily on the inner surface 
reducing the centre volume of the bone rather than increasing the CSA 
significantly (Figure 3.10). The decrease in cortical thickness at 24-28 months old 
is however reflected in a reduced CSA at this age in both bones, suggesting that 
changes in cortical thickness contribute significantly to the decrease in bone CSA. 
Changes in trabecular bone measures can be seen in Figure 3.14-3.19 and this is 
visualised in 3D in Figure 3.11. The percentage of bone in the measured volume 
was reduced throughout life with the large reductions seen in mice at two distinct 
time points, between 3 and 6 months as well as at 12 months old when compared 
which continued to decline up to 24 months old (Table 3.8). This was associated 
with a reduction in the number of individual trabecular bones present. Again large 
reductions were seen in mice between 3 and 6 months and 18 to 24 months of age. 
This also led to reductions in the connectivity of the trabecular bone as a whole 
(Table 3.5). 
Despite these changes, individual trabecular bone thickness was not significantly 
changed until later in life (24 months old) (Figure 3.16). When comparing the 
range of trabecular thicknesses with the same value in mice at 3 months of age, 
differential ranges were seen with increasing age. There was a gradual shift 
towards a higher level of thicker trabecular bone until 18 months old. This was 
due to smaller trabecular bones increasing in size and potentially the removal of 
some smaller trabecular bones occurring. Eventually the larger trabecular bones 
also became thinner. This would suggest that despite an age-related loss of 
trabecular bone within the tibia and femur, remaining trabecular bone is 
remodelled and increased in thickness until approximately 18 months of age 
(Figure 3.14, 3.15). 
What was evident is that the tibia displayed a larger number of trabecular bone 
present at three months when compared with the femur. However in mice by 28 
months of age, the femur has retained more individual trabecular bone. 
Interestingly, when comparing the number of trabecular bone present through age 
with the mean mass of the attached muscle (femur and gastrocnemius muscle, 
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tibia and anterior tibialis muscle) using Pearson correlations, a close age-related 
relationship between the two separate tissues was seen. This relationship was 
particularly striking when examined at 6, 12 and 24 months of age which 
represents time points at which significant changes were seen (Figure 3.13). 
This close relationship would suggest the mass of the muscle attached to the bone, 
and therefore the potential force that the said muscle can apply to the bone, may 
directly influence the amount of cortical and trabecular bone present. To further 
support this hypothesis, change in trabecular number was converted to a 
percentage. In mice between 6 and 24 months of age there was roughly 55% of 
trabecular bone lost at both bone sites. When this change in trabecular bone was 
divided further to show changes in mice between 6 and 12 months (where muscle 
mass was stable) and 12 to 24 months of age (where total muscle mass and 
individual muscle fibre numbers were significantly reduced), proportionally more 
bone was lost at this age when compared with between 6 and 12 months old. An 
early loss of bone tissue between 3 and 6 months in mice (whilst muscle is still 
growing and producing mechanical stimulus) was also seen, which appeared to be 
due to remodelling events to allow for optimal force handling. This loss was 
slowed whilst muscle reached a peak mass and continues in tandem with loss of 
muscle fibres. 
These finding together would therefore suggest a close relationship between the 
two tissues which is potentially dependent on mechanical influences from the 
muscle to bone. This theory has been established through computer modelling and 
is an increasing popular technique to monitor the effects of muscle force on 
underlying bone (Vickerton et al., 2014). Although other factors discussed in 
Chapter 1 such as paracrine and endocrine responses may also be having a role in 
this process. 
There have been few publications reporting age-related changes in the tibia and 
femur of the mouse. One such paper (Halloran et al., 2002) showed that tibia 
trabecular bone volume decreased continuously from 1.5 months of age until the 
end of study at 24 months old. Data presented in the current study agrees with a 
lifelong loss of tibia trabecular bone volume and this remained evident at 28 
months of age. Data presented here however also showed a steep decrease in tibia 
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trabecular bone volume from 3 to 6 months of age, and no further loss until after 
12 months of age which differs to data represented by (Halloran et al., 2002)). 
Although Halloran et al., (2002) reported a decrease in the number of trabecular 
bone in the tibia; these authors only recorded a 37% loss between 5.5 months and 
24 months compared to 52% measured in this study. Halloran et al., (2002) also 
noted no significant losses of trabecular bone between 12 and 24 months, a 
finding that was not seen in the current study (Halloran et al., 2002). A further 
discrepancy was seen in connectivity density values with Halloran et al., (2002) 
reporting constant values from 12 months of age following an increase prior to 
this, whereas in the current study no significant changes between 6 and 24 months 
of age were recorded.  
Differing patterns of changes in the cortical bone of the tibia are also seen when 
comparing the two studies. In the current study, an increase in cortical bone 
thickness between 3 and 6 months of age was seen; there were no further 
significant changes until values decline again from 18 months onwards. Halloran 
et al. (2002) described a decrease in cortical bone thickness following a peak at 6 
months of age (Halloran et al., 2002). 
The differences reported in the Halloran et al., (2002) study and the current work 
may be due to differing microCT scanners and the bones being scanned at a much 
higher resolution (18μm compared to 4.5 μm). Another issue with the Halloran 
(2002) study was that only the tibia was studied and having measured both tibia 
and femur in the current study, each site aged marginally differently from each 
other. Although time points earlier than 3 months may have been beneficial to 
study based on Halloran et al., (2002), high levels of remodelling seem to be 
occurring at these ages. This may have changed the outcome when looking at the 
entire life course, but may be beneficial to record in the future.  
Another study detailing age-related changes in the bone of C57Bl/6 mice was 
published by Glatt et al (Glatt et al., 2007). This study again mirrored the results 
presented in this study but Glatt et al. (2007) focused on early life more than later 
life. Again Glatt et al. (2007) described lifelong decreases in trabecular bone 
volume and trabecular number although values differred slightly from the 
presented values in this study (Glatt et al., 2007). This may be due to the scanning 
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techniques. Glatt et al. (2007) reported 12μm resolution which was improved 
compared to Halloran et al (2002) but was still higher then used in this study 
(Glatt et al., 2007). The Glatt paper did however show the benefits of recording 
two sexes and two different bone sites which our study did not do and would be 
beneficial to do so in the future. 
Based on the evidence presented, it is reasonable to suggest that the major 
influencing factor in the age-related loss of bone mass is the changes in the 
muscle mass and force, after initial remodelling events seen at the age of 6 
months. This change may due to a reduction in muscle force causing the 
mechanosensitive osteocytes within the bone to signal to the osteoclasts that the 
bone is not needed and the minerals held within the bone would be better used 
elsewhere (Wolff, 1988, Bren-Mattison et al., 2011). This would lead to 
reductions in both cortical and trabecular bone thickness and if broken down 
enough, can lead to the trabecular bone numbers decreasing. 
Another theory is that external influences such as changes in hormones, changes 
in cytokines and/or changes in external signals from the muscle (myokines) may 
be triggering the resorption of bone either through activation of osteoclasts or 
blocking the action of osteoblasts. 
It is most likely that a combination of these possible mechanisms is responsible 
but it is clear that the key to maintaining bone mass into later life may be through 
keeping the muscle healthy. 
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3.6 Conclusions 
The data presented here have fully characterised the major changes in the 
musculoskeletal tissues throughout life with particular focus on ageing within the 
male C57Bl/6 mouse. 
 Body mass increased from 3 months old and peaked at 9 months old until 
a significant loss was seen at 24 months old. The influence of liver mass 
on body mass suggests that care needs to be taken when expressing tissue 
mass relative to body mass. 
 
 Organs reach peak mass between 6 and 9 months of age and do not show 
major declines in mass in later life. Exceptions are organs influenced by 
the presence of tumours (Liver) or potential signs of infection (Spleen). 
 
 All hindlimb muscles examined showed a significant loss in mass between 
24 and 28 months of age with the larger muscles, losing more muscle mass 
at an earlier age. The changes in muscle fibre number and size earlier in 
life appears to be the initial point of decline in muscle function with some 
evidence of compensatory hypertrophy (Sakellariou et al., 2014a). 
 
 Ageing of musculoskeletal tissues is closely linked, particularly between 
muscle and bone. Bone modelling events occurring early on in life are 
potentially controlled in part by increasing muscle mass and force. 
 
 There were no major changes in tendon tissue with age. This may be due 
to the method used to measure function, the tendon chosen or may be that 
tendons are resistant to age-related changes in contrast to those evident in 
muscle and bone.  
 
 There appeared to be no major signs of naturally occurring osteoarthritis in 
the C57Bl/6 mouse. As previously discussed this could be due to the 
fundamental difference in movement between mice and humans. 
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In summary, this study has integrated methods of measuring and quantifying age-
related changes in musculoskeletal tissues in C57Bl/6 mice and has identified the 
time points where major changes in structures are seen. This model of 
musculoskeletal ageing in C57Bl/6 is a powerful model to study age-related 
changes in muscle mass and bone although may not be as useful in measuring 
changes in the joint or tendon with age. 
Taking these values and the methods developed for measuring and images 
musculoskeletal tissues, we feel confident in applying these to experimental 
procedures involving interventions to prevent of delay the age-related changes in 
muscle and bone in this mouse model. 
Having looked at how the C57Bl/6 mouse ages under uninterrupted environments, 
we will look to prevent these detrimental changes seen with age. To fully translate 
any therapy into future human work, we will look first to alter the diet to promote 
improvements in age related changes found in musculoskeletal tissues, providing 
a less invasive form of treatment. 
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Chapter 4 
Age-related changes in musculoskeletal tissues of 
C57Bl6 mice following short and long-term 
treatment of mice with sodium nitrate  
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4.1 Introduction 
4.1.1 Current dietary interventions aimed at improving age-related loss of 
musculoskeletal mass and function 
The transition from middle age to elderly is usually associated with a decrease in 
body mass, partly through loss of appetite (Morley, 1997). From the age of 20 to 
the age of 80, total dietary intake decreases up to 1200 kcal in men and 800 kcal 
in women per day which can be further compounded by other factors such as 
hospitalisation (Trumbo et al., 2002). In addition, advanced age often leads to 
changes in food preference and a switch to sweeter foods, ultimately missing 
dietary targets for protein, vitamin and mineral intake. Age UK (June 2015) 
estimates 1.3 million people aged over 65 suffer from malnutrition. 
As we shall see, although improving diet in aged populations has had positive 
effects in modulating some of the age-related decline in tissues (particularly 
muscle), these results have often been in combination with other interventions 
such as exercise and so far, few dietary interventions alone have resulted in 
significant improvement musculoskeletal tissues structure and function in 
humans.  
A well characterised dietary intervention aimed at improving muscle function is 
increased protein intake. As discussed previously in Section 1, muscle relies on a 
large supply of protein from the diet in order to function correctly. As we age, 
there is evidence of reduced protein intake (Kerstetter et al., 2003) and it is very 
rare to find older individuals who consume the highest recommended protein 
values (Trumbo et al., 2002). There are a number of studies showing that 
increased total protein intake or increasing the intake of essential amino acids can 
improve some measures of muscle quality in older people (Farsijani et al., 2016). 
Despite the popularity of increasing protein in the diet, very few studies have been 
conducted to determine the effects modified dietary protein intake on bone mass 
and function – a weakness shared with many dietary studies. 
One dietary intervention has recently been proposed to potentially be beneficial to 
both muscle and bone tissues. This is increased dietary nitrate. 
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4.1.2 Nitrate effects within the body 
Nitrate and nitrite were originally deemed unnecessary residues from the food 
chain that may carry a potential carcinogen risk or as the inert oxidative end 
products of nitric oxide metabolism (Gilchrist et al., 2010). This approach has 
changed since ~2000 and it is now known that these compounds are capable of 
eliciting physiological effects through the conversion to nitric oxide and other 
active nitrogen oxides (Lundberg et al., 2008). Nitrates are therefore thought of as 
dietary sources of nitric oxide, complementing the cellular nitric oxide synthase 
pathways. This had led to research into the possible function of nitrate and nitrite 
supplementation within the body (Lundberg et al., 2008). 
The most abundant source of nitrates in the diet is green vegetables (van Velzen et 
al., 2008). Nitrate is actively taken up into the blood via the salivary glands where 
it is concentrated 10-20 times within the saliva (van Velzen et al., 2008). 
Approximately 25% of nitrates are taken up this way. It has been reported that a 
portion of vegetables high in nitrate such as spinach contain more nitrate than is 
formed endogenously over the course of a day (van Velzen et al., 2008). 
Production of nitrite from nitrate appears to be facilitated through commensal 
bacteria in the oral cavity of mammals. Anaerobic bacteria in the oral cavity 
contain nitrate reductase enzymes which reduce approximately 20% of nitrate to 
nitrite (Doel et al., 2005). These bacteria assimilates nitrate for use in the 
production of energy in the absence of oxygen, forming nitrite as a by-product 
(Doel et al., 2005, Moreno-Vivian et al., 1999) so the level of nitrite found in 
saliva is increased (Lundberg and Govoni, 2004). 
Nitrite is converted to nitric oxide (NO) through the acidic conditions in the 
stomach (Benjamin et al., 1994). Much of the nitrite found here can pass into the 
systemic circulation without being further converted (Lundberg and Govoni, 
2004). Once within the circulation, there are numerous tissues that can convert 
nitrite into the active NO molecule. These include both haemoglobin and 
myoglobin amongst other compounds (Lundberg and Govoni, 2004). The well 
characterised function of NO is to modulate blood flow in times of hypoxia. In 
hypoxic conditions, nitric oxide synthase enzymes perform poorly. It has been 
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shown that the body can actually store and recycle the nitrate-nitric oxide products 
(Lundberg and Govoni, 2004). 
Both nitrate and nitrite are known to modulate oxidative stress, mitochondrial 
function and have been shown to reduce oxygen consumption during exercise - a 
property that has led to a much interest in sports science research (Larsen et al., 
2007). 
4.1.3 Effects of nitrate supplementation on muscle mass and function 
The effects of nitrate supplementation on muscle especially during exercise have 
been relatively widely studied. Larsen et al (2007) showed that supplementation 
of people with 0.1 mmol/kg/day of sodium nitrate was capable of reducing the 
amount of oxygen needed by humans to perform cycling exercises (Larsen et al., 
2007). This was followed by another report showing a 16% improvement in 
tolerable duration of high intensity exercise. Improvements have been shown in 
walking, running, cycling, and rowing exercises, with positive results in both 
acute and long-term supplementation (Affourtit et al., 2015). 
In muscle, it has been stated that nitrate supplementation alters the rate of 
oxidative ATP synthesis (reducing the amount of oxygen needed) and lowers the 
oxygen and ATP cost of contractile force production (Whitfield et al., 2016, 
Kemp, 2016). Within cell culture models of muscle, treatment with nitrate can 
lead to mitochondrial biogenesis, increasing cellular respiration (Bailey et al., 
2009).  
The effects of nitrate supplementation however appear to be specific to fast twitch 
fibres of muscles which may be due to a lower oxygen levels within the 
microvasculature of these fibres during force production (Hernandez et al., 2012). 
This furthers the evidence seen of the benefit of nitrates particularly during 
hypoxic conditions.  
Positive effects of supplementation appear to be somewhat blunted in well trained 
athletes especially those trained in endurance exercise and there is a possible 
differential effect in ageing populations (Bailey et al., 2009). 
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Older people have limitations in oxygen delivery to tissues including muscle and 
reduced skeletal muscle blood flow, both of which are improved in younger 
subjects during exercise with supplementation of nitrates (Bailey et al., 2009). The 
potential to improve or reverse this with nitrate supplementation is therefore of 
major importance. 
4.1.4 Effects of nitrate supplementation on bone 
Most studies examining the effect of nitrates on bone have examined the product 
of nitrates, nitric oxide. The effects of NO on bone cells (van't Hof and Ralston, 
2001) was summarised detailing a biphasic effect of NO on bone, low 
concentrations causing induction of bone resorption and high concentrations 
inhibiting bone resorption. NO supplementation of mice had the same effect on 
bone formation (van't Hof and Ralston, 2001). In mice lacking a subtype of nitric 
oxide synthase (eNOS), major defects in bone formation and osteoblast activity 
were found (Armour et al., 2001). This is promising considering that the amount 
of nitric oxide gained from the diet can potentially outweigh that of the synthase 
enzymes. 
The major NO donor used in animal studies is nitroglycerin, an organic nitrate, 
used in humans primarily for treatment of heart related conditions. Nitroglycerin 
treatments prevented ovarectomy- and corticoid-induced bone loss above and 
beyond the effect of treatment with oestrogen (Wimalawansa, 2000) and has been 
shown to have additional beneficial effects on both trabecular and cortical bone 
when given in combination with more recognised therapies (Wimalawansa, 1995). 
Furthermore, one daily dose of nitroglycerin was sufficient to exert these effects, 
cumulative effects were not evident. 
What is less clear is the role that dietary nitrates may have on bone mass but given 
the body of research in both bone and muscle, it may be possible to modulate the 
age-related effects of these two tissues by this treatment. 
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4.2 Aims 
This aims of this study were: 
 To examine the effects of short-term treatment of mice (from 18-24 
months old) with sodium nitrate on muscle and bone mass and function in 
C57Bl/6 mice. 
 To examine the effects of long-term treatment of mice (from 9-24 months 
old) with sodium nitrate on muscle and bone mass and function in C57Bl/6 
mice. 
Hypothesis – the treatment of mice with nitrates prior to the development of 
deteriorations in both muscle and bone will result in protection against or delay of 
development of previously characterised deteriorations.  
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4.3 Methods 
4.3.1. Mice 
C57Bl/6 mice used for the sodium nitrate intervention studies were obtained at 7 
and 16 months of age from Charles River (France) and aged within the 
Biomedical Services Unit at the University of Liverpool. Mice were fed a CRM 
(P) rodent diet and were maintained under barrier conditions in microisolator 
cages on a 12-h dark/light cycle. Body mass were recorded monthly. 
The long-term study was started when one cohort of mice reached 9 months of 
age and involved 20 mice split into two groups of 10 mice. The control group was 
given 250ml standard drinking water changed weekly. The treatment group was 
given 1mM sodium nitrate (21mg/250ml) in the drinking water which was also 
changed weekly. This was repeated until the mice reached 24 months of age. The 
short-term study began when mice reached 18 months of age. 16 mice were split 
into two groups of 8 and treated the same way as above. The study was concluded 
when the mice reached 24 months of age. 
For analysis, the control mice from each intervention study have been pooled into 
one group (n=12) as no differences were noted between any indices measured in 
the muscle or bone of these two groups of mice. 
Six control mice, 2 mice in the long-term treatment group and 2 mice in the short-
term treatment group died prior to the end of the study. 
4.3.2 Tissue collection and preparation 
All tissues were removed post mortem as described in Section 2.2.  
4.3.3 Muscle analysis 
Extensor digitorum longus (EDL) muscle contractile properties were measured in 
situ as described in Chapter 2. Muscle optimal length (Lo) was determined using a 
series of 1 Hz stimulation and set at the length that generates the maximal force. 
To assess the maximum isometric tetanic force (Po) of the EDL muscle, EDL 
muscles were electrically stimulated to contract via nerve stimulation at Lo and 
optimal stimulation voltage (8–10 V) at 2min intervals for 300ms with 0.2ms 
pulse width. 
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Anterior tibialis (AT), extensor digitorum longus (EDL), soleus and 
gastrocnemius muscles from both hindlimbs where dissected and weighed. 
Following this, muscles were snap frozen in liquid nitrogen and stored for further 
analysis at -80°C 
4.3.4 Bone analysis 
Analysis of bones was described in Section 2.8.  
4.3.5 Statistics 
Data was tested for normality and equal variance using SigmaPlot (v11.0) (Systat 
Software, Inc., London, UK). Direct comparison between two sets of data was 
made by Student's t-test. For multiple comparisons, data was analysed for 
statistical significance by one-way ANOVA incorporating pairwise comparisons. 
Data are presented as mean ±SEM. Values P<0.05 were considered significant 
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4.4 Results 
4.4.1 Changes in body mass following intervention with sodium nitrate 
Fig 6.1 Mean body mass of 24 month old control male C57Bl/6 mice following 
long or short-term nitrate treatment (Data presented as mean +/- SEM) (n=12 for 
combined controls, n=8 for long-term treated, n=6 for short-term treated).  
 
Figure 6.1 shows the mean body mass of mice at 24 months of age in C57Bl/6 
mice following short or long-term nitrate intervention. There were no significant 
differences in body mass following either intervention compared with untreated 
control mice. 
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Fig 4.2 Mean body mass of C57Bl/6 mice with and without long-term nitrate 
intervention over the experimental span (n=7 for control animals, n=8 for treated). 
Red lines indicate animals that died prior to the end of experiment due to health 
conditions.  
Mean body mass through the span of the experiment were presented. There were 
more deaths in the untreated group. Control group animals appeared to gain mass 
more often over the course of the experiment. 
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Fig 4.3 Mean change in body mass of C57Bl/6 mice with or without long-term 
nitrate intervention at 24 months of age displayed as a percentage of starting mass 
(Data presented as mean +/- SEM, n=7 for controls, n=8 for treated).  
 
Mean body mass change over the intervention time was presented. There were no 
significant changes.  
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Fig 4.4 Mean body mass of C57Bl/6 mice with and without short-term nitrate 
intervention over the experimental span. (n=5 for control, n=6 for treated) Red 
lines indicate animals that died prior to the end of experiment due to health 
conditions.  
Mean body mass through the span of the experiment were presented. There were 
more deaths in the untreated group.   
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Fig 4.5 Mean change in body mass of C57Bl/6 mice with or without short-term 
nitrate intervention at 24 months of age displayed as a percentage (Data presented 
as mean +/- SEM, n=5 for controls, n=6 for treated).  
 
Mean body mass change over the intervention time is shown in Figure 6.5. There 
were no significant differences in the change in body mass between the groups. 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
 123 
 
4.4.2 The effects of long and short-term nitrate intervention on organ mass in 
C57Bl/6 mice 
Table 4.1 Mean organ mass at 24 months of age with or without sodium nitrate 
intervention (Data presented as mean +/- SEM) (n=12 for combined controls, n=8 
for long-term treated, n=6 for short-term treated group) * values were 
significantly changed compared with control data. 
Table 4.2 Mean organ mass as a proportion of body mass (Data presented as 
mean +/- SEM) (n=12 for combined controls, n=8 for long-term treated, n=6 for 
short-term treated group) * represents values significantly changed compared with 
control. 
Treatment of mice with nitrate for either long or short-term resulted in increased 
heart mass compared with that of untreated control mice. Long-term nitrate 
intervention also caused an increase in spleen mass. Short-term intervention led to 
increased lung mass. 
When taken as a proportion of body mass, heart, lungs, and spleen mass were 
increased following both short and long-term nitrate intervention compared with 
data from untreated control mice. Long-term intervention also increase kidney 
mass. 
Control Long term nitrate Short term nitrate
Average 200 229 * 224 *
SEM 7 13 13
Average 258 277 331 *
SEM 15 12 38
Average 1751 1562 2222
SEM 103 76 576
Average 547 569 564
SEM 26 25 40
Average 89 138 * 110
SEM 6 23 13
Liver
Kidneys
Spleen
Heart
Lungs
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4.4.3 The effects of long and short-term nitrate intervention on muscle mass 
and force generation in C57Bl/6 mice 
 Table 4.3 Mean muscle mass in mice following short or long-term intervention 
from four hindlimb muscles. (Data presented as mean +/- SEM) (n=12 for 
combined controls, n=8 for long-term treated, n=6 for short-term treated group 
groups) * were significantly different compared with control; # values were 
significantly different compared with long-term treated. 
Table 4.4 Mean muscle mass as a proportion of body mass following short or 
long-term intervention. (Data presented as mean +/- SEM) (n=12 for combined 
controls, n=8 for long-term treated, n=6 for short-term treated group) * were 
significantly different compared with control; # values were significantly different 
compared with long-term treated. 
Following short-term intervention with sodium nitrate there was a general 
decrease in muscle mass which reached significance in the EDL muscle. 
Following long-term intervention with sodium nitrate, some evidence of increased 
mass in the EDL muscle but when data was expressed as per unit of body mass, 
the muscle mass values for AT, EDL and gastrocnemius muscles were all 
significantly higher than those in the control group. This appears to be primarily 
due to small decrease (~10%) in body mass of the mice without a concurrent 
decrease in muscle mass.  
Control Long term nitrate Short term nitrate
Average 49 50 38 #
SEM 2 3 8
Average 11 13 * 7 *#
SEM 0 1 2
Average 9 10 7
SEM 0 0 2
Average 143 147 114 #
SEM 4 7 22
SOL
Gas
AT
EDL
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Data also demonstrated a differential effect of short and long-term treatment with 
sodium nitrate whereby the small increases in muscle mass following long-term 
treatment was not evident following short-term treatment. 
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Fig 4.6 Mean twitch force of the EDL muscle of C57Bl/6 mice following long or 
short nitrate intervention (Data presented as mean +/- SEM) (n=12 for combined 
controls, n=8 for long-term treated group, n=6 for short-term treated group), * 
represents significant difference compared with control group, # represents 
significant difference compared with long-term nitrate treated group. 
 
There were no significant differences in mean twitch force between EDL muscles 
of the control group and muscles of the long-term nitrate intervention group. 
Short-term intervention resulted in a significant reduction in twitch force of the 
EDL compared with both control and long-term intervention groups.  
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 Fig 4.7 Mean maximum tetanic force of the EDL muscle of C57Bl/6 mice 
following long or short nitrate intervention (Data presented as mean +/- SEM) 
(n=12 for combined controls, n=8 for long-term treated, n=6 for short-term treated 
group), * represents significant change compared with control group, # represents 
significant change compared with long-term nitrate. 
 
No significant differences in maximum tetanic force generation were seen 
between EDL muscles of control and long-term nitrate intervention groups. Short-
term sodium nitrate intervention resulted in a significant reduction in maximum 
tetanic force of the EDL compared with both control and long-term intervention 
groups.  
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Fig 4.8 Mean force frequency of C57Bl/6 mice with or without long or short-term 
nitrate intervention at a range of stimulations (Data presented as mean +/- SEM) 
(n=12 for combined controls, n=8 for long-term treated, n=6 for short-term treated 
group), * represents significant change compared with control group, # represents 
significant change compared with long-term nitrate. 
 
Mean force frequency data following intervention is presented in Figure 6.8. 
There were no significant differences between control and long-term treated 
group. Data for the short-term treated group show that the maximum forces were 
significantly reduced compared with both control and long-term treatment groups 
resulting in no further analysis taken after 200Hz. 
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Fig 4.9 Mean specific force of the EDL muscle of C57Bl/6 mice following long or 
short nitrate intervention (Data presented as mean +/- SEM) (n=12 for combined 
controls, n=8 for long-term treated, n=6 for short-term treated group),  
 
There were no significant differences in specific force generation by the EDL 
between control and either nitrate intervention group.  
 
  
 130 
 
4.4.4 Visualisation of changes in the tibia and femur in C57Bl/6 mice 
following nitrate intervention 
 
Fig 4.10 Representative MicroCT images of the tibia (A) and femur (B) at 24 
months of age in C57Bl/6 mice with or without long-term nitrate intervention. 
A representative image from each bone at 24 months of age has been selected 
based on mean bone values to visualise both the cortical and trabecular bone. 
There were no visual differences in bone appearance between the treated and 
untreated groups. 
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Fig 4.11 3D representative models of trabecular bone in tibia (A) and femur (B) at 
24 months of age from both treated and untreated group. 
No visual differences in appearance of bone between the treated and untreated 
group were seen. 
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4.4.5 Effects of long and short-term nitrate intervention on cortical and 
trabecular bone measures in C57Bl/6 mice 
 
Fig 4.12 Mean cortical bone thickness of tibia (A) and femur (B) with or without 
long or short nitrate intervention (Data presented as mean +/- SEM, n=12 for 
controls, n=7 for long-term treatment group, n=6 for short-term treatment group)  
No significant differences were seen in cortical thickness following short or long-
term nitrate intervention in either bone site compared with control values. 
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Fig 4.13 Mean cross sectional area values for tibia (A) and femur (B) with or 
without long or short nitrate intervention (Data presented as mean +/- SEM, n=12 
for controls, n=7 for long-term treatment group, n=6 for short-term treatment 
group) 
There were no significant differences in cross-sectional bone area following long 
or short-term nitrate intervention in either bone site compared with control values.  
A 
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Fig 4.14 Mean trabecular bone surface density values for tibia (A) and femur (B) 
with or without long or short-term nitrate intervention (Data presented as mean +/- 
SEM, n=12 for controls, n=7 for long-term treatment group, n=6 for short-term 
treatment group). * represents significant differences compared with control 
group. 
No significant differences were seen in trabecular bone surface density following 
long-term nitrate intervention in either bone studied compared with control 
values.  
Tibia bone surface density was significantly increased following treatment with 
short-term treatment with nitrate compared with the tibia bone surface density of 
control untreated mice and a similar but non-significant trend was seen in the 
femur. 
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Fig 4.15 Mean number of trabecular bone per mm present in the tibia and femur 
with or without long or short-term nitrate intervention (Data presented as mean +/- 
SEM, n=12 for controls, n=7 for long-term treatment group, n=6 for short-term 
treatment group). * represents significant values compared with control. 
No significant differences were seen in either the tibia or femur in the number of 
trabecular bone following long-term nitrate intervention compared with that of 
control mice.  
There was a significant increase in trabecular number in the tibia following short-
term treatment compared with that of untreated control mice. A similar pattern 
was seen in the femur but these data did not reach significance 
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Fig 4.16 Changes in trabecular bone thickness at 24 months of age in the tibia and 
femur with or without long or short-term nitrate intervention (Data presented as 
mean +/- SEM, n=12 for controls, n=7 for long-term treatment group, n=6 for 
short-term treatment group). 
No significant difference in trabecular bone thickness was recorded between 
treated and untreated groups at 24 months of age. There was a trend towards 
reduced thickness in the short-term nitrate group. 
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Fig 4.17 3D representation of trabecular bone thickness through age in the tibia 
and femur of untreated mice or mice treated with sodium nitrate. White colours 
represent the thickest points, purple colours representing the thinnest areas. As 
each colour chart is based on individual thicknesses, no key is available. 
The changes in trabecular thickness properties are generally evident in 3D 
modelling.
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4.5 Discussion 
4.5.1 Effects of long-term sodium nitrate intervention on age-related changes 
in muscle and bone of C57Bl/6 mice 
4.5.1.1 Effect of long-term treatment of mice with sodium nitrate on body 
mass and organ mass 
Long-term treatment of mice with sodium nitrate had no effect on body mass.  
This allows further analysis of tissue mass to be undertaken without any 
confounding factors of changes in body mass. 
Long-term treatment of mice with nitrate resulted in a significant increase in the 
mass of both heart and spleen tissue. When expressed as a proportion of body 
mass, the long-term treatment also resulted in a significant increase in the lung 
mass compared with lung mass of the control untreated group.  
The mechanisms responsible for these increases in tissue mass are unclear, 
although nitrates are known to induce changes in the vasculature and control 
blood flow (Pironti et al., 2016). The increase in heart mass could be due to 
dilation of blood vessels with the heart compensating by increasing mass and 
force to increase blood circulation. The increase in lung mass would indicate an 
increased maximum oxygen intake to match any increases in blood flow. The 
benefits of this to musculoskeletal tissue would potentially be to increase 
oxygenation of tissues and organs. 
4.5.1.2 Effect of long-term treatment of mice with sodium nitrate on muscle 
mass and force generation 
Following long-term nitrate intervention only the EDL muscle showed a small but 
significant increase in mass compared with the EDL mass of control untreated 
mice.  
However, when expressed as a proportion of body mass, the mass of the anterior 
tibialis, EDL and gastrocnemius muscle were significantly increased compared 
with the control untreated group.  
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Interpretation of the data is difficult since these changes seem to be due to a small, 
non-significant reduction in body mass. Although this would suggest that long-
term nitrate intervention has had a significant effect on muscle mass based on the 
control group in this study.  
Due to the increase in heart and lung mass, it might be speculated that there would 
be an improvement in blood flow and oxygenation to the muscles although this 
was not measured in this study. This is one possible mechanism by which any 
increased muscle mass was seen as there is a better supply of nutrients. 
This increase in muscle mass was not accompanied by any significant changes in 
twitch force, maximum force or specific force compared with the control group 
despite presenting a significantly increased EDL muscle mass compared with the 
control group suggesting little functional effects of long-term nitrate 
supplementation or muscle function in old mice. 
These data contradict recently published studies discussed previously. However 
the majority of studies published involve human participants which may be one 
reason for the discrepancy. Results presented here also disagree with recently 
published study in comparable mice. Hernandez et al 2012 show improvement in 
muscle force generation in C57Bl/6 mice following an intervention of only seven 
days (Hernandez et al., 2012). The muscle force generation data was measured ex 
vivo compared with in vivo measurements in this study. This study provided the 
same nitrate concentration in drinking water, but was undertaken in adult mice. It 
maybe that muscles of old mice are resistant to the effect of nitrate in a similar 
manner to other anabolic agents (discussed within Chapter 1). 
4.5.1.3 Effect of long-term treatment of mice with sodium nitrate on bone 
ageing 
Treatment of mice with sodium nitrate for long-term had no effect on either the 
tibia or femur with respect to cortical bone thickness, bone area, trabecular bone 
surface density, trabecular number or trabecular thickness. This indicates that 
long-term nitrate intervention at this dose is not effective on bone structure or 
function. 
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If as previously suggested, muscle strength influences bone strength, then the lack 
of significant changes in muscle force generation may also be an influencing 
factor in the lack of changes to bone structure. 
There do not appear to be any published studies on the effect of sodium nitrate 
intervention on muscle or bone in mammals. Nitroglycerin is the most widely 
used nitric oxide donor in animal studies and studies using nitroglycerin have 
been described as beneficial for bone (Wimalawansa, 2000). Although sodium 
nitrate is capable of increasing the levels of NO within the body, it may be that it 
is not able to elicit effects on bone at the concentration given in this study. 
4.5.2 Effects of short-term treatment of mice with sodium nitrate on age-
related changes in muscle and bone of C57Bl/6 mice 
4.5.2.1 Changes to body mass 
Mean body mass following short-term treatment of mice with sodium nitrate is 
shown in Figure 4.15. As with the long-term intervention no changes in mean 
body mass were seen at 24 months old.  
Since no significant effects was seen in body mass following either treatment 
regime, body mass is not likely to be a factor to consider in further analysis of 
tissue mass. Similarly, no evidence of gross changes in liver mass were seen in 
these mice (in comparison with Table 3.1, suggesting that liver tumours are not a 
confounding factor in this study) 
4.5.2.2 Changes in organ mass 
In a similar manner to the long-term treatment, the mass of the heart and lungs 
were significantly greater following treatment. When expressing these data as a 
proportion of body mass, the heart, lungs and spleen were significantly increased 
again in a similar manner to that seen following long-term treatment. 
This may suggest again that nitrate treatment resulted in increases in the 
circulatory system and thus increasing blood flow and oxygen transport 
throughout the body by increases in lung capacity and heart mass (Pironti et al., 
2016).  
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Thus, it is clear that intervention with sodium nitrate result in improvements in 
heart and lung mass independently from the length of intervention or the age at 
which the intervention is started. 
4.5.2.3 Changes to muscle mass and force 
Although recorded muscle masses were generally smaller than the control values 
only the EDL muscle was significantly reduced compared with the control group. 
This becomes relevant when considering muscle force data as this muscle was 
used for force measurements. 
When taken as a proportion of body mass, the EDL was still significantly smaller 
in the treated group compared with the control.  
The twitch and maximum tetanic force generation values were significantly 
reduced in EDL muscles of mice treated using the short-term intervention 
compared with the control values. When force frequency was measured, there was 
a failure to respond to increases in frequency of stimulation and this became 
significant at 200Hz. However, specific force was not significantly reduced 
compared with the controls. This would suggest differences in twitch and 
maximum force can be completely explained by the smaller EDL muscle in this 
group. 
The mechanisms by which short-term treatment of mice with sodium nitrate 
results in loss of muscle mass are unclear. One would speculate that it may be due 
to a potential increase in oxygen uptake from increased heart and lung function. 
The increase oxygen would lead to an increase in respiration. A by-product of 
respiration is reactive oxygen species production. Aged cells are unable to 
effectively deal with reactive oxygen species as well as reactive nitrogen species 
(which can be derived from NO the end product of nitrate intervention) and are 
therefore potentially detrimental to muscle of older mammals (Ansari and 
Mahmood, 2015, Ansari et al., 2015). 
The differential effects of short and long-term treatment in mice with nitrate is 
also surprising but demonstrates the importance of determination of temporal 
effects of interventions, particularly in an ageing cohort. 
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4.5.2.4 Changes to bone ageing 
Following short-term intervention with sodium nitrate no significant differences 
were seen compared with controls in either bone in cortical bone thickness, bone 
area or mean trabeculae bone thickness. In the tibia there was a significant 
increase in trabecular number and trabecular bone surface density. This trend was 
also seen in the femur although the data did not reach significance. 
The mechanisms responsible for this effect are currently unknown as it was not 
seen following the long-term nitrate intervention. The change cannot be attributed 
to changes in muscle as loss of muscle mass and force is proposed to reduce the 
number of trabecular bone.  
The changes in trabecular bone were associated with an increased percentage of 
smaller trabeculae suggesting that the trabecular bone is preserved by the 
treatment. 
Thus unlike the longer-term treatment, the short-term nitrate intervention had a 
major effect on trabecular bone although the mechanisms by which this protection 
occurs are unclear. 
4.6 Conclusions 
 There appeared to be differential effects of treating mice with sodium 
nitrate from the age of 9 months or the age of 18 months.  
 By treating mice from 18 months, the data suggest this was detrimental to 
muscle mass and force generation. 
 Treating mice from 9 months old resulted in some prevention of muscle 
mass but no major effect on force generation when compared with control 
mice.  
 Treating mice from 9 months old had no major effects on bone structure 
but treating mice from 18 months appeared to result in some preservation 
of trabecular bone. The mechanism by which sodium nitrate displays this 
temporal effect is unclear but is not related to any positive effects on 
muscle function. 
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 The extent of any effects of nitrate intervention may be related to the 
increased mass of the heart, lungs and thus changes in the circulatory 
system. 
 
As the nitrate study did not prove conclusive in preventing the age related change 
we saw in Chapter 3, we must now look to a more invasive process. We will look 
to use the same mouse type but overexpress proteins known to counteract the 
increased presence of free radicals that may damage the cellular content. 
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Chapter 5 
Overexpression of heat shock protein 10 (HSP10) 
in mice to prevent age-related decline in 
musculoskeletal tissues 
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5.1 Introduction 
The previous chapter showed that introducing a general intervention to treat 
musculoskeletal ageing is not a feasible way of gaining mass and function in these 
tissues. Many hypothesize that loss of muscle mass and function results directly in 
detrimental changes seen in bone (Bren-Mattison et al., 2011, Jang et al., 2010, 
Wolff, 1988). There is evidence to suggest that by maintaining muscle mass and 
function bone tissues will be preserved (Burr, 1997). 
One leading theory behind the reduction in muscle function is an inability to 
reverse and repair contraction induced muscle damage leading to reduced force 
production with advancing age (Faulkner et al., 1995).  
Although the mechanisms for muscle losing the ability to repair itself with 
increasing age are not known, it has been observed that there are age-related loss 
in proteins responsible for controlling cellular stress and protecting the muscle 
fibres from long lasting damage such as heat shock proteins (HSPs) (Vasilaki et 
al., 2003). 
Several mouse models exist whereby muscle mass and/or function can be 
maintained into old age compared with wild type mice. These include models 
from our own lab such as those overexpressing HSP10 (Kayani et al., 2010). 
5.1.1 Heat shock proteins 
Heat shock proteins (HSP) are found within all organisms and play integral roles 
in cellular defence against cellular stresses (De Maio, 1995). The function of 
HSPs within cells is primarily to chaperone the folding and unfolding of nascent 
or misfolded proteins. This is hugely beneficial particularly in times of cellular 
stress as cell content of HSPs can be rapidly up-regulated and so can preserve the 
functionality of integral cellular proteins. Heat shock proteins are classified 
according to their molecular mass and include HSP10, 60, 70, 90 (Cuervo and 
Wong, 2014, Georgopoulos and Welch, 1993). 
One of the most widely recognised HSPs is HSP70. The main role of HSP70 is to 
assist in the folding of newly translated proteins from the ribosome. HSP70 also 
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has more specific functions such as in preventing cellular apoptosis by 
neutralising caspases found within the cell cytosol (Tavaria et al., 1996).  
However, to facilitate the wide ranging functions HSPs have within cells, many 
HSPs are specifically located within sub-compartments of the cell. In particular, 
mitochondria have a number of HSPs including HSP10 and HSP60 (Cheng et al., 
1990) (Deocaris et al., 2006). These two HSPs have been shown to work together 
as the HSP60/10 chaperonin complex which aids protein folding within 
mitochondrial matrix and prevents protein aggregation of denatured proteins 
(Cheng et al., 1990, Lin et al., 2001). 
Studies have shown that HSP10 may play a role independent of HSP60 involving 
both classic chaperone function explained above, but also possible roles in cellular 
signalling (Czarnecka et al., 2006). Although HSP10 is mostly localised within 
mitochondrial matrix, increased concentration of HSP10 has been found within 
cell cytosol in certain situations (e.g. cancerous cells) (Czarnecka et al., 2006). 
How HSP10 is retained within the cytosol during times of cellular stress or 
damage is unknown. 
5.1.2 Role of heat shock proteins in muscle tissues of adult and old mice 
Older mice have an attenuated heat shock protein responses in muscles following 
various stresses (Vasilaki et al., 2002). In particular, it has been shown that, 
following a damaging exercise protocol, adult mice can repair muscle and regain 
maximum force production whereas older mice have a 44% decrease in force 
production at 28 days recovery following damage. This decrease did not occur in 
transgenic animals overexpressing some heat shock proteins (McArdle et al., 
2004). This effect appears to be fibre specific and is more apparent in faster 
skeletal muscles such as gastrocnemius suggesting that the loss of muscle fibres 
with age reduces the ability of the whole muscle to raise heat shock protein 
defences in times of cellular stress. The inability to produce HSPs following stress 
would suggest a mechanism by which loss of muscle force production occurs with 
loss of proteostasis with increasing age. 
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5.1.3 Using heat shock proteins as a therapy for age-related diseases 
Chaperonopathies are a series of diseases in which molecular heat shock proteins 
(chaperones) are an integral role in pathological disease states. Often this involves 
either an abnormally formed heat shock protein at normal cellular levels or 
reduced levels of the heat shock protein (Cappello et al., 2014).  
Transgenic mice provide a reliable way of increasing the cellular levels of HSPs 
throughout the body. In particular, multiple mouse models have been developed to 
study the effects of up-regulating or overexpressing certain HSPs and measuring 
the beneficial or negative outcomes of this. 
One model uses muscle specific over-expression of HSP10. Work in these mice 
has shown that HSP10 can prevent the age-related loss of force production and 
showed some benefit in preserving cross-sectional area in the EDL muscle 
(Kayani et al., 2010). The role of HSP10 in bone tissue has not been studied.  
5.2 Aims 
The aims of this study were as follows:- 
 To examine the effect of muscle-specific overexpression of HSP10 on age-
related changes in musculoskeletal tissues of mice compared with wild 
type mice 
The hypothesis was that overexpression of HSP10 in muscles reportedly results in 
preservation of muscle mass and strength and that this preservation had a positive 
effect on bone structure in old mice. 
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5.3 Methods 
5.3.1. Mice 
HSP10 overexpressor mice have been previously described in Chapter 2.2.3 and 
Kayani et al 2010 (Kayani et al., 2010). Mice were generated via chimeric 
transgenes containing of human gene variants of HSP10 and HSP60 which were 
inserted into pCAGGS vectors. The pCAGGS construct allowed both genes to be 
under the control of the human cytomegalovirus (CMV) intermediate early 
(hCMV-IE) enhancer and chicken β-actin promoter and intron 1. The CAGGS-
HSP10 fragment was cut from the Bluescript II KS vector using Xho1/Not1 
digestion to produce a 3.3kb fragment. The CAGGS-HSP60 fragment was cut 
from the BlueII KS vector using Sal 1/Not1 digestion to produce a 4.8kb 
fragment. Both fragments were purified and used for microinjection into mouse 
oocytes. Mice were housed within the Biomedical Services Unit at the University 
of Liverpool. Mice were fed a CRM (P) rodent diet and were maintained under 
barrier conditions in microisolator cages on a 12-h dark/light cycle. 
5.3.2 Tissue collection and preparation 
All tissues were removed post mortem as described in Section 2.3.  
5.3.3 Muscle analysis 
Anterior tibialis, EDL, soleus and gastrocnemius muscles from both hindlimbs 
where dissected and weighed. Following this, muscles were snap frozen in liquid 
nitrogen and stored for further analysis at -80°C. 
5.3.4 Bone analysis 
Analysis of bones was described in Section 2.8.  
5.3.5 Statistics 
Data was tested for normality and equal variance using SigmaPlot (v11.0) (Systat 
Software, Inc., London, UK). Direct comparison between two sets of data was 
made by Student's t-test. For multiple comparisons, data was analysed for 
statistical significance by one-way ANOVA incorporating pairwise comparisons. 
Data are presented as mean ±SEM. Values P<0.05 were considered significant. 
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5.4 Results 
5.4.1 Age-related changes in body mass in both C57Bl/6 and HSP10 
overexpressor mice 
Fig 5.1 Mean body mass of male C57Bl/6 and HSP10 overexpressor mice at 6 
and 24 months of age (Data presented as mean +/- SEM, n=6). * represents 
significant difference compared with age matched C57Bl/6 mouse. 
 
Mean body mass at 6 and 24 months of age in C57Bl/6 mice and HSP10 
overexpressor mice are shown in Figure 5.1.  No significant differences were seen 
in body mass of C57Bl/6 or HSP10 overexpressor mice between 6 and 24 months 
of age.  However, the 24 month HSP10 overexpressor mouse was significantly 
heavier compared to the C57Bl/6 mouse at 24 months of age. 
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5.4.2 Age-related changes in organ mass in both C57Bl/6 and HSP10 
overexpressor mice 
Table 5.1 Mean organ mass (mg) at different ages. a represents significant 
differences compared with 6 month old Bl6 mice, b represents significant 
differences compared with 6 month old HSP10 overexpressor mice and * 
represents significant differences compared with age matched C57Bl/6 mouse 
data. Data presented as mean +/- SEM. 
Table 5.2 Mean organ mass as a proportion of body mass at different ages. a 
represents significant differences compared with 6 month old Bl6 mice, b 
represents significant differences compared with 6 month old HSP10 
overexpressor mice and * represents significant differences compared with age 
matched C57Bl/6 mouse data. Data presented as mean +/- SEM. 
C57Bl/6 mice showed significant increases in liver mass at 24 months of age. 
When expressed as a proportion of body mass, heart and liver were significantly 
heavier at 24 compared with 6 months old. 
HSP10 overexpressor mice had significantly increased heart, liver, kidneys and 
spleen mass at 24 months old compared with 6 months old. When expressed as a 
Bl6 6 HSP10 6 Bl6 24 HSP10 24
Average 6.5 6.4 5.0 7.2
SEM 0.3 0.4 0.6 a 0.4 *
Average 6.9 7.2 6.7 8.6
SEM 0.3 0.5 1.4 0.8
Average 52.3 54.3 39.1 66.9
SEM 1.5 1.0 9.8 a 6.6 * b
Average 2.3 3.0 5.6 3.4
SEM 0.1 0.18 * 3.0 0.2
Heart OW/BW
Lungs OW/BW
Liver OW/BW
Spleen OW/BW
Bl6 6 HSP10 6 Bl6 24 HSP10 24
Average 197 198 206 230
SEM 13 8 9 8 * b
Average 208 224 229 274
SEM 12 18 13 21 *
Average 1580 1681 1212 2137
SEM 76 42 128 153 * b
Average 403 439 450 610
SEM 13 6 35 19 * b
Average 71 94 67 109
SEM 5 6 11 5 * b
Average 388 340 383 367
SEM 31 25 23 45
Spleen
Brain
Heart
Lungs
Liver
Kidneys
 151 
 
proportion of body mass, only the liver was significantly heavier at 24 compared 
with 6 months of age. 
The kidneys of the 6 month old HSP10 overexpressor mouse were significantly 
smaller than those of the C57Bl/6 mouse. The spleen was significantly heavier 
compared with that of the C57Bl/6 mouse. At 24 months of age, the lungs and 
spleen were significantly heavier and the kidneys were significantly smaller in the 
HSP10 overexpressor mouse compared with the C57Bl/6 mouse.  
When expressed relative to body mass, the spleen of the 6 month old HSP10 
overexpressor mouse was significantly heavier than that of the C57Bl/6 and the 
heart and liver of the 24 month old HSP10 mouse was significantly increased 
compared to C57Bl/6 mice at 24 months old.  
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5.4.3 Age-related changes in muscle mass in C57Bl/6 and HSP10 
overexpressor mice 
Fig 5.2a Mean anterior tibialis muscle mass from C57Bl/6 and HSP10 
overexpressor mice at 6 and 24 months of age. (Data presented as mean +/- SEM, 
n=6). # represents significant difference compared with cohort matched 6 month 
old value. 
There was a significant decrease in mass of the anterior tibialis muscle between 6 
and 24 months of age in the C57Bl/6 mice. In contrast there was no significant 
change in anterior tibialis mass between 6 and 24 months of age in the HSP10 
overexpressor mice. 
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Fig 5.2b Mean anterior tibialis muscle mass as a proportion of body mass from 
C57Bl/6 and HSP10 overexpressor mice at 6 and 24 months of age. (Data 
presented as mean +/- SEM, n=6). * represents significant difference compared 
with age matched C57Bl/6 mouse, # represents significant difference compared 
with cohort matched 6 month old value. 
There was a significant decrease between 6 and 24 months of age in the anterior 
tibialis muscle as a proportion of body mass in the C57Bl/6 mice.  
There was a significant decrease between 6 and 24 months of age in the anterior 
tibialis muscle as a proportion of body mass in the HSP10 overexpressor mice.  
The muscle weight value for HSP10 overexpressor mice at 6 months of age was 
therefore significantly lower when compared with age-matched C57Bl/6 mice. 
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Fig 5.3a Mean EDL muscle mass from C57Bl/6 and HSP10 overexpressor mice 
at 6 and 24 months of age. (Data presented as mean +/- SEM, n=6). * represents 
significant difference compared with age matched C57Bl/6 mouse, # represents 
significant difference compared with cohort matched 6 month old value. 
There was no significant change in EDL mass between 6 and 24 months of age in 
the C57Bl/6 mice. In contrast a small but significant increase between 6 and 24 
months of age in the EDL muscle of the HSP10 overexpressor mice was seen.  
At 6 months of age, the EDL mass from the HSP10 mice was significantly 
decreased compared to EDL mass from age matched C57Bl/6 mice.  
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Fig 5.3b Mean EDL muscle mass as a proportion of body mass from C57Bl/6 and 
HSP10 overexpressor mice at 6 and 24 months of age. (Data presented as mean 
+/- SEM, n=6). * represents significant difference compared with age matched 
C57Bl/6 mouse. 
There was no significant differences between 6 and 24 months of age in the EDL 
muscle as a proportion of body mass in the C57Bl/6 mice or in the HSP10 
overexpressor mice.  
The value for HSP10 overexpressor mice at 6 months of age was significantly 
lower when compared with age-matched C57Bl/6 mice. 
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Fig 5.4a Mean soleus muscle mass from C57Bl/6 and HSP10 overexpressor mice 
at 6 and 24 months of age. (Data presented as mean +/- SEM, n=6). * represents 
significant difference compared with age matched C57Bl/6 mouse. 
There was no significant change in soleus mass between 6 and 24 months of age 
in the C57Bl/6 mice or HSP10 overexpressor mice.  
At 6 months of age, the soleus mass from the HSP10 mice was significantly 
decreased compared to soleus mass from age matched C57Bl/6 mice. There were 
no significant differences at 24 months of age. 
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Fig 5.4b Mean soleus muscle mass as a proportion of body mass from C57Bl/6 
and HSP10 overexpressor mice at 6 and 24 months of age. (Data presented as 
mean +/- SEM, n=6). * represents significant difference compared with age 
matched C57Bl/6 mouse. 
There were no significant changes between 6 and 24 months of age in the soleus 
muscle as a proportion of body mass in the C57Bl/6 mice or HSP10 overexpressor 
mice.  
The value for HSP10 overexpressor mice at 6 months of age was significantly 
lower when compared with age-matched C57Bl/6 mice. 
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Fig 5.5a Mean gastrocnemius muscle mass from C57Bl/6 and HSP10 
overexpressor mice at 6 and 24 months of age. (Data presented as mean +/- SEM, 
n=6). # represents significant difference compared with cohort matched 6 month 
old value. 
There was a significant decrease in gastrocnemius muscle mass between 6 and 24 
months of age in the C57Bl/6 mice  
There was no significant change in soleus muscle of the HSP10 overexpressor 
mice. There were no significant differences between the two cohorts of mice at 
the same age. 
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Fig 5.5b Mean gastrocnemius muscle mass as a proportion of body mass from 
C57Bl/6 and HSP10 overexpressor mice at 6 and 24 months of age. (Data 
presented as mean +/- SEM, n=6). * represents significant difference compared 
with age matched C57Bl/6 mouse, # represents significant difference compared 
with cohort matched 6 month old value. 
There was a significant decrease between 6 and 24 months of age in the 
gastrocnemius muscle as a proportion of body mass in the C57Bl/6 mice.  
There was a significant decrease between 6 and 24 months of age in the 
gastrocnemius muscle as a proportion of body mass in the HSP10 overexpressor 
mice.  
The value for HSP10 overexpressor mice at 6 months of age was significantly 
lower when compared with age-matched C57Bl/6 mice. 
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5.4.4 Age-related changes in the tibia and femur in both C57Bl/6 and HSP10 
overexpressor mice 
Fig 5.6 Representative MicroCT images of the tibia (A) and femur (B) at 6 and 24 
months of age in the C57Bl/6 and HSP10 overexpressor mouse. 
A representative image from each site at 6 and 24 months of age was selected 
based on mean bone values to visualise the cortical and trabecular bone. A change 
in 2D shape of both bone sites was seen at 24 compared with 6 months old with 
no gross differences visible between C57Bl/6 and HSP10 overexpressor mice at 
either age. 
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Fig 5.7 Representative 3D models of trabecular bone in tibia (A) and femur (B) at 
6 and 24 months of age in C57Bl/6 and HSP10 overexpressor mice. 
 
Loss of trabecular bone was seen at both bone sites. The trabecular bone mass 
became less connected in both strains of mice. Smaller trabecular bones appeared 
to be lost first with larger bones becoming thinner. There were no visual 
differences in trabecular bone between the two mouse strains. 
 
 
 
 
 
 
 
 
 
Bl6
6
HSP10 Bl6
24
HSP10
Age (Months)
Cohort
Bl6
6
HSP10 Bl6
24
HSP10
Age (Months)
Cohort
A
B
 162 
 
5.4.5 Comparison of age-related changes cortical and trabecular bone 
measures in both C57Bl/6 and HSP10 overexpressor mice 
Fig 5.8 Mean cortical bone thickness values for tibia (A) and femur (B) from 
C57Bl/6 and HSP10 overexpressor mice at 6 and 24 months of age. (Data 
presented as mean +/- SEM, n=6). * represents significant difference compared 
with age matched C57Bl/6 mouse, # represents significant difference compared 
with cohort matched 6 month old value. 
There was no significant change in the cortical bone thickness of the tibia between 
6 and 24 months of age from the C57Bl/6 mice whereas there was a significant 
decrease in cortical bone thickness of the femur between at 24 months of age in 
the C57Bl/6 mice. This decrease in cortical thickness with age was evident in both 
the tibia and femur of HSP10 overexpressor mice. 
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Fig 5.9 Mean cross sectional area values for tibia (A) and femur (B) of C57Bl/6 
and HSP10 overexpressor mice at 6 and 24 months of age. (Data presented as 
mean +/- SEM, n=6). * represents significant difference compared with age 
matched C57Bl/6 mice, # represents significant difference compared with strain 
matched 6 month old value. 
Both HSP10 overexpressor mice and C57Bl/6 mice showed a decrease in area at 
24 months of age at both bone sites when compared with 6 month values. The 
HSP10 overexpressor mice had a larger area of tibia and femur bone at 6 months 
old compared with age matched C57Bl/6 mice. 
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Fig 5.10 Mean bone surface density values for tibia (A) and femur (B) from 
C57Bl/6 and HSP10 overexpressor mice at 6 and 24 months of age. (Data 
presented as mean +/- SEM, n=6). * represents significant difference compared 
with age matched C57Bl/6 mice, # represents significant difference compared 
with strain matched 6 month old value. 
At both bone sites both C57Bl/6 and HSP10 mice had significantly decreased 
bone surface density at 24 months of age compared with 6 month old strain 
matched mice. The HSP10 overexpressor mice showed a minor reduction in bone 
surface density values at 6 months old compared with age matched C57Bl/6 mice. 
In contrast, in the femur, HSP10 overexpressor mice showed a minor but 
significantly larger surface density at 6 months old compared with age-matched 
C57Bl/6 mice. 
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Fig 5.11 Mean number of trabeculae present in tibia (A) and femur (B) from 
C57Bl/6 and HSP10 overexpressor mice at 6 and 24 months of age. (Data 
presented as mean +/- SEM, n=6). * represents significant difference compared 
with age matched C57Bl/6 mouse, # represents significant difference compared 
with cohort matched 6 month old value. 
At both bone sites, C57Bl/6 and HSP10 mice showed significantly decreased 
numbers of trabeculae present at 24 months of age compared with 6 month old 
mice.HSP10 overexpressor mice showed a decrease in trabeculae numbers at 24 
months of age in both bone sites when compared with 6 month old. In the femur, 
HSP10 overexpressor mice showed a minor but greater number of trabeculae per 
mm at 6 months old compared with C57Bl/6 mice at this age. 
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Fig 5.12 Changes in trabecular bone thickness in the tibia (A) and femur (B) from 
C57Bl/6 and HSP10 overexpressor mice at 6 and 24 months of age. (Data 
presented as mean +/- SEM) 
No significant effect of age of HSP10 overexpression on trabecular thickness was 
seen. 
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Fig 5.13 3D representation of trabecular bone thickness through age in the tibia 
and femur in C57Bl/6 and HSP10 overexpressor mice. White colours represent 
the thickest points, purple colours representing the thinnest areas. 
Despite the lack of change in the mean values, clear decreases in trabecular 
thicknesses were seen between 6 and 24 months of age. The loss of trabecular 
bone was also evident. 
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5.5 Discussion 
5.5.1 Age-related changes in the HSP10 overexpressor mice and comparison 
to age matched C57Bl/6 mice 
5.5.1.1 Age-related changes in hindlimb muscle mass 
The mass of 4 major hindlimb muscles was measured at both 6 and 24 months of 
age in the HSP10 overexpressor mice and compared with data from the wild type 
C57Bl/6 mice. No significant changes were seen with age in any of the four 
muscles measured in the HSP10 overexpressor mice indicating that there appeared 
to be preservation of muscle mass in these mice with advancing age.  
This is in contrast to data from the C57Bl/6 mice were significant decreases 
occurred in the mass of the anterior tibialis and gastrocnemius muscles although 
no significant changes in the EDL and soleus muscle were seen. These data would 
indicate that the over-expression of HSP10 preserves muscle mass as previously 
reported (Kayani et al., 2010).  
However, when expressing the muscle mass as a proportion of body mass, 
significant changes in the muscle mass were seen. In the larger, anterior tibialis 
and gastrocnemius muscles significant decreases in mass with increased age were 
seen. No significant changes were seen in the EDL and soleus muscles. 
Comparing these normalised values with those seen in the C57Bl/6 mice, the 
pattern of muscle loss was the same in both groups - the anterior tibialis and 
gastrocnemius muscle showed clear declines with age. When comparing the 
groups at each age, the muscles of the C57Bl/6 were significantly larger as a 
proportion of body mass at 6 months old in all four muscles measured. This 
differential effect was lost at 24 months old. This would therefore indicate that the 
total age-related loss of muscle was higher in the C57Bl/6 mice compared with 
the HSP10 overexpressor mice. 
Data presented here are similar to those published in 2010 (Kayani et al., 2010). It 
must be noted however differential ages were used – our study used 6 month and 
24 month old mice, the Kayani paper used mice aged 10-12 months and 26-28 
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months of age (Kayani et al., 2010). Where the two studies differ was that the new 
study measured more muscles than the 2010 paper.  
In summary, although loss of muscle mass was still somewhat evident, there was 
clear preservation of the rate of loss with ageing in the muscles of HSP10 
overexpressor mice in terms of overall muscle loss. These findings indicate an 
effect of HSP10 in preserving muscle with increasing age which agrees with 
earlier work (Kayani et al., 2010). 
5.5.1.2 Age-related changes in the bones of the hindlimb 
Based on raw micro CT scan images and the 3D rendering from these scans, there 
was a visible loss of trabecular bone in both tibia and femur through age. This was 
visibly comparable to the changes seen in similar images from the C57Bl/6 mice. 
When focusing on measures of cortical bone, in the femur there was an age-
related thinning of the cortical bone. There appeared to be a trend toward this also 
occurring in the tibia but the values were not significant. However both bones 
displayed a reduced cross sectional area with age indicating that the thinning of 
the cortical bone was leading to an overall smaller bone. This effect was more 
apparent on the tibia which showed differential ageing of the two hindlimb bones. 
In C57Bl/6 mice similar trends were seen. The cortical thickness of the tibia did 
not show age-related thinning, but this was apparent in the femur. Although there 
were no significant differences across age, when comparing the 24 month age 
point in both groups, there was a significant reduction in cortical thickness in the 
tibia, but no changes in the femur. Again this would indicate that there were 
differential changes in the two hindlimb bones but HSP10 overexpression was not 
improving the age-related changes. 
When looking at bone cross sectional area, the same pattern was seen in C57Bl/6 
mice as in HSP10 overexpressor mice. There was an age-related reduction in 
cross sectional area in both bones measured. There were no further differences 
within age groups between the two mouse types indicating that this reduction in 
area was not improved by overexpression of HSP10. 
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It was interesting to note that despite the mice not losing muscle mass, the bones 
were still detrimentally affected. This would suggest that HSP10 was not 
preserving bone tissue unlike in the muscle. This could be explained through the 
role of HSPs being a lot lower in bone then other tissues such as muscle. There is 
currently no real understanding on the antioxidant levels of roles in bone cells due 
in part, to the difficulty in isolating bone cells for further analysis. It may be that 
increases in ROS may not play a role in the ageing of bone and in the disruption 
of bone cells. We then must turn to the role muscle has on controlling bone tissue. 
As muscle mass does not decline in this model, we cannot be certain of muscles 
dominant role. We can therefore only really base these results on the genetics of 
the mice and that bone is predisposed to breakdown as the mouse ages or that as 
the mice age and they take in fewer nutrients (reported previously) then the need 
for calcium is rerouted to maintaining the muscle and thus taken away from the 
bone. Further studies are needed to fully understand these points. 
When looking at the changes in trabecular bone with increasing age in the HSP10 
overexpressor mice, there was a reduction in trabecular bone number at both bone 
sites with associated reductions in bone surface density. This was mimicked in the 
C57Bl/6 mice with similar reductions. There were no significant differences 
between age groups except for a slightly higher trabecular number at 24 months 
old in the HSP10 overexpressor mice group. 
Despite the loss of trabecular bone with age in both groups, no changes in mean 
thickness of the trabecular bone was seen. However when applying thickness to 
the 3D model, large variations were seen in the age groups at both sites. When 
looking at the mean ranges of trabecular thickness through in the tibia of the 
HSP10 overexpressor mouse, there was an age-related decrease in the thicker 
trabecular bone and a shift towards thinner trabecular bone. The change in the 
femur was focused more on the loss of thicker trabecular bone with no significant 
increases in thinner bone. This would suggest that the loss of trabeculae bone was 
a result of thinning of the bone causing the thinnest trabeculae to be removed. 
When the ranges of trabecular thickness were compared between the HSP10 
overexpressor and the C57Bl/6 mice there were no significant changes in either 
site at 6 months old. However, at 24 months there were significantly lower 
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numbers of thicker trabecular in the HSP10 overexpressor mice and a larger 
number of smaller trabecular bones. This would suggest that the trabecular bone 
thinning and loss was more apparent in the HSP10 overexpressor mouse then the 
C57Bl/6 mouse. 
Taken together, although there were few significant changes between the C57Bl/6 
and HSP10 overexpressor mouse, the bones of the HSP10 overexpressor mouse 
appeared to have been affected by age to a greater extent than the C57Bl/6 mouse. 
This could be a failed ability to adapt to the maintained muscle mass in the HSP10 
mouse or that HSP10 overexpression was detrimental to the bone itself. 
5.6 Conclusions 
The potential for increasing heat shock proteins in aged tissues to elicit a 
beneficial effect has long been considered and many attempts have been 
undertaken to achieve this response. 
 We can utilise overexpression of heat shock proteins in mice to show 
lifelong effects of heat shock protein increases which clearly could not be 
achieved in humans.  
 From this study, it can be clearly seen that overexpression of heat shock 
protein 10 had beneficial outcomes in terms of muscle tissue through age. 
The larger muscles measured in this study were resistant to age-related 
loss of mass to 24 months old.  
 There were no significant changes in the bone between the groups at 6 
months, indicating overexpression of HSP10 in muscle and preservation of 
muscle did not affect bone loss. Thus by the age of 24 months old, the 
HSP10 overexpressor mice were showing similar losses to C57Bl/6 mice.  
In summary, over-expression of HSP10 in muscle of mice appeared to rescue the 
age-related loss of muscle mass to some extent but this did not appear to confer 
any additional benefits on the underlying bone. 
It has become apparent that work in the C57Bl/6 mouse is not providing positive 
outcomes in preventing the onset of age related musculoskeletal decline or 
recovering the damage in old age. Is this because the C57Bl/6 mouse is already 
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bred to be at its optimum and protected from negative stimuli? Is the C57Bl/6 
mouse a true representation of mouse ageing? 
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Chapter 6 
Characterising age-related changes in 
musculoskeletal tissues of male and female wild 
mice 
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6.1 Introduction 
We have already show in the previous chapters how ageing occurs in the lab 
based strain of mice C57Bl/6 and how the chosen interventions only have very 
limited effects on reversing the detrimental changes we see with increased age. It 
is now sensible to investigate whether our original chose of model animal was not 
optimal and whether these lab based strains are already optimised for ageing well. 
6.1.1 Using wild mice as a model of human ageing 
Mouse models are commonly used to study the effects of age-related conditions 
primarily due to the shorter life span and the ability to manipulate gene expression 
in tissues. The use of model organisms to research ageing is not a new 
phenomenon and despite the quadruped locomotion used by mice, multiple 
studies have shown many similarities between mice and humans. Mouse models 
used tend to be genetically identical mice which provide the reliable information. 
This has the benefit of reproducibility and allows for integration of data across 
experiments (Threadgill et al., 2011). Since the sequencing of the C57Bl/6 mouse 
genome, it has been shown that 99% of mouse genes have human homologues 
(Boguski, 2002). Although this would indicate that the data can be translated into 
human work, there is a drive for other mouse models of ageing. Due to mouse 
lines being derived from brother-sister mating through generations, the mouse 
strains are inbred (Bailey, 1971). In essence the genetic pool of inbred laboratory 
strain mice has become smaller and smaller over time. When compared with the 
large variation in natural genetic polymorphisms displayed within the human 
population, the use of these laboratory mice is not optimal.  
Alongside these findings, work comparing wild mice and laboratory mice 
concluded that there are a number of differences between the two groups 
including genetic diversity, less responsiveness to environmental cues, higher 
growth rates and more docile behaviour in the laboratory strain mice (Garland et 
al., 1995, Olsson and Sherwin, 2006). Studies have also shown that laboratory 
strain mice are generally larger in mass through the life span and display a lack of 
interest in voluntary activity – both of which would impact on musculoskeletal 
ageing in these rodents (Garland et al., 1995). However it must be noted that most 
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wild mice will adapt to a domesticated lifestyle within approximately 10 
generations, which may impact on any findings (Nelson et al., 2013). 
Studies have attempted to reintroduce genetic variability amongst common 
laboratory mouse strains. Miller et al (2009) published a paper detailing a 
programme coordinated by the National Institute on Ageing (Miller et al., 1999). 
This involved a four-way cross of commonly used laboratory mouse strains 
creating offspring with 25% of genes from each grandparent. These mice were 
therefore not genetically similar to each other, creating a new mouse strain (Miller 
et al., 1999). The Collaborative Cross Study further developed these initial 
experiments and mice were derived from 8 inbred strains through three 
generations of random intercrossing and at least 20 generations of brother-sister 
mating to produce new strains (Threadgill et al., 2011). These processes have 
allowed for mice to be developed with high genetic diversity and this is being 
further applied to future mouse lines. It has also removed genetic drifting seen in 
more common laboratory strains with apparently the same strain in multiple labs 
developing 'local' changes in genetics due to lack of local diversity. However both 
techniques used large amounts of time and expense to create genetically unique 
mice that are still reared in a laboratory environment. 
6.1.2 Differential ageing between male and female mice 
The main consequences of ageing in musculoskeletal tissues are a severe and 
progressive loss of muscle mass and force, a continued loss of bone mass and 
bone quality leading to osteoporosis, an increased risk of joint diseases such as 
arthritis and an increased risk of fractures due to increased falls. 
Although these are ubiquitous between the sexes, the rate of development and 
presentation of each disease state can be widely different. One of the main causes 
of these differences is proposed to be the dimorphisms in size and body mass 
between males and females. Females on mean tend to be of smaller size and mass 
compared with male counterparts and it directly influences the mean size of 
muscles and bones (Hanrahan and Eisen, 1973). As muscle and bone mass is lost 
at generally similar rates in both sexes until menopause (at which females show 
an accelerated loss), females may develop the symptoms of sarcopenia and 
osteoporosis at an earlier time point then males. This leads to more time spent 
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with mobility problems and a higher risk of falls since female lifespan tends to be 
longer.  
Three key papers show age-related changes in the muscles of female compared to 
male mice. Sheard and Anderson et al (2012) published data on age-related 
decline in muscle fibre number in male and female mice (Sheard and Anderson, 
2012). In accordance with work presented in Chapter 3, Sheard and Anderson et 
al. (2012) showed that the leg muscles of the male mouse had significant muscle 
fibre loss. This study also showed that this occurred in leg muscles of female 
mice. Despite earlier work to the contrary (Rowe and Goldspink, 1969), the 
Anderson study could find no correlation with specific fibre typing and 
prevalence of fibre loss. Rowe (1969) did however find a sex related difference in 
the proportion of slow fibres in the soleus muscle, with female mice having a 
higher proportion of slow fibres compared with male mice. This study also 
showed a higher percentage of fibres lost in the EDL with increasing age in the 
female compared with the male mice. 
Complementing this work, a further study by Moran et al (2005) showed that the 
force generating capacity of soleus muscles from aged female mice decreased by 
20% (Moran et al., 2005). This decrease was not attributed to reduced muscle size 
or reduction in contractile protein levels in the soleus (Moran et al., 2005). Again, 
female mice displayed reduced values compared with the male counterparts. 
However a new finding was that the significant decrease in force generation 
occurred earlier in the female mice. The authors recorded the age of 
approximately 10-16 months of age for this decrease in force generation capacity 
in females compared with the males (This was not seen in the EDL muscle in this 
study) (Moran et al., 2005). 
This age range is of significance in female mice as it is the age at which levels of 
ovarian hormones drop and the ovaries fail in mice (Cargill et al., 2003). This 
would imply that the decreases in force generation occur simultaneously with the 
onset of these hormonal changes. However whether this was coincidental or not 
was not investigated in this study. 
The onset of the menopause has direct consequences with skeletal health and is a 
key differing point in the ageing of musculoskeletal tissues between the sexes. 
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Postmenopausal osteoporosis is the most common form of osteoporosis. The 
decline of ovarian hormones occurs in humans many years before the onset of the 
menopause (48-50 years) and in the first ten years of the menopause, humans on 
mean lose 1% of bone mass every year, which does not occur until later time 
points in males. 
Although the mechanisms by which that loss of oestrogen affect bone turnover is 
not yet understood fully, it is known that all bone cells carry a receptor for 
oestrogen and it is hypothesised that the loss of these hormones, potentially in 
combination with an increase in serum cytokine levels leads to the loss of bone 
(Smith, 2005). 
What has clouded the field is the use of mouse models of menopause. Often 
studies use younger mice which undergo ovariectomy to induce artificial 
oestrogen deficiency. One study by Glatt et al. (2007) examined the age-related 
changes in bone of both male and female mice without surgical or pharmaceutical 
intervention (Glatt et al., 2007). The authors showed that changes in trabecular 
bone occurred much earlier and to a greater extent in the female mice when 
compared with male. Female mice also showed a more rapid decline in bone 
volume during the adolescence phase and slowed down in adulthood (Glatt et al., 
2007). This would mimic data of muscle loss previously described. Females in 
general in this study displayed lower values for each of the bone measurements 
and showed a higher rate of decline through age (Glatt et al., 2007). 
6.1.3 Benefits of increased activity on age-related conditions 
There is a large body of research investigating the effect of inactivity or reduced 
exercise levels has on ageing and musculoskeletal tissue decline. Physical 
inactivity is closely associated with admissions to hospital with chronic conditions 
(Bielemann et al., 2015). There is also a high correlation between increasing age 
and decreasing physical activity and this has a clear negative impact on skeletal 
muscle mass and function (Kortebein et al., 2007, Gianoudis et al., 2015) 
(Sardinha et al., 2015). This is also seen with loss of bone mass (Emaus et al., 
2014, Dallanezi et al., 2016). 
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Resistance exercise has the largest effect on muscle tissue. It has been shown that 
resistance exercise can increase muscle mass and improve muscle function 
including increased muscle force generation (Sipila and Suominen, 1995). 
However, prolonged exercise regardless of type does not prevent the onset of 
sarcopenia. In a group of veteran athletes of either endurance or power activities, 
there was still evidence of muscle loss with increased age (Drey et al., 2016).  
Regular exercise is proposed as the most beneficial approach for osteoporosis 
(Berard et al., 1997, Gomez-Cabello et al., 2012). The type of exercise that is 
potentially beneficial to bone differs slightly to what is reported for muscle and 
suggests a programme of high load non mass bearing exercise is optimal. 
Exercise has also been shown to reduce serum levels of inflammatory cytokines 
which increase in old age and are also thought to be detrimental in later life 
(Greiwe et al., 2001, Petersen and Pedersen, 2005).  
There are currently no exercise regimes in particular that show universal benefits 
for all musculoskeletal tissues however resistance exercise is clearly beneficial for 
muscles and this may induce improvements in the other tissues. Increased exercise 
prior to reaching old age may ensure individuals reach peak muscle and bone 
mass before the declines start as with the veteran athletes.  
6.1.4 Wild mice for study of increased activity 
Wild mice used in this study were obtained from Professor Jane Hurst (Green et 
al., 2015). Mice were captive bred Mus musculus domesticus derived from 
ancestors captured from five different populations in the northwest of England, 
UK. All ancestors were captured within 20 miles of each other except for 2, which 
were captured 80 miles away to ensure genetically differing strains (Green et al., 
2015) (Ramm et al., 2015). The captive bred offspring were housed in standard 
cages with increased enrichment. As well as being the offspring of wild mice, 
they also displayed increased levels of activity and were more prone to climbing 
and jumping activities (Green et al., 2015, Ramm et al., 2015). This may be due to 
cage enrichment (Olsson and Sherwin, 2006) although C57Bl/6 mice do not show 
increased activity even with this enrichment. 
 179 
 
In contrast to the C57Bl/6 mice ageing described in the previous chapter, here we 
aim to establish a model of ageing in both male and female mice from a 
genetically wild background. These mice also have the benefit of increased levels 
of activity. 
 
6.2 Aims 
The aims of this study were as follows; 
 To investigate age-related changes in musculoskeletal tissues of wild mice 
compared with the C57Bl/6 laboratory strain of mice. 
 To investigate differences in ageing between male and female wild mice. 
 
The hypothesis of this study was that musculoskeletal tissues of wild mice 
demonstrate delayed ageing compared with tissues of C57Bl/6 mice due to 
the reported increased activity of the wild mice. In addition, female mice 
will demonstrate earlier onset of musculoskeletal dysfunction compared 
with male mice independent of the strain of mice. 
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6.3 Methods 
6.3.1 Mice 
All experiments were undertaken in accordance with UK home office guidelines 
under the UK Animals (scientific Procedures) Act 1986 and with ethical approval 
from the University of Liverpool Animal Welfare and Ethical Review Body.  
A total of 38 mice were used. These were divided into groups based on sex and 
age. Final group numbers for males were – 6 mice aged 6 months, 6 mice aged 12 
months and 4 mice aged 24/25 months. Final group numbers for female mice were 
– 4 mice aged 6 months, 6 mice aged 12 months, 6 mice aged 24/25 months and 6 
mice aged 31 months. These age groups were chosen to match key time points 
identified in Chapter 3 although the age groups were somewhat limited due to the 
availability of the wild mice. Six months was chosen to record muscle masses 
prior to significant declines in mass occurring, 12 months to represent a mid-point 
in the life course, 24 months to represent a time of significant muscle and bone 
decline in C57Bl/6 mice. 31 month old female mice were included as additional 
time point as they remained in good health. They were included to examine 
whether these mice have prolonged preservation of musculoskeletal tissue 
compared to the C57Bl/6 laboratory strain. 
Mice were kindly donated by Professor Jane Hurst (University of Liverpool, UK). 
6.3.2 Tissue collection and preparation 
All tissues were obtained post mortem as described in Section 2.3. Briefly, all 
muscles and organs were removed and snap frozen prior to storage at -80°C. Feet 
with both achilles and posterior tibialis tendon attached were stored at -80°C. 
Hindlimbs had remaining muscle tissue removed and were stored in formalin 
solution for 24 hours before transferred into 70% ethanol solution. 
6.3.3 Muscle analysis 
Anterior tibialis, extensor digitorum longus, soleus and gastrocnemius muscles 
from both hindlimbs where dissected and weighed. Following this, muscles were 
snap frozen in liquid nitrogen and stored for further analysis at -80°C. 
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6.3.4 Bone analysis 
Analysis of bones was described in Section 2.8. Briefly, both tibia and femurs of 
each hindlimb were scanned using a μCT system (Skyscan 1272 X-Ray 
microtomograph, Bruker Corporation, Kontich, Belgium) at high-resolution with 
an isotropic voxel size of 5 μm (60 kV, 0.5 mm aluminium filter, 0.7° rotation 
angle). The isotropic voxel size was changed to 10 μm for cortical analysis. Two 
images were taken at each rotation angle. The scans were reconstructed using 
NRecon software (Bruker, Massachusetts, USA). CTAn software (Bruker, 
Massachusetts, USA) was used to analyse the appropriate parameters previously 
outlined (Bouxsein et al. 2010). 
6.3.5 Analysis of hindlimb joint structure 
Joint analysis has been described in Section 2.7. Briefly, one hindlimb from each 
mouse was transferred into a decalcification solution (EDTA, pH 7), left at room 
temperature for 4 weeks without agitation and then embedded in paraffin 
coronally.  
Transverse sections were cut via HM355S microtome (Thermo Fisher Scientific, 
Massachusetts, USA). The cutting was done until the condyles were seen. 
Sections were stained for H&E and Safranin-O. Normality test indicated the n 
number was too small to allow for wild type male and female to be separated 
based on sex. As this was a prolonged process, 6 and 24 month time points were 
chosen for the analysis to match optimal stages shown by data gained in Chapter 
3. 
6.3.6 Statistics 
Data was tested for normality and equal variance using SigmaPlot (v11.0) (Systat 
Software, Inc., London, UK). Direct comparison between two sets of data was 
made by Student's t-test. For multiple comparisons, data was analysed for 
statistical significance by one-way ANOVA incorporating pairwise comparisons. 
Data are presented as mean ±SEM. Values P<0.05 were considered significant. 
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6.4 Results 
6.4.1 Measurement of age-related changes in body mass in both male and 
female wild mice 
Fig 6.1 Mean body mass of male and female wild mice at different ages (Data 
presented as mean +/- SEM) (n=6). * represents significant differences compared 
with values for age matched male mice value, # represents significant differences 
compared with sex matched 6 month old mice value. 
 
Mean body mass at different ages in both wild male and female mice are 
presented in Figure 4.1. Female mice were significantly smaller compared with 
males at both 6 and 12 month old. The body mass of male mice did not 
significantly change up to 24 months old. Female mice were significantly heavier 
at 31 months old compared to 6 months old.  
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6.4.2 Age-related changes in organ mass in both male and female wild mice  
 Table 6.1 Mean organ mass in wild male and female mice at different ages. (Data 
presented as mean +/- SEM) (n=6 per group) * represents significant difference 
compared with age matched male mice. Letters depict a significant sex matched 
difference, (a - 6 month old male mice, b - 12 month old male mice, c - 6 month 
old female mice, d - 12 month old female mice and e - 24 month old female 
mice).  
Table 6.2 Mean organ mass as a proportion of body mass. * represent significant 
difference compared with age matched male mice (Data presented as mean +/- 
SEM) (n=6 per group). Letters depict a significant sex matched difference, (a - 6 
month old male mice, b - 12 month old male mice, c - 6 month old female mice, d 
- 12 month old female mice and e - 24 month old female mice).  
The tissue mass of female mice were generally smaller than those of age-matched 
male mice although this difference was generally lost when data were expressed 
per unit body mass suggesting that body size was primarily responsible for the 
difference in these mass. 
Male mice had significantly increased mass for the heart, lungs, kidneys and brain 
at 12 months old compared with mice at 6 months old. The mass of the lung, 
kidneys and brain were decreased in mass in male mice at 24 months old 
compared with those in 12 month old mice.  
There was a significant increase in mass of most measured organs in female mice 
at 12 months old compared with the 6 month old mice and most tissues had 
generally increased further in mass at 24 months old. 
31
Male Female Male Female Male Female Female
Average 4.8 4.1 * 5.0 5.5 *,c 7.5 a,b 5.7 c 5.9 c,d
SEM 0.2 0.9 0.2 0.2 1.9 0.2 0.2
Average 5.3 4.4 6.1 a 6.7 c 5.4 b 7.3 * 6.5
SEM 0.2 1.3 0.2 0.3 0.3 0.7 0.3
Average 34.3 37.3 35.3 36.0 34.4 41.7 37.2
SEM 1.6 3.3 1.9 1.6 3.0 5.4 2.2
Average 1.4 1.5 1.6 2.6 *,c 19.0 5.2 d 3.33 c
SEM 0.1 0.5 0.2 0.2 17.4 2.1 0.6
Age 6 12 24
Sex
Heart OW/BW
Lungs OW/BW
Liver OW/BW
Spleen OW/BW
31
Male Female Male Female Male Female Female
Average 127 79 * 143 a 121 * c 135 135 c,d 140 c,d
SEM 5 11 7 4 15 6 9
Average 141 83 * 176 a 146 * c 139 b 172 * c,d 153 c
SEM 9 19 8 6 10 17 8
Average 909 730 * 1019 788 * 1116 1012 c,d 876 c
SEM 75 51 80 44 231 162 64
Average 306 249 * 385 a 281 * 146 a,b 152 c,d 319 c,d,e
SEM 8 19 6 12 19 9 11
Average 37 27 * 46 57 * c 77 a,b 127 * c,d 77 c,d
SEM 4 7 4 5 17 51 13
Average 228 163 * 304 a 348 c 237 b 345 * c 308 c
SEM 26 23 10 35 37 39 23
Age 6 12 24
Spleen
Brain
Sex
Heart
Lungs
Liver
Kidneys
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When accounting for body mass by converting data to a proportion of body mass, 
most of the observed changes with age in male mice were lost, with the exception 
of the heart and spleen. In contrast, most tissues in female mice maintained the 
increases seen at 12 months compared with 6 months old. 
Inclusion of the 31 month old female mice has demonstrated that tissue mass 
remained elevated compared with data for 6 month old mice, In general, reduced 
mass were seen in some tissue of mice at this age, although these did not reach 
significance. 
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6.4.3 Age-related changes in muscle mass of male and female wild mice 
Table 6.3 Mean muscle mass (mg) of mice at different ages from four hindlimb 
muscles * represents significant difference compared with age matched male 
mice. Letters depict a significant sex matched difference, (a - 6 month old male 
mice, b - 12 month old male mice, c - 6 month old female mice, d - 12 month old 
female mice and e - 24 month old female mice). (n=6 per group, data presented as 
mean +/- SEM) 
Table 6.4 Mean muscle mass as a proportion of body mass. * represents 
significant difference compared with age matched male mice. Letters depict a 
significant sex matched difference, (a - 6 month old male mice, b - 12 month old 
male mice, c - 6 month old female mice, d - 12 month old female mice and e - 24 
month old female mice). (n=6 per group, data presented as mean +/- SEM). (n=6 
per group, data presented as mean +/- SEM) 
Muscles were generally smaller in 6 and 12 month old female mice compared 
with male mice although this difference was lost at 24 months old. This difference 
was lost at 12 months old when data were expressed per unit of body mass, 
suggesting that the smaller muscle size of female mice was a reflection of smaller 
body mass. 
The anterior tibialis muscle and soleus of male mice reached peak mass at 12 
months old. The mass of all male mice were significantly reduced in 24 month old 
mice compared with 12 month old mice. 
In the female mice, all muscles reached peak mass at 12 months of age and the 
anterior tibialis muscle showed some evidence of reduced mass at 24 months 
31
Male Female Male Female Male Female Female
Average 1.5 1.1 * 1.5 1.7 c 1.2 a,b 1.4 c,d 1.1 d,e
SEM 0.1 0.1 0.1 0.0 0.1 0.1 0.0
Average 0.3 0.1 * 0.3 0.3 c 0.3 a,b 0.4 c 0.3 c
SEM 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Average 0.2 0.1 * 0.3 a 0.3c 0.2 b 0.4 c,d 0.2 c,d,e
SEM 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Average 5.0 4.6 4.6 5.1 3.9 a,b 4.9 4.1 c,d,e
SEM 0.4 0.3 0.2 0.2 0.1 0.5 0.0
Age 6 12 24
Sex
AT MW/BW
EDL MW/BW
Sol MW/BW
Gas MW/BW
31
Male Female Male Female Male Female Female
Average 39 22 * 44 a 37 *c 34 b 32 * c,d 20 d,e
SEM 2 2 1 1 4 2 1
Average 9 2 * 9 7 *c 7 a,b 7 c 6 c
SEM 1 1 1 2 1 1 1
Average 6 1 * 0 6 c 6 b 8 *c 4 c,e
SEM 0 0 1 3 1 1 1
Average 130 90 * 133 112 *c 108 a,b 111 c 96 d,e
SEM 7 2 5 4 10 7 6
Age 6 12 24
Sex
AT
EDL
Sol
Gas
 186 
 
compared with 12 months old. No evidence of muscle loss seen in any muscle. At 
31 months of age most muscles showed a significant reduced mass. 
Expressing muscle mass as a proportion of body mass had little effect on a 
differences seen in absolute muscle mass. Thus, when expressed as a proportion 
of body mass of the anterior tibialis and gastrocnemius muscle in the male mice 
declined at 24 months old compared with the 12 month old mice. The mass of 
EDL muscle was significantly reduced at 24 months old compared with EDL 
mass at the 6 month old with no changes in the soleus muscle. 
Similarly, when expressed as a proportion of body mass, anterior tibialis muscle 
of female mice showed evidence of reduction in mass at 24 months compared 
with 12 months old but no evidence of age-related reduction in mass, in a similar 
manner to absolute muscle mass. 
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6.4.4 Analysis of joint and ligament structure by histological sections of knee 
joints of male and female wild mice 
Fig 6.2 Representative histological sections of the knee joint in wild male mice at 
6 and 24 months of age. Photographs A-C were stained with H&E. A was 
magnified x4 to show the whole joint, B (cartilage region) and C (cruciate 
ligament region) were magnified x20 to show detailed structures.  
There was a visual change in the shape and structure of the joint in the male wild 
mice between 6 and 24 months of age. The meniscus and ligament were no longer 
recognisable at 24 months of age.  
Wild male 6 month Wild male 24 month
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Fig 6.3 Representative histological sections of the knee joint in wild male mice at 
6 and 24 months of age. Photographs SA-SC is stained with Safranin-O to show 
the proteoglycans (red). SA was magnified x4 to show the whole joint, SB 
(cartilage region) and SC (cruciate ligament region) were magnified x20 to show 
detailed structures. Erosion to the calcified cartilage (black arrow). Abnormal 
structure of cruciate ligaments with (dashed arrow). Osteophyte formation was 
also observed (orange arrow). 
The ligament was stained for proteoglycan structures. Clear erosion of cartilage 
was evident between 6 and 24 months of age, with cartilage lesions and boney 
osteophyte formation. 
Wild male 6 month Wild male 24 month
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Fig 6.4 Representative histological sections of the knee joint in wild female mice 
at 6 and 24 months of age. Photographs A-C were stained with H&E. A was 
magnified x4 to show the whole joint, B (cartilage region) and C (cruciate 
ligament region) were magnified x20 to show detailed structures.  
There was a visual change in the shape and structure of the joint in the female 
wild mice between 6 and 24 months of age. The meniscus and ligament were no 
longer recognisable at 24 months of age.  
Wild female 6 month Wild female 24 month
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Fig 6.5 Representative histological sections of the knee joint in wild female mice 
at 6 and 24 months of age. SA-SC is stained with Safranin-O to show the 
proteoglycans (red). SA was magnified x4 to show the whole joint, SB (cartilage 
region) and SC (cruciate ligament region) were magnified x20 to show detailed 
structures. Erosion to the calcified cartilage (black arrow). Abnormal structure of 
cruciate ligaments with (dashed arrow). Osteophyte formation was also observed 
(orange arrow). 
The ligament was stained for proteoglycan structures. There was a clear erosion of 
cartilage between 6 and 24 months of age, with cartilage lesions and bony 
osteophyte formation 
Wild female 6 month Wild female 24 month
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Fig 6.6 Representative histological sections of the knee joint in wild male and 
female mice at 6 and 24 months of age. Photographs were stained with H&E. and 
was magnified x4 to show the whole joint,  
There were no gross differences between the male and female wild mice 
suggesting that the changes seen were not sex-dependent but were a naturally 
occurring condition in the wild mouse population. 
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Fig 6.7 Representative histological sections of the knee joint in wild male and 
female mice at 6 and 24 months of age. Photographs were stained with Safranin-O 
to show the proteoglycans (red) and was magnified x4 to show the whole joint,  
There were no gross differences between the male and female wild mice at any 
age suggesting that the changes displayed were not sex-dependent but were a 
naturally occurring condition in the wild mouse population.  
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6.4.5 Visualisation of age-related changes in the hindlimb bones in male and 
female wild mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.8 Representative microCT images of the tibia (A) and femur (B) in the wild 
male and female mice at different ages. 
A representative image from each bone through the life course studied was 
selected based on mean bone values. In both sexes the cortical and trabecular bone 
was clearly evident. A change in 2D shape of both bones was shown with 
increasing age. Loss of trabecular bone was also seen at advancing age, with 
potential differential effects seen between male and female mice. 
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Fig 6.9 Representative 3D models of trabecular bone in tibia (A) and femur (B) 
through age in the wild male and female mouse. 
Loss of trabecular bone was seen in both bones studied. The trabecular bone also 
became less connected. Smaller trabecular bones appeared to be lost first with 
larger bones becoming thinner. There were clear visual differences between the 
male and female mice. 
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6.4.6 Age-related changes in cortical and trabecular bone in hindlimb bones 
of male and female wild mice 
Fig 6.10 Mean cortical bone thickness of tibia (A) and femur (B) at different ages 
in wild male and female mice (Data presented as mean +/- SEM) (n=6) * p <0.05 
compared with values for age matched male mice, # p <0.05 compared with sex 
matched mice at 6 months old. 
Data showed that cortical bone thickness generally decreased in tibia of male mice 
at 24 months old but this was not evident in the femur of the male mice. Female 
mice showed a small but significant decrease in tibia and femur cortical thickness 
at 12 months compared with 6 months old although the relevance of this is 
difficult to interpret as this was not maintained at 24 or 31 months old. No clear 
sex effects were seen. 
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Fig 6.11 Mean bone cross-sectional area of tibia (A) and femur (B) at different 
ages in wild male and female mice (Data presented as mean +/- SEM) (n=6) * p 
<0.05 compared with age matched data for male mice, # p <0.05 compared with 
data sex matched for mice at 6 months old. 
Data show a minor but significant reduction in tibia in bone CSA in 6 month old 
female compared with male mice with a similar although non-significant 
reduction seen in the femur. Tibia and femur CSA was generally reduced with age 
in male mice but not in female mice, resulting in a higher CSA in both tibia and 
femur of female compared with male mice at 24 months old. 
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Fig 6.12 Mean trabecular bone surface density values for tibia (A) and femur (B) 
at different ages in wild male and female mice (Data presented as mean +/- SEM) 
(n=6) * p <0.05 compared with data for age matched male mice, # p <0.05 
compared with data for sex matched 6 month old mice. 
Trabecular bone surface density of both the tibia and femur was significantly 
lower in 6 month old female compared with male mice. This was then 
dramatically reduced in male mice with increasing age and in female mice, 
resulting in loss of a high proportion of bone surface density by 24 months old in 
both male and female mice. 
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Fig 6.13 Mean trabecular number/mm values for tibia (A) and femur (B) at 
different ages in wild male and female mice (Data presented as mean +/- SEM) 
(n=6) * p <0.05 compared with values for age matched male mice, # p <0.05 
compared with values for sex matched 6 month mice. 
In a similar manner to trabecular bone density, trabecular bone number was 
significantly lower in female mice at 6 months old and both showed a dramatic 
and significant reduction by 12 months resulting in a dramatic loss of trabecular 
bone by 24 months old. 
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Fig 6.14 Changes in trabecular bone thickness at different ages in the tibia and 
femur in wild male and female mice (Data presented as mean +/- SEM) (n=6) * p 
<0.05 compared with male values. 
There were no significant differences in trabecular bone thickness in either bone 
at any age in either male or female mice. 
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Fig 6.15 3D representation of trabecular bone thickness through age in the tibia. 
White colours represent the thicker areas, purple colours representing the thinner 
areas. Scale is specific to each individual bone based of mean and SEM as such, 
no key is present. 
There were visual decreases in trabecular thicknesses in the mouse between 6 and 
24 months of age and differences between the sexes. The loss of trabecular bone 
was also evident. 
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Fig 6.16 3D representation of trabecular bone thickness through age in the femur. 
White colours represent the thicker areas, purple colours representing the thinner 
areas. Scale is specific to each individual bone based of mean and SEM as such, 
no key is present. 
There were visual decreases in trabecular thicknesses in the mouse between 6 and 
24 months of age and differences between the sexes. The loss of trabecular bone 
was also evident. 
Fe
m
u
r
W
ild
 m
al
e 
12
W
ild
 m
al
e 
24
W
ild
 m
al
e 
6
W
ild
 fe
m
al
e 
6
W
ild
 fe
m
al
e 
12
W
ild
 fe
m
al
e 
24
 202 
 
6.4.7 Comparison of age-related changes in body mass in both male C57Bl/6 
and male wild mice 
Fig 6.17 Mean body mass of male C57Bl/6 mice and male wild mice at different 
ages (Data presented as mean +/- SEM) (n=4/6* p <0.05 compared with value for 
age matched male C57Bl/6 mice. 
 
The body mass of wild male mice were significantly reduced compared with 
C57Bl/6 males at both 6 and 12 month old, but whereas C57Bl/6 mice showed an 
age-related loss of body mass, this wasn't evident in wild mice, resulting in no 
significant difference in body mass between C57Bl/6 and wild mice at 24 months 
old. 
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6.4.8 Comparison of age-related changes in organ mass in both male C57Bl/6 
and male wild mice 
Table 6.5 Mean organ mass at different ages. * represent significant differences 
compared with data from age matched C57Bl/6 mouse data (n=6 per group). 
Letters depict a significant breed matched difference, (a - 6 month old Bl/6 mice, 
b - 12 month old Bl/6 mice, c - 6 month old wild mice, d - 12 month old wild 
mice). Data presented as mean +/- SEM. 
Table 6.6 Mean organ mass as a proportion of body mass. * represent significant 
differences compared with age matched C57Bl/6 mouse data (n=6 per group). 
Letters depict a significant breed matched difference, (a - 6 month old Bl/6 mice, 
b - 12 month old Bl/6 mice, c - 6 month old wild mice, d - 12 month old wild 
mice and e - 24 month old female mice). Data presented as mean +/- SEM. 
The mass of tissues was significantly reduced in male wild mice at all ages 
compared with age matched male C57Bl/6 mice (Table 4.7) and this decrease was 
maintained when data was expressed per unit of body mass (Table 4.8). 
Bl6 Wild Bl6 Wild Bl6 Wild
Average 197.2 127.2 * 240.2 142.6 * c 205.7 135.1 *
SEM 13.4 5.5 30.8 6.5 8.8 15.0
Average 208.3 140.9 * 240.9 a 176.2 * c 228.5 138.6 * d
SEM 12.1 8.5 11.4 8.1 12.8 10.2
Average 1580.3 908.9 * 1758.4 1019.3 * 1212.1 a,b 1116.3
SEM 76.2 75.1 130.9 79.7 127.7 231.3
Average 402.9 306.4 * 496.8 a 384.9 *,c 450.1 145.7 * c,d
SEM 12.5 8.1 23.9 5.8 35.5 18.9
Average 70.8 37.2 * 100.3 a 46.2 * 66.9 b 77.5 c,d
SEM 5.4 4.5 7.4 4.1 10.6 16.5
Average 388.4 228.3 * 386.7 303.9 * c 383.1 237.4 * d
SEM 31.4 26.5 25.4 9.6 22.7 36.9
Brain
Cohort
Heart
Liver
Kidneys
Spleen
Lungs
Age 6 12 24
Bl6 Wild Bl6 Wild Bl6 Wild
Average 6.5 4.9 * 7.2 4.9 * 5.0 a,b 7.5 c,d
SEM 0.3 0.2 0.8 0.2 0.6 1.9
Average 6.9 5.3 * 7.3 6.1 *,c 6.7 5.4 d
SEM 0.3 0.2 0.3 0.2 1.4 0.3
Average 52.3 34.3 * 53.3 35.3 * 39.1 a,b 34.4
SEM 1.5 1.6 3.4 1.9 9.8 3.0
Average 2.3 1.4 * 3.0 a 1.6 * 5.6 19.0
SEM 0.1 0.1 0.2 0.2 3.0 17.4
Liver OW/BW
Spleen OW/BW
Cohort
Heart OW/BW
Lungs OW/BW
Age 6 12 24
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6.4.9 Comparison of age-related changes in muscle mass in male C57Bl/6 and 
male wild mice 
Table 6.7 Mean muscle mass (mg) of mice from four hindlimb muscles at 
different ages. * represent significant differences compared with age matched 
C57Bl/6 mouse data (n=6 per group). Letters depict a significant breed matched 
difference, (a - 6 month old Bl/6 mice, b - 12 month old Bl/6 mice, c - 6 month 
old wild mice, d - 12 month old wild mice and e - 24 month old female mice).. 
Data presented as mean +/- SEM. 
Table 6.8 Mean muscle mass as a proportion of body mass. * represent significant 
differences compared with age matched C57Bl/6 mouse data (n=6 per group). 
Letters depict a significant breed matched difference, (a - 6 month old Bl/6 mice, 
b - 12 month old Bl/6 mice, c - 6 month old wild mice, d - 12 month old wild 
mice and e - 24 month old female mice). Data presented as mean +/- SEM. 
The mass of muscles was significantly reduced in male wild mice at 6 months 
compared with age matched male C57Bl/6 mice (Table 4.9). All muscles were 
significantly reduced by 24 months in both wild and C57Bl/6 mice. 
When expressed as a proportion of body mass anterior tibialis and soleus muscles 
where still significantly smaller in the wild mice at 6 months. All muscles of both 
types where significantly smaller at 24 months compared with 6 month old values. 
 
 
 
Bl6 Wild Bl6 Wild Bl6 Wild
Average 56.4 38.7 * 57.7 43.7 *c 45.3 a,b 34.1 * d
SEM 3.7 1.8 3.6 0.8 3.5 4.1
Average 12.4 8.6 * 11.6 8.7 11.5 6.8 * c,d
SEM 1.3 0.6 1.9 0.6 2.0 0.7
Average 11.2 6.1 * 10.6 8.2 c 9.9 a 6.4 * d
SEM 0.7 0.3 1.5 1.3 0.6 0.9
Average 174.9 129.8 * 160.1 a 132.6 * 138.1 a,b 108.2 c,d
SEM 7.3 7.3 5.2 5.3 12.0 10.4
EDL
Sol
Gas
Cohort
AT
Age 6 12 24
Bl6 Wild Bl6 Wild Bl6 Wild
Average 1.9 1.5 * 1.7 a 1.5 * 1.7 a 1.2 * c,d
SEM 0.0 0.1 0.1 0.1 0.1 0.1
Average 0.4 0.3 0.4 0.3 0.4 0.2 * c,d
SEM 0.0 0.0 0.1 0.0 0.0 0.0
Average 0.4 0.2 * 0.3 0.3 c 0.4 0.2 *,d
SEM 0.0 0.0 0.0 0.0 0.0 0.0
Average 5.8 5.0 4.9 a 4.6 4.9 a 3.9 * c,d
SEM 0.1 0.4 0.2 0.2 0.2 0.1
AT MW/BW
EDL MW/BW
Cohort
Age 6 12 24
Sol BW/MW
Gas BW/MW
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6.4.10 Comparison of age-related changes in joint and ligament structure in 
both male C57Bl/6 and male wild mice 
Fig 6.18 Representative histological sections of the knee joint of C57Bl/6 and 
wild male mice at 6 and 24 months of age. Photographs A-C were stained with 
H&E. A was magnified x4 to show the whole joint, B (cartilage region) and C 
(cruciate ligament region) were magnified x20 to show detailed structures.  
There were no major visual differences in the structure of the joint or associated 
joint tissues between C57Bl/6 mice and the wild male mice at 6 months old. 
However significant differences were evident at 24 months old in wild mice 
including disruption of the ligament and meniscus. These changes were not 
evident in the C57Bl/6 mice at this age. 
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Fig 6.19 Representative histological sections of the knee joint in C57Bl/6 and 
wild male mice at 6 and 24 months of age. SA-SC is stained with Safranin-O to 
show the proteoglycans (red). SA was magnified x4 to show the whole joint, SB 
(cartilage region) and SC (cruciate ligament region) were magnified x20 to show 
detailed structures. Erosion to the calcified cartilage (black arrow). Abnormal 
structure of cruciate ligaments with (dashed arrow). Osteophyte formation was 
also observed (orange arrow). 
There were no major visual differences in the structure of the joint or joint tissues 
between C57Bl/6 mice and the wild male mice at 6 months old. However 
significant differences were evident at 24 months old in wild mice including 
reduction of articular cartilage and increase in cartilage lesions and formation of 
osteophytes in wild male mice, none of which were seen in the C57Bl/6 mice.  
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6.4.11 Visualisation of age-related changes in the tibia and femur in both 
male C57Bl/6 and male wild mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.20 Representative microCT images of the tibia (A) and femur (B) in the 
male C57Bl/6 and wild mice at different ages. 
A representative image from each bone site at different ages has been selected 
based on mean bone values. In both bones, the cortical and trabecular bone was 
clearly evident. A change in 2D shape of both bone sites is seen with advancing 
age. Loss of trabecular bone was also seen with advancing age in both wild mice 
and C57Bl/6 mice. 
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Fig 6.21 Representative 3D models of trabecular bone in tibia (A) and femur (B) 
through age in the wild and C57Bl/6 male mouse. 
The loss of trabecular bone was seen at both bone sites. The trabecular bone mass 
also became less connected. Smaller trabecular bones appeared to be lost first 
with larger bones becoming thinner. There were clear visual differences between 
the wild mice and C57Bl/6 mice. 
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6.4.12 Comparison of age-related changes cortical and trabecular bone 
measures in both male C57Bl/6 and male wild mice 
Fig 6.22 Mean cortical bone thickness values for tibia (A) and femur (B) at 
different ages in wild and C57Bl/6 male mice (Data presented as mean +/- SEM, 
n=6) * p <0.05 compared with data from age matched C57Bl/6 mice, # p <0.05 
compared with cohort matched 6 month old values.  
The wild male mice values for cortical bone thickness were significantly 
decreased compared with the C57Bl/6 mouse at 6 months of age in both bones. 
There was no age related change in the C57Bl/6 mice. There was an age-related 
decrease in the wild mice in the tibia only.  
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Fig 6.23 Mean cross-sectional area values for tibia (A) and femur (B) at different 
ages in wild and C57Bl/6 male mice (Data presented as mean +/- SEM, n=6) * p 
<0.05 compared with age matched C57Bl/6 values, # p <0.05 compared with 
cohort matched 6 month old values, + p <0.05 compared with cohort matched 12 
month values.  
The tibia trabecular bone surface density was significantly reduced in wild mice 
compared with that of C57Bl/6 mice at 6 months.  The tibia and femur bone 
surface density decreased with increasing age although the decline in wild mice 
was considerably more dramatic.  
A 
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Fig 6.24 Mean bone surface density values for tibia (A) and femur (B) at different 
ages in wild and C57Bl/6 male mice (Data presented as mean +/- SEM, n=6) * p 
<0.05 compared with age matched C57Bl/6 values, # p <0.05 compared with 
cohort matched 6 month old values, + p <0.05 compared with cohort matched 12 
month values.  
The tibia trabecular bone surface density was significantly reduced in wild mice 
compared with that of C57Bl/6 mice at 6 months. The tibia and femur bone 
surface density decreased with increasing age although the decline in wild mice 
was considerably more dramatic. 
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Fig 6.25 Mean trabecular number values for tibia (A) and femur (B at different 
ages in wild and C57Bl/6 male mice (Data presented as mean +/- SEM, n=6) * p 
<0.05 compared with age matched C57Bl/6 values, # p <0.05 compared with 
cohort matched 6 month old values, + p <0.05 compared with cohort matched 12 
month values.  
The trabecular bone number was not significantly reduced in wild mice compared 
with that of C57Bl/6 mice at 6 months. The tibia and femur bone number 
decreased with increasing age although the decline in wild mice was considerably 
more dramatic. 
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 Table 6.9 Percentage change of trabecular number at chosen age points in both 
tibia (A) and femur (B) bone and at different ages (C) in C57Bl/6 and wild male 
mice.  
 
B 
A 
C 
C57 Bl6 Tibia trabecular number % Change
6 Months 2.67 22.22
12 Months 2.08 SEM ± 2.7
12 Months 2.08 38.55
24 Months 1.28 SEM ± 5.6
Wild male Tibia trabecular number % Change
6 Months 2.35 69.40
12 Months 0.72 SEM ± 12.8
12 Months 0.72 57.87
24 Months 0.30 SEM ± 27.7
C57 Bl6 Femur trabecular number % Change
6 Months 2.78 11.31
12 Months 2.46 SEM ± 3.0
12 Months 2.46 53.14
24 Months 1.15 SEM ± 5.3
Wild male Femur trabecular number % Change
6 Months 2.72 74.40
12 Months 0.70 SEM ± 9.9
12 Months 0.70 57.71
24 Months 0.29 SEM ± 14.5
C57 Bl6 Tibia trabecular number % Change
6 Months 2.67 50.40
24 Months 2.08 SEM ± 4.7
Femur trabecular number
6 Months 2.78 58.44
24 Months 1.15 SEM ± 4.2
Wild male Tibia trabecular number % Change
6 Months 2.35 87.11
24 Months 0.30 SEM ± 3.4
Femur trabecular number
6 Months 2.72 89.17
24 Months 0.29 SEM ± 2.8
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Table 6.10 Pearson correlation calculations comparing the cortical bone thickness 
and trabecular number and the attached muscle mass in C57Bl/6 (A,B) and wild 
male mice (C,D).  
There were close correlations between loss of muscle mass and loss of trabecular 
bone in the C57Bl/6 mice. This was not seen in the wild male mice.   
A 
C 
D 
B 
C57 Bl6 Gastrocnemius weight Femur trabecular number Pearson
6 Months 0.17 2.78
12 Months 0.16 2.46
24 Months 0.14 1.15
C57 Bl6 Anterior tibialis weight Tibia trabecular number Pearson
6 Months 0.06 2.67
12 Months 0.06 2.08
24 Months 0.05 1.28
C57 Bl6 Gastrocnemius weight Femur cortical bone thickness Pearson
6 Months 0.17 0.13
12 Months 0.16 0.13
24 Months 0.14 0.09
C57 Bl6 Anterior tibialis weight Tibia cortical bone thickness Pearson
6 Months 0.06 0.13
12 Months 0.06 0.13
24 Months 0.05 0.12
Wild male Gastrocnemius weight Femur trabecular number Pearson
6 Months 0.13 2.72
12 Months 0.13 0.70
24 Months 0.11 0.29
Wild male Anterior tibialis weight Tibia trabecular number Pearson
6 Months 0.04 2.35
12 Months 0.04 0.72
24 Months 0.03 0.30
Wild male Gastrocnemius weight Femur cortical bone thickness Pearson
6 Months 0.13 0.13
12 Months 0.13 0.13
24 Months 0.11 0.10
Wild male Anterior tibialis weight Tibia cortical bone thickness Pearson
6 Months 0.04 0.12
12 Months 0.04 0.13
24 Months 0.03 0.11
0.87
0.86
0.92
1.00
0.97
0.63
0.66
1.00
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Fig 6.26 Changes in trabecular bone thickness in the tibia (A) and femur (B) at 
different ages in wild and C57Bl/6 male mice (Data presented as mean +/- SEM, 
n=6) * p <0.05 compared with age matched C57Bl/6 values. 
Minor differences in trabecular bone thickness were seen when comparing to 
C57Bl/6 mice. Trabecular bone thickness was significantly reduced in wild male 
mice compared with C57Bl/6 mice at 12 months old at both sites measured. No 
other differences were noted between species or with advancing age. 
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Fig 6.27 3D representation of trabecular bone thickness through age in the tibia 
and femur of C57Bl/6 and wild male mice. White colours represent the thickest 
points, purple colours representing the thinnest areas. Scale is specific to each 
individual bone based of mean and SEM as such, no key is present. 
There were visual decreases in trabecular thicknesses between 6 and 24 months of 
age in both strains. The loss of trabecular bone was also evident.   
Tibia
Femur
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6.5 Discussion 
6.5.1 Comparison of age-related changes between male and female wild mice 
As seen in Figure 4.1, female wild mice were generally significantly smaller in 
body mass at both 6 and 12 months of age however this significance was removed 
at later ages. This loss of significance was due to females maintaining body mass 
with increasing age whereas the males lost body mass with increasing age. 
The effect on body mass is possibly partly due to differences in organ mass shown 
in Table 4.1 which showed at 6 and 12 months of age all organs were smaller in 
the female mice compared with the males. At 24 months, females had 
significantly larger brain and lung tissues. This effect remained evident when 
removing body mass as a factor (Table 4.2). The effect was due to the male mice 
losing tissue mass by this age. This would suggest that the female mice preserve 
tissue mass better than males with increasing age.  
The hind limb muscles of the female mice at both 6 and 12 months were smaller 
than the male counterpart (Table 4.4). When the body mass differences were 
accounted for, the anterior tibialis, EDL and soleus muscle were only smaller at 6 
months old (Table 4.4) with no significant differences from that point on. This 
would suggest that females were able to adapt to ageing and were able to preserve 
muscle mass to a greater extent than the males. 
Mechanisms responsible for this are not understood. However, in most species 
studied females generally out-live the male counterpart and may therefore be 
primed to maintain tissue integrity for longer than the male (1999, Borras et al., 
2003). One explanation may be due to the absence of breeding within the groups. 
A study published in 1967 examined lifespan in rats which had undergone 
differential breeding patterns, castration or no breeding at all (Asdell et al., 1967). 
This study clearly showed that females that were never bred lived much longer 
and conversely males that were never bred lived the shortest (Asdell et al., 1967). 
This study also noted the benefit of oestrogen on life span where both males and 
females lived longer if supplemented with oestrogen, an effect which has been 
show by other groups (Vina et al., 2005). It was therefore hypothesised that 
females that never breed have higher than normal levels of oestrogen (Asdell et 
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al., 1967), despite females already having a higher level of oestrogen compared 
with males (Goodman-Gruen and Barrett-Connor, 2000). Despite the mouse 
undergoing reproductive senescence between 9 and 12 months of age, the lack of 
breeding may also be preventing the onset of menopause within these animals, 
thus maintaining the production of female hormones (Mobbs et al., 1984, Bellino, 
2000).  
Oestrogen is classed as an ‘antioxidant’ and is capable of up-regulating longevity 
genes as well as dampening of harmful inflammatory chemicals (Kendall and 
Eston, 2002, Vina et al., 2005, Vina et al., 2006). However the low levels seen in 
circulation show that they are not chemical antioxidants but works through the 
oestrogen receptor which can in turn up regulate antioxidant enzymes within a 
given tissue (Vina et al., 2013). 
Muscle deterioration and preservation in particular have been linked with 
oestrogen and other variants such as estradiol (Maltais et al., 2009, Moran et al., 
2007). A lack of estradiol has been shown to significantly reduced muscle force 
generation which can be recovered with hormone replacement (Moran et al., 
2007). This link between female sex hormones and muscle preservation as well as 
their role in improving antioxidant enzyme levels may explain why there is a lack 
of change in muscle tissue and even organ tissues with increasing age in this 
population of female wild mice. When examining the male mice, these mice lose 
male sex hormone levels with increasing age. The loss of these hormones is 
clearly linked with loss of muscle mass and force, again suggesting a role for sex 
hormones in muscle deterioration and preservation. It is therefore apparent that 
the wild male mice are undergoing a normal loss of muscle mass with increasing 
age and that the female wild mice are being preserved.  
Both sexes displayed large disruption of the knee joint with increasing age (Figure 
4.2-4.4). However there were no gross differences between the sexes. This may 
have been due to the low n numbers for analysis; however the severity of the 
disruption indicates this was a natural phenomenon within the wild mouse 
population. The disruption of the joints would suggest the underlying bone was 
also affected. As discussed previously, there were severe age-related effects on 
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the bone in the males and this was seen, although at a lesser extent in the female 
wild mice.  
Although the females do show a reduced bone structure in a number of measures, 
they are often comparable if not significantly higher than age-matched male mice. 
The female mice also show a lack of age-related decline in the cortical bone in 
particular and significant but minor decreases in trabecular bone measures with 
increased age. It is more striking when compared with the male counterparts 
where hugely significant bone loss is seen. 
This potential preservation may also be due to maintained levels of female sex 
hormones into later life. Oestrogen and others are known to be key in maintenance 
of bone mass and is often prescribed for cases of osteoporosis.  
If we assume that these females are maintaining the levels of female sex 
hormones into later life (possibly due to a lack of breeding) then muscle mass and 
possibly bone mass may be being maintained. This scenario is similar to humans 
undergoing hormone replacement therapy. These patients have significantly 
stronger muscles than those not receiving the therapy and also display a higher 
bone mass. 
6.5.2 Age-related changes in the wild male mouse compared with a 
laboratory strain mouse 
In general, the wild male mice were significantly smaller in body mass then the 
C57Bl/6 lab strain (Figure 4.17), had smaller organs even when body mass was 
removed as a compounding factor and had smaller muscle mass. However both 
groups display age-related decreases in body and tissue mass, the wild male mice 
show this to a greater extent. 
This would suggest that the laboratory grown mice are bigger in body mass and 
this appeared to be due to larger tissue mass. As the wild mice were more active, 
the fact they have smaller muscle masses compared with a sedentary laboratory 
strain would show that the activity was not a major factor in the muscle mass of 
the wild mice. However it could be that the muscles were leaner with less fatty 
deposits and were therefore healthier, but this was not examined in this study. 
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Cortical bone thickness was significantly higher in the wild male mice at both 6 
and 12 months of age compared with the C57Bl/6 mouse (Figure 4.21). However 
the CSA is smaller than the C57Bl/6 mouse at every age (Figure 4.22). The 
trabecular bone of wild male mice showed dramatic reductions in number of 
bones at 12 and 24 months of age compared with the C57Bl/6 mouse suggesting 
that in terms of bone health, 12 months old is deemed very old age in the wild 
mice (Figure 4.23-4.25). 
When examining the association with the muscle mass and number of trabecular 
bone, a close association between these two tissues in the C57Bl/6 mice was seen, 
but there was only a poor correlation in the wild male mice (Figure 4.26). This 
would indicate that another factor other than muscle mass and strength may be 
causing the dramatic reductions in trabecular bone number in wild mice. This 
factor is currently unknown. As mentioned previously, the hormone levels may be 
different between the groups but this could also be due to how the mice were 
housed, the genetic background and the presence of pathogens in the wild mice 
group and would all have an effect on the musculoskeletal health of these wild 
mice. Further indepth investigations must be undertaken to truly elucidate the 
reasons behind this abnormal decline in bone health compared to the C57Bl/6 
mice. 
Following on from the dramatic changes seen in the bones of wild male mice 
compared with the C57Bl/6 mice, there were significant gross age-related 
differences seen in the joint. This included loss of ligament and meniscus tissues, 
loss of cartilage tissue and the presence of cartilage lesions and the formation of 
osteophytes, none of these were present in the laboratory strain C57Bl/6 mouse, 
even at older ages. 
This would suggest that the quadrupedal locomotion of mice was not the reason 
C57Bl/6 mice do not naturally develop osteoarthritis or show age-related 
disruption to the joints. The appearance of naturally occurring joint disruption in 
the wild mice suggests that joint protection in the C57Bl/6 mice was a 
consequence of either the inbreeding of strains, or the environment the laboratory 
mice compared with the wild mice.  
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6.6 Conclusions 
The aim of this study was to examine a population of mice that have increased 
activity levels compared with laboratory strains. The predicted outcome was that 
increased activity would lead to increased muscle mass and improve bone values, 
ultimately leading to preservation of musculoskeletal tissues into old age. 
 Female wild mice which appeared to have prolonged muscle mass until a 
much later age then was measured in the C57Bl/6 cohort but still showed 
loss with increasing age. 
 Wild male mice appeared to be poorer in terms of musculoskeletal health 
compared to the female mice.  
 Prolonged production of female sex hormones in the wild female mice due 
to lack of breeding may be playing a protective role on musculoskeletal 
tissues and may explain the lack of age-related change seen. 
 One theory explaining why these wild mice did not age as well as the 
laboratory based strain C57Bl/6 may be due to the artificial lengthening of 
a wild mouse lifespan. If in the wild, these mice would only live a 
maximum of 12 months old, then it is reasonable to suggest that the wild 
mice are not genetically capable of ageing in the same way the inbred 
laboratory strains are, and will therefore degenerate rapidly after this point.  
 The strength this cohort of mice has over the lab based strain C57Bl/6 is 
that they do appear to naturally develop osteoarthritis, a condition not 
present in the C57Bl/6 mice. 
These mice provide a model to determine how ‘healthy’ murine ageing occurs 
normally, with our genetically identical laboratory strains being the abnormal 
ageing group. Normal ageing of a wild population of mice has been shown here, 
the increased activity that was initially the aim of the study should instead be 
considered normal activity levels. 
Laboratory strains of mice are commonly used, but these may now be masking the 
normal ageing process for the mouse itself, therefore, any interventions and drug 
treatments that have affects in this cohorts (positively or negatively) may not 
represent a valuable result and may need to be displayed in a number of stains or 
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species before truly representable. Conversely, attention should be focused on 
laboratory bred strains of mice as successfully ageing animals, determining why 
they doing so. 
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Chapter 7 
General discussion and future directions 
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7.1 General Discussion 
The main aim of this thesis was to determine how musculoskeletal tissues age and 
to integrate interventions targeted at a specific musculoskeletal tissue, multiple 
musculoskeletal tissues or the whole body to alter age-related changes in 
musculoskeletal tissues. Initially, the development of a reliable and expansive 
model to measure age-related changes in all musculoskeletal tissues was required 
which then informed our approach to any possible interventions. 
This multidisciplined approach to identifying age-related changes in 
musculoskeletal tissues has significant advantages through the use of in vivo, ex 
vivo and in silico methods, as well as interactions with engineers, computer 
scientists, behavioural biologists alongside cell biologists and musculoskeletal 
biologists to give, for the first time, a detailed representation of how 
musculoskeletal tissues age, and of the effects of possible treatments to improve 
the age-related declines that for so long have seemed inevitable. 
The main hypothesis of this thesis is that with increasing age in mice, there is a 
decline in the mass and function of all musculoskeletal tissues. The secondary 
hypothesis is that this decline could be prevented through a series of interventions 
including increased lifelong activity, a whole body over-expression of Heat Shock 
Protein 10 (HSP10) or an increase in dietary nitrates.  
As stated in 1.7 this aims of this study were as follows: 
 To integrate methods of visualising and measuring age-related changes in 
musculoskeletal tissues. 
 To identify changes in musculoskeletal tissues throughout the life span of 
C57BL/6 mice. 
 To determine the effects of increased sodium nitrate intervention, both 
short-term and longer-term, on changes seen in the musculoskeletal system 
of C57Bl/6 mice with age.  
 To examine the effect of lifelong overexpression of HSP10, known to 
preserve muscle CSA on other tissues from the musculoskeletal system. 
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 To compare data from C57Bl/6 mice with changes in musculoskeletal 
tissues of male and female wild mice which demonstrate a significant 
increase in activity 
The first aim was addressed throughout this thesis as a number of practical and 
analytical methods were implemented to allow for a full analysis of 
musculoskeletal tissue ageing. These included identifying specific muscles and 
organs to reliably dissect and measure. Muscle force testing was updated and used 
here to gauge changes in muscle force. Through collaboration with experts in 
engineering we developed testing protocols for mouse tendon and a number of 
novel methods of measuring bone and cartilage have been used throughout.  
The second aim was achieved and detailed in Chapter 3 were it were we pin 
pointed the specific age in mice where the decline in muscle and bone occurred. 
We were unable to successfully measure tendon changes (discussed further) and 
there were no changes in the joint cartilage to report. The methods created for the 
first aim were brought through to answer the third aim and measure the effect of 
both long and short term treatment of mice with sodium nitrate in the drinking 
water. As seen in Chapter 4, this had a surprising affect as there was no difference 
when treated from 9 months of age until 24 months old, but when treated from 18 
months it had a deleterious effect on the muscle force production indicating this 
treatment is unsuitable to reverse the ageing process in musculoskeletal tissues. 
Aim 4 was addressed in Chapter 5 following the unsuccessful dietary intervention. 
Effect of overexpressing HSP10 on muscle tissue has been reported previously 
and the results here support this. The novel finding from this was that preserving 
the muscle mass had no effect on the underlying bone tissue and led to the theory 
that both tissues may age independently from each other. Following surprising 
results in the previous chapters, we decided to use a different mouse strain to see 
if lab based strains of mice are protected from ageing to a greater extent then what 
is deemed normal for the species. A colony of wild bred mice was used in Chapter 
6 and the methods gained through aim 1 were applied to show that indeed, lab 
based mice age slower than the wild mice. 
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Fig 7.1 Schematic showing the flow of aims through the thesis and how they 
interact with each other. Aim 1 umbrellas all other aims and primarily feeds into 
Aim 2. Aim 2 directed the following aims. Aim 5 due to the nature of the findings 
led directly back to Aim 2 and potentially changes the outcomes of Aim 1. 
7.2 Summary of major findings  
7.2.1 Integration of methods to determine age-related changes in 
musculoskeletal tissues 
It is possible to use a range of in vivo, ex vivo and in silico techniques to 
measure all musculoskeletal tissues through age. This study has integrated 
muscle force generation measured in vivo with muscle mass to show how muscle 
mass and muscle force changes through life. Cross-sectional analysis of muscle 
allowed for further analysis of the effect of age on individual muscle fibres. 
Tendon tissue can be dissected intact and analysed for both histological and 
mechanical characteristics to identify how changes in tendon size with age may 
impact on the mechanical forces. The joint and associated structures can be 
visualised and quantified and the joint can be stained for signs of osteoarthritis, 
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the presence of bony outgrowths and ligament morphology and cellular number 
can be quantified. MicroCT scanning of hindlimbs allowed for a large number of 
complex bone analyses to be undertaken. This gave an appreciation for the 
mechanical strength of both cortical and trabecular bone as well as detailing the 
age-related changes in bone. This allowed for a vast array of computational 
models to be produced for visualisation of these various measures in high 
resolution. The inclusion of recording body mass was necessary to eliminate age-
related increases in body mass as a compounding factor when investigating 
changes in tissues, especially in the case of organ pathologies which may have 
had influences on the musculoskeletal tissues. Furthermore, the storing of blood 
for further analysis provides another element when considering the causes age-
related changes measured in musculoskeletal tissues. 
7.2.2 Changes in musculoskeletal tissues throughout the lifespan of the 
C57Bl/6 mouse 
The muscles of the hindlimb undergo age-related loss of mass, although 
muscles were affected by age differently. As a general principle, the larger the 
muscle, the earlier age-related loss of mass was seen. The gastrocnemius muscle 
first showed significant loss of mass by 12 months of age which represent 
approximately 30-50 years of age in humans. The anterior tibialis was the next 
muscle to show age-related declines in mass at 24 months representing a human 
age of approximately 70 years of age. The remaining two muscles, the EDL and 
soleus displayed age-related loss of muscle mass at 28 months. This showed the 
need to study multiple muscles. When accounting for body mass as an influencing 
factor on muscle mass, the larger muscles again displayed age-related loss of 
muscle mass earlier with the gastrocnemius and anterior tibialis showing 
significant loss at 6 months of age although this may relate to muscle and organ 
remodelling between 3 and 6 months old. The remaining two muscles only 
showed significant declines at 28 months. 
Tendons appear to be resistant to age-related changes. There were no 
significant changes in diameter or the cross-sectional area of the posterior tibialis 
tendon. However when measuring the ability of this tendon to handle mechanical 
force, at an older age, the tendon was unable to correctly manage higher stresses 
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and strains when applied indicating an age-related change in this index and a 
weaker tendon tissue. However, the inability to study other tendons was a 
limitation of this study 
The knee joint of the C57Bl/6 mouse does not appear to undergo significant 
age-related changes. There was no indication of a loss of articular cartilage with 
increasing age. Although there did appear to be some minor reduction in cellular 
presence within the cartilage and ligament, as well as some disorganisation of the 
ligament structure, no gross alterations were seen. 
There was clear evidence for age-related changes in the bone were seen in 
both cortical and trabecular bone compartments. There were some differential 
results between the tibia and femur bones indicating that external factors may be 
playing a role in bone ageing and again demonstrating the need to study more than 
one bone. Both bones measured showed significant increases in cortical bone 
thickness from 3 to 6 months of age which remained significantly high until 24 
months of age. Both had significant declines in cortical bone thickness by 28 
months of age. There was little significant change in bone cross-sectional area 
however until it decreased from 24 months of age indicating the cortical bone 
dictates the cross-sectional area. Trabecular bone values show significant age-
related declines from 3 months of age including loss of trabecular bone number 
and bone surface density which have ramifications for the mechanical properties 
of the bone. Trabecular thickness appeared unaffected by increasing age but did 
increase significantly at 18 months only. 
There was an association between muscle and bone tissues. There was a close 
correlation between the mass of the attached muscle and the cortical bone 
thickness of the underlying bone e.g. gastrocnemius mass change is closely 
correlated with femoral cortical bone thickness. There are also close correlations 
between muscle mass and trabecular bone number although the correlation is 
lower than with the cortical bone thickness.  
7.2.3 Comparison of musculoskeletal ageing between C57Bl/6 laboratory 
mice and wild mice. 
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Wild male mice musculoskeletal tissues age differently to laboratory grown 
C57Bl/6 mice. The muscle mass data shows wild male mice muscles are 
significantly smaller then C57Bl/6 mice at 6 months of age and 24 months of age 
but muscle loss occurred in a similar pattern in both strains of mice although the 
percentage loss of mass appears greater in the wild mice between 12 and 24 
months old  
Wild male mice display age-related changes in both joint and ligament tissues 
with disintegration of the knee ligament and meniscus, removal of articular 
cartilage and bony growths. This would suggest wild male mice naturally 
develop knee osteoarthritis whereas the laboratory strain showed no evidence of 
such changes.  
There were differential age-related changes between male and female wild 
mice. Female wild mice had significantly smaller muscle mass at 6 months old in 
all muscle measured, all muscles remained significantly smaller except soleus at 
12 months and this remained in the anterior tibialis and soleus muscles at 24 
months of age. When removing body mass as a factor, only the anterior tibialis, 
EDL and soleus muscles only remained smaller at 6 months of age suggesting that 
the major reason for smaller muscles was the reduced body mass.  
Both sexes showed age-related disruption of the joint and signs of 
osteoarthritis to a similar extent.  
7.2.4 Effect of muscle overexpression of HSP10 on musculoskeletal tissue 
structure 
Overexpression of HSP10 in mice led to some preservation of muscle mass 
compared to C57Bl/6 mice. Absolute mass of anterior tibialis and gastrocnemius 
muscle was preserved in HSP10 overexpressor mice compared with wild type 
mice although this preservation was lost when accounting for body mass. 
Bones of the HSP10 overexpressor mice displayed significantly larger cross-
sectional area compared to C57Bl/6 mice at 6 months, with no significant 
differences at 24 months. In general terms, HSP10 overexpression in muscle had 
little effect on bone structure. 
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7.2.5 Effect of nitrate interventions on musculoskeletal tissue deterioration 
during ageing 
Mice appear to tolerate both long and short-term interventions with 1mM 
sodium nitrate solution with no effects of death rates. 
Long-term nitrate treatment can improve age-related muscle mass declines. 
Long-term nitrate treatment led to a significant increase in EDL mass, when 
accounting for body mass the anterior tibialis, EDL and gastrocnemius muscle 
masses were significantly increased.  
Short-term nitrate treatment led to significantly smaller EDL compared to 
control. This remained even after accounting for body mass.  
Neither intervention led to any major effects on cortical thickness or cross-
sectional bone area. There were no significant changes in trabecular bone 
measures between control and long-term nitrate; short-term nitrate treatment 
increased trabecular number which seemed to be reflected in a larger number of 
smaller trabecular.  
Both nitrate interventions increased heart and lung tissue weight. 
 
7.3 Limitations of this study 
7.3.1 The use of mice to study the effects of musculoskeletal ageing. 
Since the sequencing of the C57Bl/6 mouse genome, it has been shown that 99% 
of mouse genes have human homologues (Mouse Genome Sequencing et al., 
2002). There are many examples of mouse studies involving the alterations of 
genes/proteins to potentially resemble an ageing animal or human through 
accelerating the ageing process. In muscle studies this include a reduction of 
antioxidant enzymes level (Sakellariou et al., 2014b), deletion of maintenance 
proteins such as heat shock proteins (Kim et al., 2006), reduce the calorie intake 
(Sohal and Forster, 2014), which all aim to mimic, accelerate or delay ageing. 
The mouse models used tend to be genetically identical mice which provide the 
most reliable information in a given genotype. This has the benefit of 
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reproducibility and allows for integration of data across experiments and time 
points (Threadgill et al., 2011) meaning the genetic pool of inbred laboratory 
strain mice has become smaller and smaller over time. 
This study attempted to examine the effects of this lack of diversity with the 
inclusion of a cohort of wild mice, directly comparing the two strains. There were 
a number of differences between the two strains and it appears that the potential 
shorter life span of wild mice may be influential. This is important to note when 
trying to translate the findings from this study into future mouse ageing studies. 
A further limitation of this study is studying a quadrupedal animal model, which 
is a change in locomotion compared to the bipedal human. This essentially results 
in body mass and muscle mass being evenly distributed amongst 4 limbs rather 
than two and may result in differing stresses and strains placed upon joints and 
bones. This may be an influential difference and a limitation to using such animal 
models. 
Through the use of the C57Bl/6 mouse as our control group, we wanted to study 
ageing in a commonly used laboratory strain of mice. However these mice do not 
appear to naturally develop osteoarthritis, a common condition within the human 
population. This may be attributed to the quadrupedal movement. However, 
osteoarthritis does develop naturally in the wild mice. This shows that mice can 
develop the condition despite the differential locomotion and shows that as a 
control, C57Bl/6 mice may not be the ideal choice for this condition.  
Ultimately despite these limitations, the positives to using animal models are 
outweigh the negative but caution is needed when focusing on one strain of 
animal, before applying findings directly to humans.  
7.3.2 The use of male mice throughout this study 
Although the effects of age on musculoskeletal tissues are basically the same 
between the sexes, the rate of development and presentation of each dysfunction 
can be widely different. One of the main causes of these differences is proposed to 
be the dimorphisms in size and body mass between males and females and the 
levels of sex hormones. The ideal future study would be to repeat the study in 
female mice. 
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One benefit of using solely male mice is to remove the influential effects of 
circulating hormones and how they change with age, especially in females. The 
onset of the menopause has direct consequences on skeletal health and is a key 
differing point in the ageing of musculoskeletal tissues between the sexes. 
A study by Glatt et al. (2007) examined the age-related changes in bone of both 
male and female mice without surgical or pharmaceutical intervention (Glatt et 
al., 2007). The authors showed that changes in trabecular bone occur much earlier 
and to a greater extent in the female mice when compared with male. Females in 
general in this study displayed lower values for each bone measurements and 
showed a higher rate of decline with age (Glatt et al., 2007). 
7.3.3 The ages at which measurements were taken, the choice against ageing 
a cohort continuously. 
For this study, the start of testing was chosen as 3 months and end at 28 months. 
Although it would have been beneficial to study from birth to natural death, this 
was not possible for several reasons including time and financial restrictions. This 
meant that rapid changes seen in mice between 0-3 months were not measured 
and the study commenced at an age that equated to post puberty in humans. 28 
months was chosen as an end point as this resembled 50% survived based on 
Jackson laboratory data and also avoided the development of unrelated 
pathologies developing such as tumours.  
7.3.4 Examination of age-related changes in tendon structure and function. 
The posterior tibialis tendon was chosen due to the ease at which it could be 
reproducibly dissected and analysed. The Achilles tendon was considered but in 
the mice this is very short and could not be used for functional studies. 
There was a possibility that due to the tendon having such a small size, any 
structural or functional changes were too small to identify, in a similar manner to 
mass of the smaller hindlimb muscles.  
Due to the small size of the tendons, stress-strain measurements may have been 
influenced directly by the grips causing unnatural strains. As the samples had to 
be glued in place, there was a risk of glue detrimentally affecting the tendon. 
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In conclusion, although this study has provided some useful information on 
tendon ageing, mouse tendons were not deemed suitable for the mechanical 
testing that was performed. In retrospect, structural analysis of other tendons 
would have been optimal. 
7.3.5 Unfeasibility of gathering important data out of the base location 
There are a few important pieces of data that have been unable to be recorded. 
These include the activity level of the wild mice, force measurements of wild 
mice muscles and direct measurement of dietary intake of mice under nitrate 
supplementation.  
The activity levels were not measured due to how the cohort of wild mice were 
gifted to the study. There was not sufficient time to integrate an activity study 
prior to the need to cull the animals to gain the other data. As this cohort was not 
originally part of the thesis, the other studies had already been concluded and so 
there was no opportunity to measure activity in the other animals either.  
Again, as these wild animals were housed at our facility in Leahurst and not the 
same location as the other animals in the thesis, the equipment used to measure 
muscle forces could not be transported. 
Daily nitrate intake was also not measured although water bottles were weighed 
upon change over for the first month to gauge any animal welfare issues arising 
from sodium nitrate intervention. There were practical issues with availability of 
staff or researchers to do this process as well as a consideration of disrupting the 
mice excessively. 
7.3.6 Wet-mass over dry-mass measurements 
 Wet mass measurements were used as a standard throughout this thesis due to 
past experiences in this method and ease of process during periods of dissection. 
Dry mass measurements however are deemed much more accurate due to the 
removal of points of variability. For future work, dry-mass should be preferred 
when applicable to use. 
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7.3.7 Possible issues with choice of statistical analysis 
One way ANOVA was used throughout this thesis. After discussions with people 
with more expertise in statistics, it was decided that for some of the measures, 
more appropriate statistical tests should have been applied in some of the analysis 
provided in this thesis. Although not integral to the overall results gained and the 
overriding conclusions, it may influence specific results and is therefore a 
limitation of this thesis. 
7.4 Future directions 
7.4.1 The inclusion of more musculoskeletal sites of interest 
This study examined all of the major musculoskeletal tissues in the hindlimb of 
the mouse. A major site that was not included was the spine. Inclusion of spinal 
tissue would have been helpful to compare bone ageing within the spine, in a site 
of minimal stress and strain compared to the tibia and femur measured in this 
study as the spine is not primarily load bearing within these animals.  
Despite this, spine samples were stored from each mouse and would be useful to 
use in a future study to ultimately compare bone loss between the spine and 
hindlimb with increasing age. 
7.4.2 Investigation into the role of the nerve in musculoskeletal ageing. 
There is a growing body of evidence that suggest a change in nervous tissue could 
be the trigger for age-related changes in the muscle and potentially for changes in 
the underlying joint and bone. 
It would be advantageous to monitor age-related changes in nervous tissue. This 
analysis may give some insight into the mechanisms by which muscle mass is lost 
with increasing age and possibly why the bigger muscles lose mass at an earlier 
time point. 
As the ability of muscle to generate force is lost, the underlying bone is likely to 
be affected and may lead to resorption of bone minerals, thus explaining the close 
association between muscle and bone. 
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7.4.3 The use of in silico modelling of ageing of the musculoskeletal system as 
a whole. 
Finite element (FE) methods are computational methods which have been used 
since the 1940s. They are the chosen method for predicting how an object or 
material will perform when subjected to loads (Panagiotopoulou, 2009). A chosen 
object must be represented by a finite group of elements, each defined by a small 
number of nodes. It is the alteration or deformation of each element and 
associated node during an application of load that determines the placement of 
stresses and strains throughout the material being tested (Richmond et al., 2005, 
Rayfield, 2007). 
Due to FE processing being able to represent highly complex structures in simpler 
parts, FE has been used in the study of bone tissue to show the stresses and strains 
through the whole or part of the bone via the muscle. 
This has been shown in an earlier study aiming to display the effects of a 
reduction in muscle force on the underlying bone (Fig 7.2). Through this, it is 
possible to predict the areas of trabecular bone loss when muscle mass is reduced 
in this study the areas of significant loss of force appeared to be confined to the 
lower trabecular bones situated distally and away from the areas of high strain 
placed upon the cortical bone (Fig 7.2). 
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Fig 7.2 Finite element analysis of total principle strain applied to the tibia 
following application of force gained from 9 month muscles and following a 50% 
reduction in these forces. Areas of red indicate regions of high strain, regions of 
blue represent areas of low strain. Areas displaying large change under force 
reduction are predicted to be resorbed. 
7.5 Conclusion 
This thesis focused on how ageing in musculoskeletal tissues can be measured in 
the C57Bl/6 male mouse and by using these methods, can interventions be shown 
to improve the ageing process. Using the C57Bl/6 mouse, we can clearly see 
ageing occurring in the muscle and bone tissue however, it was difficult to 
measure changes in the tendon of these mice and they developed no age-related 
changes in the joint tissue. Intervention with sodium nitrate was ineffective at 
reversing the ageing process despite a large body of research reporting the 
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opposite. Overexpression of HSP10 in these mice did provide some protection 
against ageing in the muscle, but this protection did not apply to other 
musculoskeletal tissues. Due to these surprising results, we argued whether the 
C57Bl/6 mouse was the most suitable model to study musculoskeletal ageing. The 
same measures were applied to a cohort of wild mice which displayed ageing in 
all musculoskeletal tissues, which also occurred much earlier in their lifespan 
indicating that lab based strains of mice are actually ageing artificially compared 
to what is normal for the species. It is our conclusion that lab based strains of 
mice are not suitable for studying ageing processes due to the fact they are already 
“better” at ageing then normal wild mice.  
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Supplementary Data 
Fig SD.1.Percentage levels of measured tissues compared to 3 month values in 
C57Bl/6 mice.  
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Fig SD.2.Percentage levels of body mass and muscle tissues compared to 3 month 
values in C57Bl/6 mice.  
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Fig SD.3.Percentage levels of bone measures compared to 3 month values in 
C57Bl/6 mice 
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Fig SD.4.Percentage levels of body mass and muscle tissues compared to 6 month 
values in C57Bl/6 and wild male mice. 
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Fig SD.5.Percentage levels of cortical bone measures compared to 6 month values 
in C57Bl/6 and wild male mice. 
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Fig SD.6.Percentage levels of trabecular bone measures compared to 6 month 
values in C57Bl/6 and wild male mice. 
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Appendix 
A.1 Poster – Experimental Biology, San Diego (2014) 
A.2 Poster - Characterising musculoskeletal changes throughout age in C57Bl/6 
mice, British Society of Research into Ageing, Liverpool (2014) 
A.3 Poster - Characterising musculoskeletal changes throughout age in C57Bl/6 
mice and male wild mice, CIMA annual meeting, Sheffield (2015) 
A.4 Poster - Characterising musculoskeletal changes throughout age in C57Bl/6 
mice and wild mice, CIMA/CMAR joint meeting, Nottingham (2015) 
A.5 Poster – Characterising musculoskeletal changes throughout age in C57Bl/6 
mice Faculty of Health and Life sciences Poster day, Liverpool (2016) *Prize 
winning* 
A.6 Poster - Creating an in vivo model system to measure age-related changes in 
musculoskeletal tissues and test interventions to improve musculoskeletal 
function, British Society of Research into Ageing, Durham (2016) 
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